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ABSTRACT 
Mass spectrometry was used to investigate three important biological molecules, 
deoxyribonucleic acid (DNA), phosphopeptides and oxaliplatin. The quantification of DNA 
is traditionally performed by UV spectroscopy; however the results can be affected greatly by 
the sample matrix. The method developed quantified phosphorus in digested calf thymus 
DNA and human DNA by high performance liquid chromatography (HPLC) coupled to 
inductively coupled plasma mass spectrometry (ICP-MS). The method presented showed 
excellent baseline separation between all 4 DNA mono-nucleotides and 5’UMP. Column 
recoveries ranging from 95% to 99% for phosphorus resulted in a mass balance of 95% ± 
0.5% for standard nucleotides, determined by LC-ICP-MS, compared to total DNA 
determined by flow injection coupled to ICP-MS (FI-ICP-MS). Protein phosphorylation and 
de-phosphorylation is one of the most common signalling pathways within cells, it is 
involved in regulating cellular processes, mediating enzyme inhibition, protein-protein 
recognition and protein degradation. A novel approach to the selective detection of 
phosphopeptides based on the incorporation of a metal tag, gallium–N,N-biscarboxymethyl 
lysine (Ga-LysNTA), in solution before separation and detection by liquid chromatography 
coupled to inductively coupled plasma mass spectrometry (LC-ICP-MS) was developed.  
Linear ion trap electrospray ionisation mass spectrometry (ESI-MS) was employed to study 
the interaction of the gallium tag with platelet derived growth factor beta receptor (β-PDGF), 
a small phosphopeptide. In addition molecular modelling was used to investigate the 
energetically favoured structures of both the Ga-LysNTA material and the β-PDGF-Ga-
LysNTA complex.  The complexation of the Pt-based anti-cancer drug oxaliplatin (OxPt) 
with biological ligands other than DNA is believed to be a major cellular sink for the drug 
reducing its therapeutic potential and acting as a potential cause of toxicity. The role of the 
naturally abundant cytoplasmic dipeptide ligand β-alanyl-L-histidine dipeptide (carnosine) in 
OxPt detoxification was investigated.  Various mass spectrometry techniques employing 
electrospray ionization and chip nanospray were employed to study the interaction of 
oxaliplatin with carnosine as well as two of its derivatives β-alanyl-N-methylhistidine 
(anserine) and N-acetylcarnosine (NAC). Evidence of complexation between OxPt and each 
of the three ligands examined is presented. Most species observed were unambiguously 
assigned and compared to their theoretical isotopic patterns.  
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1 BACKGROUND TO THE RESEARCH 
 
 
1.1 INTRODUCTION 
 
This chapter provides an introduction to the overall theme of the EngD thesis; it outlines the 
different projects, giving background information on the importance of DNA quantitation and 
selective phosphopeptide determination in the wider community. The overall aim of the 
thesis and the individual objectives for each project are described, also the scope and 
justification for the work is included. This chapter also includes a summary of the papers 
published as a result of the EngD project, which should be read in conjunction with this 
thesis. 
 
1.2 BACKGROUND  
 
The first two projects of this thesis were designed to support the work performed by the UK 
National Measurement System, which is responsible for providing good measurement 
practice for the benefit of the nation. The National Chemical and Biological Metrology 
programme is responsible for new approaches to measurement and standardisation; the 
programme recognised the need for validated methods and certified reference materials 
(CRMs) for the measurement of DNA and proteins.   
Recent research into protein and DNA quantification utilises the unique capabilities of 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS), such as large dynamic range, 
excellent detection limits, near matrix independent analysis, and the capability to provide 
mass balanced separation when coupled with separation by High Performance Liquid 
Chromatography (HPLC). However, the research cannot be fully implemented in main 
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stream industry without robust and validated measurements and methods. As such the 
research performed during the EngD was designed to support the development of reference 
methods for the quantification and identification of phosphorus (P) containing compounds, 
for the characterisation of standard materials, clinical samples and pharmaceutical products.  
 
1.3 THE INDUSTRIAL SPONSOR 
 
LGC Ltd is an international leader in laboratory services, measurement standards, reference 
materials and proficiency testing, offering products and services in analytical and 
bioanalytical assays. The company’s client base is diverse and extensive, with activities 
ranging from forensic science; pharmaceutical and biotechnology research, to those in the 
food chain and environmental surveillance and safety; life science and basic research. LGC 
Ltd is the UK’s designated National Measurement Institute (NMI) for chemical and 
biochemical analysis and the National Reference Laboratory for a range of key areas 
including; added water in poultry, genetically modified organisms, and heavy metals and 
veterinary residues in products of animal origin. As the UK's designated NMI for chemical 
and biochemical measurements, LGC Ltd focuses on improving the accuracy and reliability 
of chemical and bio-measurements that are important to the UK's industrial competitiveness 
and quality of life.  
 
1.4 THE CONTEXT OF THE RESEARCH 
 
1.4.1 QUANTITATION OF DNA 
Gene quantification is a vital technique which is commonly used in many analytical areas, 
such as the monitoring and labelling of genetically modified food stuffs, disease diagnosis 
and forensic analysis. The preferred method of gene quantification uses real-time polymerase 
chain reaction (PCR) technologies. The PCR technique is a method for the amplification of 
Background to the Research  Claire Camp 
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DNA and RNA using single strand DNA and the enzyme DNA polymerase. The steps in 
PCR are outlined in Figure 1. Briefly the DNA is first denatured to unwind the DNA double 
helix; a primer is added to initiate the replication of the complimentary DNA strand. 
Deoxynucleotide triphosphates (dNTP’s), the building blocks of DNA, are added with the 
enzyme DNA polymerase and the amplification process begins.  Real-time PCR is able to 
detect DNA and RNA concentration as the reaction is occurring compared to conventional 
PCR which is only able to quantify at the end-point of the reaction. 
1
  It also has several other 
advantages over conventional PCR in that it has greater sensitivity and can be performed 
easily in closed-tube assays. 
1
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Figure 1: Polymerase chain reaction (PCR) mechanism of DNA replication, the template DNA strands A and B are 
replicated to give two new DNA strands.  
Template DNA (strand A)  
3’ 5’ 
5’ 3’ 
Denaturing 
 
Template DNA (strand B)  
3’ 5’ 
5’ 3’ 
Hybridisation of strand 
specific primers  
 
Template DNA (strand A) 
3’ 5’ 
5’ 3’ 
Polymerase reaction 
Primer A Primer B 
Template DNA (strand A)  
Template DNA (strand B)  
Elongation of primers to form 
two daughter strands 
Template DNA (strand A)  
3’ 5’ 
5’ 
3’ 
Extension, the process is repeated until 
the desired number of copies is reached.  
Template DNA (strand B) 
Copy strand A 
Copy strand B 
Template DNA (strand B)  
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Since the mapping of the human genome in 2003, the number of gene therapy treatments and 
tests has increased. Due to advances in PCR technology and with the whole of the human 
genome mapped, links between specific gene sequences and disease states has increased.  As 
such, hundreds of specific tests have been designed to identify a patient’s susceptibility to a 
disease prior to any symptoms being displayed. However, there is concern that the accuracy 
of these tests varies greatly between institutions. The accurate quantification of DNA is of 
great importance to many areas of the research community. One of the most important is the 
identification of genetic defects resulting in disease. Limitations arise as large sample sizes 
are needed to identify small genetic defects and often the yield of DNA from patients is 
small, also the conservation of precious DNA samples is of great importance for clinical 
research in order to verify and validate findings. To prevent unnecessary DNA consumption 
for high-throughput genotyping, accurate and precise DNA quantification is needed. 
Genotyping is the method of comparing the genetic make-up of an individual to that of a 
reference sequence. Identifying single nucleotide polymorphisms (SNPs), a difference in one 
single nucleotide in the genome between members of the same species, by SNP genotyping 
can help predict a person’s susceptibility to disease by identifying relevant genes. It is 
believed that characteristic SNP profiles will be identified and DNA testing will be able to 
screen for common diseases by analysing a patients DNA for specific SNP patterns.  
Imprecise quantification of small amounts of patient DNA increases variability in the amount 
of DNA gained by polymerase chain reactions, and leads to lower confidence in scoring of 
genotypes.  
 
Advances in technology and improved methodology have resulted in more laboratories 
having the ability to conduct detailed analyses of food composition. 
2
 The development of 
genetically modified crops and public concerns over the consumption of these crops has led 
many countries to introduce strategies for accurate labelling and tracing of GM crops. This 
has resulted in the need for validating and standardising methods, certifying laboratories and 
having reliable standards and certified reference materials widely available. 
2
 The availability 
of certified reference materials in the analysis of GM crops is especially important as all 
foodstuffs containing more than the threshold must be correctly labelled, this requires great 
accuracy, which is routinely measured against a CRM. 
1
 
 
Background to the Research  Claire Camp 
1-6 
To provide a complete picture of the genetic and compositional changes in food produced by 
either genetic engineering or conventional breeding, a targeted analysis using the tools of 
modern molecular biology should be used to provide information regarding the specific 
genetic changes that have occurred. 
 
The research work described in this thesis was designed to produce a quantitative method that 
could be used to quantify small amounts of DNA based on the phosphorus content by ICP-
MS.  
 
1.4.2 SELECTIVE ANALYSIS OF PHOSPHOPEPTIDES 
Protein structure and function is of great importance in the generation of new small-molecule 
drugs and in diagnosing and understanding disease processes. Many drugs have been 
developed as a direct result of understanding the signalling pathways in cells that cause 
proteins and other molecules within cells to be destroyed, exported or imported. Protein 
phosphorylation or de-phosphorylation is one of the most common signalling triggers within 
cells.   The reversible, covalent attachment of a phosphate group to one or more amino acids 
is the most common posttranslational modification for regulating cellular processes, and it is 
estimated that as many as 30-50% of proteins are phosphorylated at any given time. 
Phosphorylation changes regions on a protein from hydrophobic to hydrophilic, and this can 
result in a conformational change of the whole protein. The phosphorylated amino acid can 
also form part of a structure recognized by the binding sites of other proteins, thus driving the 
regulated assembly and disassembly of protein complexes. 
 
Kinases and phosphatases are the enzymes that phosphorylate and dephosphorylate proteins, 
respectively, on a timescale of seconds to minutes, the mechanism of phosphorylation is 
Shown in Figure 2. Many kinases are phosphoproteins themselves and are active only when 
phosphorylated. Cellular signalling is a cascade of reactions: phosphorylation activates kinase 
x, then x phosphorylates kinase y, and so on. Disruptions of these cascades have been linked 
to several diseases, including cancer. 
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Figure 2: Mechanism of phosphorylation by ATP on a serine, threonine or tyrosine containing protein. 
 
Compared with regular proteomics, phosphoproteomics poses some additional challenges. 
Phosphorylation is a dynamic, reversible process, and the ratio of phosphorylated to 
unphosphorylated proteins can be rather low in vivo. Phosphoproteomics experiments are 
more technically challenging because they require more initial separation and additional 
sensitivity. Moreover, the objectives for phosphoproteomics research are somewhat different 
from those of regular proteomics. 
 
The research work described in this thesis was designed to produce a methodology that could 
be used to selectively detect slight changes in the degree of protein phosphorylation, in order 
to gain a greater understanding of the signalling pathways in cells, by the tagging of model 
phosphopeptides with gallium.  
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1.4.3 IDENTIFICATION OF PROTEINS INVOLVED IN TOXICITY CAUSED BY 
PLATINUM BASED CANCER DRUGS 
In 2009, 41,000 people were diagnosed with colorectal cancer in the UK, in Europe it was 
estimated that there were over 300,000 new cases and 1.24 million new cases of colorectal 
cancer Worldwide in 2008. It is one of the most prolific cancers, accounting for 
approximately 13% of all cancer diagnosis in the UK. 
3
 Colorectal cancer develops via 
complex abnormalities that transform normal epithelium, the tissue that lines cavities within 
the body, such as the colon, into dysplastic epithelium which may lead to disease. Patients 
with colorectal cancer who are treated by the surgical removal of disease tissue are likely to 
suffer relapses and unfortunately die from this form of cancer, with the five year survival rate 
of patients with Stage II and Stage III tumours being only 80 and 60% respectively. 
4
 
 
Cisplatin has been used to treat cancer for over 30 years 
5
, and when used in combination 
with other anti-cancer drugs, such as bleomycin and vinblastine, it has been shown to cure 
80% of testicular cancers. 
5
 There are tens of platinum based anti-cancer drugs entered into 
clinical trials, but only four are approved world-wide, cisplatin, carboplatin, oxaliplatin and 
nedaplatin. 
5, 6
  However, as with all drugs, there are side-effects associated with all these 
drugs, including nephrotoxicity, nausea and vomiting, ototoxicity and peripheral neuropathy. 
7, 8
 Oxaliplatin is more commonly used in the treatment of colorectal cancer as it is better 
tolerated in terms of renal toxicity but its main disadvantage is that is has serious 
neurotoxicity side effects; including cold induced paresthesia, muscle spasms and muscle 
twitching. 
4, 9
 Neuropathy from oxaliplatin treatment ranges from acute sensory neuropathy 
immediately following oxaliplatin infusion, to chronic dose-limiting neuropathy, which only 
presents after several treatments. 
8
  Neurotoxicity is thought to be caused by the inhibition of 
voltage-gated sodium currents and by the presence of free oxalate ions acting as calcium 
chelators.  
 
It has been found by the analysis of several cancer cell lines that the largest proportion of the 
drugs remains in the cytosol, see Figure 3. 
10
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Figure 3: Proportion of platinum found in the different cellular components of various colorectal cancer cell lines.  10 
 
The overall aim of this project was to identify which proteins and peptides in the cytosolic 
fraction of cancer cell lines bind to the platinum containing drug. Identification of these 
proteins may lead to the discovery of why patients suffer from neurotoxicity and to identify 
other complementary therapeutic agents which may increase the proportion of oxaliplatin 
reaching the nucleus, leading to lower doses. To simplify the project, peptides found in the 
cytosol at relatively high concentrations and which are known to be metal chelators were 
chosen to model the interaction of oxaliplatin with cytosolic peptides. The peptides identified 
as likely candidates for oxaliplatin scavenging were glutathione, carnosine and anserine, and 
their interactions with oxaliplatin were investigated by electrospray ionisation tandem mass 
spectrometry (ESI-MS
n
) and molecular modelling.  
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1.5 OVERARCHING AIM AND OBJECTIVES 
 
To develop and validate a HPLC ICP-MS method for the quantification of trace levels of 
DNA nucleotides and phosphorylated peptides/proteins via their constant phosphorus content. 
The specific objectives agreed by LGC and Loughborough University were:  
1. To produce a literature survey of the current methods for DNA and phosphopeptide 
quantification 
2. To produce a validated LC-ICP-MS method for the quantification of DNA based on 
the P content of DNA. 
3. To produce a journal article based on the validated method stated in part 2.  
4. To develop a validated LC-ICP-MS method for the selective detection of 
phosphopeptides.  
5. To produce a journal article based on the validated method stated in part 4.  
 
In addition to this the scope of the research was extended to include the identification of 
oxaliplatin bound peptides from cancer cell lines. The specific aims of this research were:  
1. To identify peptides, or peptide motifs, likely to bind to oxaliplatin and investigate the 
structures of these adducts by ESI-MS
n
. 
2. To produce a journal article based on the findings of part 1.  
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1.6 STRUCTURE OF THESIS 
 
This thesis comprises five main chapters: 
Chapter 1 provides an overview of the three projects, the context of the research and the 
aims of each individual project.  
Chapter 2 is a literature review of the research done to date into each of the projects outlined 
in Chapter 1.   
Chapter 3 explains the research methodologies adopted to address the objectives of the 
EngD, and maps out the research activities. 
Chapter 4 outlines the instrumentation used for data collection in this thesis, outlining their 
basic principles, structure and mode of operation.  
Chapter 5 is a commentary of the work conducted to determine methods for quantifying 
DNA, selective detection of phosphopeptides by liquid chromatography inductively coupled 
plasma mass spectrometry (LC-ICP-MS) and investigation of the adducts of oxaliplatin with 
carnosine, anserine and glutathione by ESI-MS.  
Chapter 6 details the key findings of the project and the implications for the sponsor and 
wider industry, as well as presenting a critical review of the work and recommendation for 
future research related to the theme of this EngD. 
 
Appendices A to C contain the full contents of the three papers referred to throughout this 
thesis, which were published as a result of the work undertaken. These papers should be read 
in conjunction with the thesis so that the link can be established between the detailed research 
work of the EngD, and the overall EngD theme. 
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Paper ID Name  Journal  
1 Analysis of mono-phosphate nucleotides as a 
potential method for quantification of DNA using 
high performance liquid chromatography–
inductively coupled plasma-mass spectrometry 
Analytical and Bio-
analytical Chemistry, 2012, 
Volume 402, Number 
1, 367-372 
2 An ICP-MS, ESI-MS and molecular modelling 
investigation of homogeneous gallium affinity 
tagging (HMAT) of phosphopeptides 
International Journal of 
Mass Spectrometry, 2013,  
Volumes 341-342, 18-27 
3 Oxaliplatin Complexes with Carnosine and its 
Derivatives: In Vitro cytotoxicity, Mass 
Spectrometric and Computational Studies with a 
focus on Complex Fragmentation. 
Metallomics, 2013, DOI 
10.1039/C3MT00180F.  
4 An isotope dilution strategy for the quantification 
of Pt-GG adducts in lung cancer cells exposed to 
carboplatin at doses relevant to the clinic (In 
preparation) 
Intended Journal for 
publication : Metallomics 
Table 1: List of publications as a result of the research carried out as part of the EngD. 
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2 LITERATURE REVIEW  
 
 
2.1 INTRODUCTION 
 
This chapter provides a detailed review of the existing literature on each of the 3 projects that 
form this thesis. The literature review is split into three sections; the quantification of DNA, 
the analysis of phosphopeptides and the interaction of platinum drugs with small peptides.  
  
2.2 DNA QUANTIFICATION  
 
Due to its importance in the human body the analysis and quantification of phosphorus in 
DNA is of great interest to food safety, bio-medical and pharmaceutical research. Nucleotides 
are the building blocks of DNA, nucleotide mutations are believed to be linked to cancer and 
genetic diseases. 
11
 Analogues of nucleotides make effective drugs for the treatment of AIDS 
and cancer. 
11
 In the food industry nucleotides can taint the taste of foods. 
11
 Traditionally the 
quantification of phosphorus in DNA has been achieved by UV absorbance, fluorescence via 
the incorporation of dyes, or β radiation emission from radioisotope labelled 32P and 33P.  
 
UV measurements have been used for the quantification of DNA in biological samples for 
over 60 years however, results acquired with spectrometric methods can be erroneous. UV 
absorbance methods are cheap and easy to perform; however, results are often compromised 
by impurities in the sample. The technique also requires relatively large sample volumes.
12
 
DNA quantification by UV absorbance measures both double and single stranded DNA and 
is based on extinction coefficients, the measure of how strongly a chemical species absorbs 
light at a given wavelength. For 1 mg mL
-1
of DNA, the extinctions are generally accepted to 
be 20 m
2
 mol
-1 
at 260 nm and 10 at 280 nm. Proteins also absorb at 260 and 280 nm, at 
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concentrations of 1 mg mL
-1
 extinction coefficients are accepted as 57 at 260 nm and 1 at 280 
nm. The difference in extinction coefficients between DNA and protein at 280 nm, is a source 
of intrinsic error as a significant amount of protein can be hidden in a DNA preparation. 
13
  
 
Fluorescent dyes such as Hoechst 33258 and Pico Green, are relatively selective to double 
stranded DNA and do not bind protein.  Fluorescent dyes or probes bind to specific regions of 
the DNA, when bound, a photon of energy from an external source such as a laser or lamp is 
absorbed by the fluorophore and raises it to an excited state.  In the excited state the 
fluorophore undergoes a conformational change, which helps to partially dissipate the energy 
in the higher energy state and allows secondary processes to occur such as collisional 
quenching, fluorescence resonance energy transfer and intersystem crossing. The excited 
state lasts for 1 – 10 nanoseconds, after which a photon of lower energy at a longer 
wavelength to that used to excite the fluorophore may be emitted. The difference in 
wavelength of the exciting and emitted photon, the Stokes Shift, generates the sensitivity of 
fluorescence analysis, as it allows emitted photons to be detected against low backgrounds.  
Fluorescence spectroscopy has good sensitivity and specificity however, the techniques relies 
strongly on light scatter, suffers from quenching of fluorescence by competing processes and 
the technique is affected greatly by physical factors such as temperature, pH, ionic strength 
and viscosity.  
 
Differences in DNA quantification by spectroscopic and fluorescent methods were 
investigated by Holden et. al. 
13
 and English et. al. 
14
. The study by Holden et. al. 
13
 
compared two methods for the quantification of DNA; UV absorbance and florescent 
(PicoGreen) analysis, whilst English et. al. compared four quantitative methods, two UV and 
two fluorescent techniques against each other and to ICP-OES . Holden et. al. 
13
 investigated 
the variation in results for the quantification of DNA extracted from plant tissue and found 
that quantification based on UV absorbance had good correlation to the quantification based 
on 
31
P content. 
15
 However, quantification based on fluorescence using PicoGreen did not 
agree with the P content, results from the fluorescent method were consistently lower than 
those from UV measurements. 
15
 This finding was supported by the results of English et. al. 
14
 which showed that PicoGreen gave a lower DNA concentration compared to the expected 
value. English et. al. 
14
 compared four different quantification methods, two UV absorbance 
methods and two different fluorescent probe techniques.  Findings from each of the four 
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techniques were compared against each other and from an independent ICP-OES method. UV 
absorbance measurements were carried out using a conventional UV spectrometer and a 
NanoDrop spectrometer; the fluorescence dyes used were PicoGreen and Quant-iT. 
14
 Results 
showed that PicoGreen gave the lowest DNA value compared to the value given by ICP-
OES, due to the fact it only measured doubled stranded DNA, a limitation also noted by 
Holden et. al.. 
13
  Whilst the three remaining techniques reported higher values, by up to 33% 
more than the result reported by ICP-OES. 
14
 Higher readings from spectroscopic methods 
were due to interference from non DNA molecules absorbing at 260 nm, which resulted in 
values of 28 and 33% higher than those obtained by ICP-OES. 
14
 The results from the Quant-
IT fluorescence dye gave best precision, but the uncertainty of the method was found to be 
large.  
 
However, technological advances have been able to overcome the limitations of large sample 
volume; for example, the palmtop spectrometer as described by Qiu et. al. 
16 
, the NanoDrop 
spectrometer by ThermoScientific Inc., Wilmington, USA, the Pico100 and 200, (Picodrop, 
United Kingdom) and highly automated systems such as the DopSense96 by Trinean, 
Belgium. Qiu et. al. 
16
 developed a palmtop spectrometer that utilised a fibre transmission 
and a fibre reflection absorbance detection system, which was illuminated by either a UV-
LED or deuterium lamp. The palmtop spectrometer achieved a sensitivity of 0.5 ng/µL and a 
wide measuring range of 0.5-2000 ng/µL for DNA, with sample consumption of only 1 µL 
for fibre reflection and 0.5 µL for fibre transmission detection. 
16
 
 
The need for alternative and accurate methods for DNA quantification, lead to an increase in 
studies conducted using elemental mass spectrometry utilising the stoichiometric amount of 
31
P in DNA. The advantages of using elemental mass spectrometry to quantify DNA are 
listed below:  
1. Specificity to 31P 
2. Compound and matrix independent sensitivity 
3. High elemental sensitivity 
4. Robust 
5. Ability to couple easily to liquid chromatography, capillary electrophoresis, gel 
electrophoresis and gas chromatography. 
17
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These aspects of elemental mass spectrometry were utilised by several groups to quantify 
DNA and to develop methods which could be used to develop reference materials. Whilst the 
traditional methods for DNA quantitation, such as UV absorbance and fluorescence detection 
are most applicable for routine analysis, these methods still need to be validated with 
standard reference materials. The generation of standard reference materials requires more 
accurate analytical techniques and must be traceable back to the International System of 
Units (SI Units). Several elemental mass spectrometry approaches have been investigated, 
including acid digestion of whole DNA to inorganic 
31
P, enzymatic digestion of DNA to 
single nucleotides and direct analysis of oligomers. To accomplish this, various separation 
techniques have been coupled to ICP spectrometers including gel electrophoresis, capillary 
electrophoresis and liquid chromatography. Whilst elemental mass spectrometry has many 
advantages for the quantification of DNA, one of the major disadvantages of detection by 
ICP-MS is that phosphorus has only one isotope, therefore isotope ratio analysis cannot be 
performed.   
 
Relatively few reports have been published using gel-electrophoresis coupled to ICP-MS for 
the quantitation of DNA, possibly due to the fact that many separations require highly salted 
buffers often incompatible with ICP analysis. However, Brϋchert and Bettmer 18 developed a 
quantification method for whole DNA by gel electrophoresis coupled to sector field ICP-MS. 
The use of whole DNA overcomes the problems of incomplete digestion of DNA to 
nucleotides. The elution of whole DNA from the gel is isocratic therefore there is no change 
in sensitivity to 
31
P therefore no internal standard was used to monitor baseline drift. Two 
different calibration methods were employed; the first used the commercially available 
QuantLadder standards and the second used the total phosphorus content from acidic 
digestions of whole DNA at equivalent concentrations to the QuantLadder standards analysed 
by flow injection ICP-MS (FI-ICP-MS). 
18
 The method was successful for the quantification 
of DNA fragments from 100-700 base-pairs (bp); however, larger fragments suffered from 
band broadening which prevented baseline separation from being achieved. 
18
 Additionally 
the method was unable to separate smaller DNA fragments from inorganic phosphates 
making quantitation of DNA fragments of less than 100 bp impossible. Good agreement in 
DNA concentration was reached between the manufacturer’s values and those for small 
fragments (100-300 bp) but a significant difference was noted for fragments of higher 
molecular masses. 
18
 The poor correlation was explained by degradation of the sample prior 
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to analysis; however, it is more likely that sample was lost either on the gel, through 
nebulisation or ionisation.  
 
Whilst the coupling of capillary electrophoresis to ICP-MS/OES can prove to be difficult, 
coupling should allow a stable electrical connection to the outlet end of the capillary, prevent 
a laminar flow being introduced into the capillary and provide high sample transfer. 
19
 
Electrical connections are achieved by the use of liquid junctions or metallic conductors. 
19
 
Additionally the use of specialised nebulisers are required. The most commonly employed 
nebulisers in the coupling of capillary electrophoresis to ICP-MS are the micro-concentric 
nebulisers (MCNs), ultrasonic nebulisers and more recently the direct injection high 
efficiency nebulisers (DIHEN). These smaller volume nebulisers offer higher sample transfer 
efficiency whilst preventing the introduction of a laminar flow in the capillary, compromising 
the efficiency of the capillary separation which can occur when pneumatic nebulisers are 
employed. 
19
 
 
The determination of 
31
P in deoxyribonucleotides has also been investigated by coupling 
capillary electrophoresis to ICP-MS, as reported by Pröfrock et al. 
20
, Yeh et. al.  
21
 and Fuji 
et. al. 
22, 23
. Profrock et. al. 
20
 coupled capillary electrophoresis (CE) and HPLC to an 
Octopole reaction system (ORS-ICP-MS). To overcome the problem of the negatively 
charged nucleotides moving in the opposite direction to the positively charged capillary 
outlet, a highly acidic mobile phase was used and coupling to the ICP-MS was achieved via a 
sheathed Teflon tube direct to the torch. 
20
 Results showed that the detection limits for 
coupling HPLC to ORS-ICP-MS were improved by an order of magnitude compared to those 
for CE-ORS-ICP-MS. Detection limits for 
31
P of 53 µg/L, equating to 0.6 pg 
31
P absolute, 
were achieved by CE-ICP-MS, whilst detection limits of 3 µg/L, giving 0.03 ng 
31
P absolute, 
were achieved with HPLC-ICP-MS. All four nucleotides from calf thymus DNA were 
identified, however not all sample peaks were identified using standards, positive 
identification being achieved with ESI-MS. The P content of the DNA was quantified using 
flow injection analysis (FIA) however, this technique was deemed to be in need of further 
optimisation to improve accuracy.  
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Fujii et. al. 
23
 published a study describing the quantification of deoxynucleotides using the 
31
P signal by ICP-MS. Whilst the study by Profrock et. al. 
20
 utilized a more commercially 
available coupling, Fujii et. al. 
23
 developed a novel glass interface. The interface was 
developed to decrease the volume of sample needed to provide accurate quantification. The 
interface described improved robustness preventing choking and capillary breakages 
23
 and 
consisted of a custom made nebuliser (i.d. 200 µm) and a low-volume vaporising chamber, 
again custom-made. A polymer based fitting was used to connect the nebuliser to the 
nebuliser capillary (50 μm for HPLC coupling and 75 μm for CE coupling). 23 The set-up 
described was used for the separation of deoxyadenosine monophosphate (dAMP), 
deoxyguanosine monophosphate (dGMP), deoxycytosine monophosphate (dCMP) and 
deoxythymidine monophosphate (dTMP). Detection limits were reported as 0.77-6.5 ng/mL 
for dNMP’s by CE-ICP-MS and 4.0-6.5 ng/mL by μHPLC-ICP-MS. The absolute detection 
limit for phosphorus was reported as 0.012 pg for both the μHPLC-ICP-MS and the CE-ICP-
MS experiments, 
23
 demonstrating the flexibility of the novel sample introduction system. 
Fujii et. al. 
23
 reported better analytical results than previously reported for phosphorus within 
nucleotides, with detection limits two orders of magnitude lower with CE-ICP-MS.  
 
Fujii et. al. 
22
 later utilised the interface described above for the quantification of 
31
P in 
enzymatically digested  DNA. All 4 dNMP’s were identified in the electropherograms as well 
as free phosphate and an unknown peak, 
82
Se was used as an internal standard and 
133
Cs to 
monitor the sheath liquid flow. 
22
  To establish the accuracy of the method, the DNA 
concentration was determined by fluorescence also, the average DNA concentration by CE-
ICP-MS was reported as 28.6 µg/mL and by fluorescence 24.5 µg/mL, detection limits 
achieved by CE-ICP-MS were equal to that obtained by conventional fluorescence assay, 
which ranged from 3.1 – 26 ng/mL. 22 
 
Yeh et. al. 
21
 utilised a modified micro-concentric nebuliser to couple capillary 
electrophoresis to ICP-MS for the study of monophosphate nucleotides, AMP, GMP, uridine 
5’-monophosphate (UMP) and inosine 5’-monophosphate (IMP).  Detection limits achieved 
were in the range of 0.036-0.054 µg/mL for 
31
P, equivalent to 1.1-1.6 pg 
31
P.  
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The lack of suitable accurate quantitation standards for DNA measurements was tackled by 
Yang et. al. 
24
. The report concluded that the method developed for the quantitation of 
oligonucleotides could be applied to produce commercially available quantitation standards 
for DNA. The study highlighted the need for a metrologically sound quantification method 
for DNA. Their approach for the absolute quantification of DNA was based on the 
stoichiometric amount of P in the phosophodiester backbone of DNA. Oligomers underwent 
acid digestion to inorganic P and were measured by ICP-OES with yttrium as an internal 
standard. 
24
 Moles of inorganic P were converted to moles of oligonucleotide and extremely 
reproducible results were obtained. The study outlined the problems which hinder the 
absolute quantification of DNA; complete recovery of P from acid digestion, removal of all P 
interfering components from DNA prior to analysis and the molecular purity of the 
oligonucleotide analyte. 
24
 To confirm the molecular purity of the oligomer the group 
analysed the sample by matrix assisted laser desorption ionisation time of flight mass 
spectrometry (MALDI-TOF MS) with standard additions and to check the recovery of 
inorganic P from acid digestion of deoxymethyl thymidine (d’TMP). 24 The concentration of 
the oligomer was accurately measured by ICP-OES and compared to the value obtained by 
UV analysis. The results of their studies indicated that an oligonucleotide could be certified 
and used as a reference material with uncertainties of less than 1%. 
24
  
 
Quantification of DNA by liquid chromatography coupled to ICP-MS has been reported in 
numerous studies including one by Liang et. al. 
25
, who separated all 4 deoxyribonucleic 
acids by high performance liquid chromatography using ammonium acetate as a mobile 
phase. Limits of detection were reported as ranging from 0.173 – 0.225 µM 25 and absolute 
31
P limits of 3.1 – 4.5 pM.  The hyphenated technique was applied to the quantitation of 
enzymatically digested plasmid DNA, however this method was not validated against a 
reference material despite good correlation of the retention times from the digested DNA to 
the nucleotide standards. 
 
Donald et. al. 
26
 reported an excellent study on the analysis of a 20 mer oligonucleotide by 
the coupling of liquid chromatography to molecular mass spectrometry and quantification by 
ICP-OES this work followed up their previous study on the quantitation of an oligomer by 
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LC-MS/MS with isotope dilution analysis (IDA) 
27
 which was submitted as a proof of 
concept. The use of labelled nucleotide standards allowed the quantification of an 
oligonucleotide by enzymatic digestion into monomers and quantitation by LC-MS/MS-IDA, 
without the need for a pure oligonucleotide standard. 
27
 However, they found that this method 
did not account for the end terminal nucleotide where the phosphate group was replaced with 
a hydroxyl group during the digest procedure, in their subsequent study a different enzyme 
was used to produce nucleosides. The approach taken was very much focussed on 
quantitation by IDA by LC-MS/MS with confirmation of quantitation by ICP-OES and 
recovery of nucleotides and nucleosides by two different enzymatic digestion protocols. The 
most preferred enzyme digestion protocol involved digestion first to nucleotides with snake 
venom phosphodiesterase (SVP) followed by digestion to nucleosides with shrimp alkaline 
phosphatase (SAP), as this by-passed the problem of the terminal phosphate being converted 
to a hydroxyl during the digest with SVP only. 
26
 By IDMS and confirmation by ICP-OES, 
they found good agreement with the oligomer concentration of 108 and 109 µg/g with good 
uncertainties at the 95% confidence levels.  
 
The majority of work on 
31
P detection in DNA using ICP-MS has been in the detection of 
DNA adducts with the anti-cancer drugs cis-platin and melphalan and with the possible 
cancer causing adduct formation with styrene oxide.  Edler et al. 
28
 utilised ICP-MS to 
quantify the formation of styrene oxide DNA adducts using bis (4-nitro phenyl) hydrogen 
phosphate (BNPP) as an internal standard. 
28 The group’s work was based on the earlier work 
by Siethoff et al. 
29
 with the improvement to that work being achieved by the use of hexapole 
and reaction cell ICP-MS. The advantages of using this technique compared to the use of a 
sector field ICP-MS is that spectral and non-spectral interferences were reduced and so direct 
quantification of the modified nucleotides could be achieved without any mathematical 
corrections for signal intensities when using gradient elution. 
28
 Sar et al. 
30
 employed LC-
ICP-MS for the speciation of both Pt and P in DNA adducts with cis-platin with structural 
characterisation by ESI-MS. Quantification of the 5’-monophosphates and adducts was 
obtained via the construction of a calibration curve with good correlation between the 
concentration of dGMP and  
31
P Peak area (r
2
 =0.999). 
30 
It was demonstrated that they were 
able to separate the 
31
P containing nucleobases from the dGMP adduct using a narrow bore 
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column and noted that when using low flow rates (0.2 ml/min) very low backgrounds of 
polyatomic inferences were observed. 
30
 
 
Huang, Xi et al .
31
 published a paper examining the efficiency and effectiveness of several 
enzymes and combinations of enzymes for DNA digestion.  The study found that using 
DNase I at the beginning and phosphodiesterases (PDE) I and II the end of the DNA 
digestion processes, 8-oxo-dG can be much more efficiently released from DNA than when 
Nuclease P1 (NP1) and alkaline phosphatase (AP) are used. Their results showed that their 
modified DNA digestion conditions can significantly improve accuracy and reproducibility of 
their analyses.  
 
Brennan et. al. 
32
 have recently published a paper for the quantification of DNA using high 
performance ICP-OES to detect phosphorus in acid digested nucleotides and DNA. The 
group employed a DIHEN which was used to reduce the volume of sample consumed during 
the analysis and to improve the robustness of the plasma. The use of this nebuliser decreased 
the sample uptake rate from 170 to 30 μL/min and the volume used from 10 to 2.4 mL. 32 The 
increased sensitivity observed with the DIHEN also meant that the mass of DNA required to 
perform the analysis could also be reduced from 300 μg for a 3 μg/g solution (P) to 12 μg for 
a 0.5 μg/g solution (P). 32 The phosphorus measurement was made using a germanium 
internal standard, this corrected for low-frequency noise, and to correct for any difference 
between the calibration standard and the sample. Brennan et. al. 
32
 reported a 4 fold increase 
in P sensitivity at 213.617 nm, allowing for a decrease in the P mass fraction (from 3 to 0.5 
μg/g) analysed and the mass of DNA consumed. 32 
 
Interest in accurately quantifying the amount of DNA in biological samples continues, with 
recent studies investigating the use of both MS and nuclear magnetic resonance (NMR) for 
this purpose. 
15 
To date the application of ICP-MS to the quantification of DNA has not been 
investigated to such an extent as the quantification of phosphoproteins. 
18  
The lack of a 
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suitable certified quantitative DNA reference material has contributed to the lack of research 
into this field; however several attempts have been made.  
 
2.3 PHOSPHOPEPTIDE ANALYSIS 
The phosphorylation or dephosphorylation of proteins, enzymes and receptors acts as a 
switch to “turn on” or “off” their activity by inducing a conformational change in the 
structure of these macromolecules.  The phosphorylation process is controlled by the 
opposing action of two enzymes, kinase enzymes control phosphorylation and phosphatases 
control dephosphorylation. 
33
 Only three amino acids undergo phosphorylation within the 
macromolecule, these being tyrosine, threonine and serine, as these amino acid residues 
contain a hydroxyl group. 
33
 The addition of a phosphate group (PO4) to the hydroxyl of one 
of these residues within a hydrophobic region can turn that region into a polar, extremely 
hydrophilic region, introducing a conformational change in the structure of the protein due to 
changes in the interactions with other hydrophobic and hydrophilic residues within the 
protein. The determination of phosphorylation sites within a protein of a given cell is 
extremely complicated as there are thousands of different proteins within a cell and 
phosphorylation may occur at more than one site on any given protein.   
 
The analysis of phosphopeptides by mass spectrometry faces many challenges; there are 
several reasons for this. 
34- 38
  
 
 Phosphorylated proteins are found at very low concentrations in the body. 39-41  
  The sub-stoichiometric levels at which phosphorylation takes place results in only a 
small portion of the actual protein under investigation being phosphorylated. 
39-41
  
 The complexity of the phosphorylation and de-phosphorylation processes make 
analysis difficult, a single protein can be acted on by various kinases and 
phosphatases at different sites and at different times. 
34, 35, 42
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 During analysis, phosphorylated proteins may become de-phosphorylated unless 
precautions are taken to inhibit the action of the phosphatase enzymes.  
36
 
 Post-translation modification bonds tend to be more labile than peptide amide bonds, 
and therefore become the preferred site of fragmentation, which can affect peptide 
identification by impeding efficient backbone fragmentation. 
43
 
To improve selectivity, sensitivity and in some cases quantification, phosphopeptides and 
phosphoproteins are often labelled prior to analysis. 
 
Quantification strategies involve the 
inclusion of isotopic labelled agents, whilst sensitivity and selectivity can be improved by the 
inclusion of a metal labelled tag. 
 
2.3.1 PHOSPHOPEPTIDE TAGGING STRATEGIES 
Gruhler et. al. 
43
 incorporated both an enrichment procedure, namely immobilised metal 
affinity chromatography (IMAC) with a labelling strategy, and stable isotope labelling with 
amino acids in cell culture (SILAC), see Figure 4. The approach taken by Gruhler et. al. 
43
 
was used to quantify phosphopeptides involved in the Yeast pheromone signalling pathway. 
SILAC encoding involved the incorporation of [
13
C6] arginine and [
13
C6] lysine in a double 
auxotroph yeast strain. To act as a control, pheromone-treated yeast cells were mixed with 
SILAC encoded cells, and after replication the cells were lysed and extracted proteins were 
digested with trypsin. Phosphopeptides were then enriched with a combination of strong 
cation exchange (SCX) and IMAC. A linear ion-trap Fourier transform ion cyclotron 
resonance mass spectrometer was used to analyse the phosphopeptide fractions by LC-MS.  
43
 
More than 700 phosphopeptides were identified, 139 were identified as being up-regulated in 
response to mating pheromone by over 2-fold. The efficiency of the IMAC enrichment varied 
with the complexity of the sample. More complex samples gave poorer recovery than simple 
samples; therefore sub-fractionation was required prior to IMAC. Despite the large number of 
phosphopeptides identified, complete coverage was not achieved due to inefficiency in 
protein extraction, digestion and uneven sampling of peptides for fragmentation by mass 
spectrometry. 
43
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Figure 4: The principle of SILAC, cells are differentially labelled by growing them in two different media, the light 
containing the stable isotope and the heavy containing an isotopicially heavy version. The ratio of heavy to light ratios 
detected by the mass spectra gives the relative abundance.  
 
Cantin et. al. 
44
 also combined SILAC with SCX and IMAC in a multidimensional protein 
identification tool, coined MudPIT to identify the epidermal growth factor (EGF) pathway in 
mammalian cells. Using this approach the group were able to identify 4470 unique 
phosphopeptides with 4729 phosphorylation sites. 
44
 Light SILAC HeLA cell cultures were 
treated with EGF, whilst heavy HeLa cell cultures were left untreated. The cells were lysed, 
proteins extracted by dialysis, digested to peptides with trypsin and phosphopeptides were 
enriched by IMAC spin columns. Prior to analysis by MS and MS
n 
on a Thermo LTQ 
Orbitrap, the phosphoepeptides were separated by SCX and reverse phase liquid 
chromatography. Of the 4470 unique phosphopeptides found, 37% were quantified by Census 
software 
45
 and of those 15% were found to be either up-regulated or down-regulated by 2-
fold or more by the addition of EGF. 
44
 
 
 
 
Control (A) light Labelled (B) heavy 
Mix in 1:1 ratio 
Protein/peptide fractionation and analysis by mass spectrometry.  
The intensity of the light 
and heavy peptide signals 
gives the relative abundance 
of the peptide in both the A 
and B state.  
In
te
n
si
ty
 
m/z 
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Weber et. al. 
46
 used SILAC based MS to determine over 10 thousand distinct 
phosphorylation sites in the phosphoproteome of KG1 acute myeloid leukemia (AML) and 
the effect of treatment with two drugs;  erlotinib and gefitinib. Less than 50 phosphorylation 
sites were identified as varying with drug treatment, which indicated specific interference 
with AML cell signalling. Of the changes observed a significant amount were associated with 
tyrosine phosphorylated protein network, including the Scr family kinases and the tyrosine 
kinases btk and Syk.  
46
  
 
The isobaric tagging for relative and absolute quantitation (iTRAQ) technique employed by 
Wu et. al. 
47
 in combination with high energy collision dissociation (HCD) in LTQ-Orbitrap 
allows the simultaneous identification and quantification of iTRAQ labelled phosphopeptides 
due to the combination of high mass accuracy MS/MS spectra and wide m/z scan range. An 
ITRAQ labelling workflow begins with the N-terminus of peptides being covalently bound to 
tags of varying mass. The labelled peptides are then pooled and analysed by mass 
spectrometry, see Figure 5. 
 
Figure 5: iTRAQ labelling workflow with mass spectroscopy detection. 
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Sachon et. al. 
48
 applied a commercially available iTRAQ reagent to quantify 
phosphopeptides following in gel trypsin digests of proteins and phosphoproteins. 
Phosphopeptides were analysed by MALDI-MS after excess reagent was removed and 
phosphopeptides enriched by Fe(III)-IMAC. Abundance was determined by LC-MS/MS by 
either MALDI-MS or ESI-MS.  
 
2.3.2 PHOSPHOPEPTIDE ENRICHMENT STRATEGIES 
Wang et. al. 
49
 described a simple and effective immune-dot blot method for the detection of 
phosphopeptides by mass spectrometry. Initially three dot-blot immunoassays typically used 
for the detection of non-phosphorylated peptides were undertaken and tested with 
phosphopeptide standards. The first method tested utilised a pre-soaked polyvinylidene 
fluoride membrane (PVDF) in phosphate saline. 
49
 The wet membrane was spotted with 
standard phosphopeptides and left to dry. In the second method phosphopeptide standards 
were directly spotted onto nitrocellulose membranes. 
49
 In the final method, nitrocellulose 
membranes were treated with 1% glutaraldehyde for 10 minutes, prior to being spotted with 
the phosphopeptide standards. 
49
 All three blotted membranes were probed with anti-
phosphoserine antibody; of the three methods tested the membrane treated with 
glutaraldehyde gave the best signal to noise ratio by detection with tandem mass 
spectrometry. It was concluded that the greater retention was due to cross-linking between the 
peptide and the divalent cross-linker glutaraldehyde. 
49
 
 
The limit of detection was determined for the glutaraldehyde method as 10 pmol of 
pohosphopeptide with an anti-phosphoserine probe. To test the specificity for the anti-
phosphoserine antibody for phosphopeptides, the phosphopeptides were treated with a 
phosphatase to remove the phosphate group. 
49
 Three probes were tested, anti-phosphoserine, 
anti-phosphotyrosine and anti-phosphothreonine, all three gave positive responses for 
phosphopeptides and negative responses for phosphopeptides treated with phosphatase. The 
glutaraldehyde method developed was also tested with real biological samples. The biological 
samples tested were separated by gel electrophoresis, stained, excised and tryptically 
digested. Phosphopeptides from the digests were enriched using titanium dioxide affinity 
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chromatography. The results showed a positive result for the peptides eluted from the TiO2 
column, a negative result for the flow through from the TiO2 column, and a much weaker 
response from the peptides not enriched by TiO2. 
49
 Eluted peptides were analysed by LTQ-
Orbitrap mass spectrometer.  
 
Niklew et. al. 
50
 also employed titanium dioxide as an enrichment material but as a 
nanocrystalline film rather than as support material. These films were used as Affinity 
MALDI Targets for the analysis of proteolytic digests of α and β–casein. 50 The titanium 
dioxide films were synthesised via the sol-gel route for producing mesoporous film, these 
films have an increased internal surface area compared to a flat surface of the same diameter, 
increasing the available binding sites for phosphopeptides. 
50
 β-casein was digested using 
trypsin, and the digest was applied to the film and incubated for up to 45 minutes. On 
application of the digest to the film a colour change was observed indicating that the matrix 
molecules had bound to the Ti metal centres. 
50
 In order to release the phosphopeptides from 
the metal, the film was washed with NH4H2PO4, the inorganic phosphate displaces all other 
ligands from the Ti metal centres. Three major peaks were observed corresponding to the 
phosphopeptides expected from β-casein, to further prove the effectiveness of the enrichment 
procedure, the bound phosphopeptides were treated with phosphatase prior to desorption of 
the phosphopeptides, in order to improve the ionisation efficiency of the phosphopeptides in 
positive mode. 
50
 
 
Choi et. al. 
51
 used both magnetic iron oxide particles (Fe3O4) and titanium dioxide (TiO2) 
particles to selective enrich phosphopeptides from bovine α-casein. The enriched 
phosphopeptides were eluted from the metal oxide particles and combined, the resulting 
mixture was then separated and analysed by LC-MS/MS. The results from the sequential 
enrichment process support the findings of others that Fe3O4 particles retain more multi-
phosphorylated peptides than TiO2 particles but are not as good as TiO2 particles in retaining 
mono-phosphorylated peptides. 
51
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Tang et. al. 
52
 developed mesoporpous TiO2 microspheres for the enrichment of 
phosphopeptides. The microspheres synthesised by a simple hydrothermal reaction had a 
higher surface area to volume ratio than commercially available TiO2 microspheres. 
52
 
Compared to smooth TiO2 microspheres,  mesoporous TiO2 microspheres have a surface area 
of approximately 25 times larger. They were successfully applied to the analysis of casein 
phosphopeptides and to a real biological sample obtained from rat brain. Phosphopeptides 
from a tryptic digest of β-casein were enriched using both smooth and mesoporpous TiO2, 
and the results for both types of material were similar. The experiment was then repeated 
with a mixture containing tryptic digests of both bovine serum albumin (BSA) and β-casein 
in a 1:1 and a 10:1 ratio. 
52
 With a constant concentration of β-casein and in identical 
experimental conditions, the mesoporous TiO2 microspheres performed better than the 
smooth microspheres, in that the signals corresponding to the phosphopeptides were 
enhanced compared to those from unphosphorylated peptides in the mass spectra resulting 
from the enrichment by mesoporous microspheres. 
52
 It was concluded that the mesoporous 
TiO2 microspheres have a much larger binding capacity for phosphate groups as well as much 
higher capture efficiency for phosphopeptides than smooth TiO2 microspheres. 
52
 
 
Zhao et. al. 
53
 reported an automated metal-free multiple column nanoLC method for high 
throughput analysis of phosphopeptides with MS detection. The method used a combination 
of online solid phase extraction columns and a capillary C18 column connected via an 
automatic switching valve. A limit of detection of 0.4 fmol was obtained using a linear ion 
trap tandem mass spectrometer. 
53
 
 
Leitner et. al. 
54
 reported on the use of tin dioxide as an enrichment material for 
phosphopeptides. Tin dioxide (SnO2) microspheres were produced by a nanocasting 
technique using silica of different morphology to give microspheres that varied in their 
particle size and porosity. 
54 
The nanocasting process used, utilised porous silica spheres as a 
template for the generation of metal oxide replicas in the pores of the silica material. 
54
 The 
SnO2 particles were produced by impregnating the SiO2 particles with SnCl2 solution, heated 
in air to decompose the salt to SnO2, silica was then removed by leaching with HF or NaOH. 
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HCl was used for activation of SnO2 microspheres, the SnO2 material was refluxed overnight 
with HCl, collected by filtration, washed with water and dried in vacuo. 
54
  
 
The efficiency of the enrichment process was analysed using LC-MS, higher specificity for 
phosphopeptides was observed when NaOH was used for leaching compared to HF. It was 
also observed that when dilute HCl was used for activation the microspheres produced had 
increased performance. 
54
 To confirm these early conclusions, microspheres were produced 
from a single starting material, one half of the starting material was treated with HF and the 
other half treated with NaOH. These two portions were then split in half again to give four 
portions, one half of the silica treated with HF was treated with dilute HCl, and one half of 
the silica treated with NaOH was treated with dilute HCl. 
54
 From the data obtained from LC-
MS, the amount of unspecific binding was lowest for the SnO2 microspheres produced by 
treatment of silica with NaOH and HCl. One of the synthesised peptides used in the study, 
Glu-fibrinopeptide B, exhibited the strongest unspecific binding due to its acidic nature. 37% 
and 14% of the total amount of peptides was bound to SnO2 microspheres treated with HF 
and NaOH respectively, whilst those treated with HCl had only 15% and 9% bound to SnO2 
microspheres, leached with HF and NaOH respectively. 
54
 
 
2.3.3 PHOSPHOPEPTIDE ANALYSIS BY MASS SPECTROMETRY  
McLachlin and Chait 
55
 described the improvements in mass spectrometry technology and the 
benefits these improvements made to the analysis in phosphopeptide and phosphorylation site 
identification. In the crudest form Mass Spectrometry can accurately predict the molecular 
mass of the phosphorylated protein, comparison with the molecular mass of the un-modified 
phosphoprotein or the phosphoprotein treated with phosphatase can give the average number 
of phosphorylation sites. 
55
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2.3.4 PHOSPHOPEPTIDE ANALYSIS BY ICP-MS 
Navaza et. al. 
56
 investigated peptide dephosphorylation by coupling capillary HPLC (capLC) 
to ICP-MS, the lower flow rates allowed the use of higher percentages of organic modifier 
than would normally be tolerated by the ICP-MS. The group also utilised a post-column 
sheath flow to compensate the gradient conditions used during the capLC separation as 
gradient flows affect the sensitivity of the ICP-MS signal. To quantify the amount of 
phosphopeptides present, bis(4-nitro-phenyl) phosphate (BNPP) was spiked into each sample 
to act as a P-standard. The sensitivity factor for BNPP was calculated and used to quantify 
the amount of each phosphopeptide. Model phosphopeptide solutions were prepared and 
treated with phosphatase enzymes and analysed at different time periods. 
56
  
 
The technique employed allowed even small differences in phosphorylation degrees to be 
detected, due to the high precision and accuracy associated with the absolute phosphopetide 
and phosphorylation degree measurements, reported as 0.6 - 4.1% RSD and from 1.5 - 4.3% 
RSD respectively. 
56
 The absolute quantitative data for one of the model phosphopeptides at 
each time point was calculated as 0.2 – 2.4% RSD over the dephosphorylation process. This 
approach developed by Navasa et.al. 
56
 allows phosphorylation dynamics to be studied; its 
ability to quantify the absolute amount of each separated phosphopeptide at any given time 
may have significance for clinical applications. 
56
 
 
CapLC-ICP-MS was also used by Ellis et. al. 
57
 to study protein phosphorylation in low 
molecular weight cerebral spinal fluid fractions. Detection limits for 
31
P by capLC-ICP-MS 
were 5µg/L for the synthetic peptide Pp60 c-src and 10µg/L for P60 c-src, using a 1µL 
injection.
57
 Following 
31
P screening by capLC-ICP-MS fractions were collected off-line and 
analysed by nano-LC chip ion trap mass spectrometry to provide confirmation of protein and 
peptide molecular weight and sequence. The paper showed that the sensitivity achieved with 
capLC-ICP-MS in combination with nanoLC-CHIP/ITMS is a very powerful technique for 
characterising phosphopeptides in complex matrices such as cerebral spinal fluid. 
57
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Bettmer et. al. 
58
 have recently published a review outlining the role of ICP-MS in proteomic 
analysis. The review states the reasons for using ICP-MS for proteomic studies, including;  
1. Its specificity for the heteroatom  
2. Non-species dependent detection sensitivity 
3. Direct isotope information, allowing quantification by IDMS and metabolic studies 
4. Robust sample preparation 
5. Variability in sample introduction. 58 
The use of ICP-MS for the fast screening of complex peptide mixtures for phosphopeptides 
was also outlined, the specificity of the ICP-MS allows the exact elution time for the 
phosphopeptides to be found, therefore allowing fraction collection and subsequent 
identification via ESI-MS. 
58
 This decreases the complexity of the sample for molecular 
spectrometry, which is often a barrier to analysis of phosphopeptides by this technique. 
2.3.5 PHOSPHOPEPTIDE QUANTIFICATION 
Wu et. al. 
47
 produced a comprehensive study of HeLa cell lysates, in which they identified 
3557 distinct phosphopeptides and were able to quantify 2709 of those from 5 mg of the 
HeLa cell lysate. Separation of the phosphopeptides from the lysate was achieved by trapping 
the phosphopeptides on a titania packed column, labelling with iTRAQ reagents and 
fractionation using a SCX column. Identification and relative quantification was achieved by 
high-energy collision dissociation (HCD) and using the iTRAQ reporter ions. 
47
 
 
Wu et. al. 
47
 compared two different enrichment strategies. In the first method fractionation 
was achieved by strong cation exchange at pH 2.7, the resulting fractions were then incubated 
with titania beads 
47 
 and  analysed by LC-MS/MS on an Orbitrap instrument. 
47
 The second 
method used a titania bead packed column to enrich the phosphopeptides from the 
unfractionated cell lysate digest. Phosphopeptides were eluted from the column in ammonia 
solution and fractionated using a strong cation exchange column, the resulting fractions were 
analysed by an Orbitrap instrument using the same conditions as in the first method. 
47
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The first method using the SCX-TiO2 protocol, repeated in parallel, identified 3106 and 2838 
distinct peptides, with a false discovery rate of ~2.0% 
47
 , the second method using the TiO2-
SCX protocol identified 4845 and 4340 distinct peptides under the same conditions. It was 
reported that on average the TiO2-SCX protocol led to the identification of 54.5% more 
phosphopeptides than the traditional method of SCX-TiO2 enrichment. 
47
 The overlap of 
identified peptides between method replicates was also investigated; the overlaps observed 
were relatively low, 58% and 51% for TiO2-SCX and SCX-TiO2 workflows respectively. 
47
 It 
was concluded that the error came from irreproducible sampling of the mass spectrometer in 
data-dependent scan mode as an overlap of 60% was observed when running two replicate 
LC-MS/MS analyses of the same TiO2-SCX sample. 
47
  
 
Metal oxide affinity (MOA) chromatography for the enrichment of phosphopeptides was 
reviewed by Leitner. 
59
 In the review Leitner reported on improvements in technology that 
have aided the advancements in phosphopeptide analysis, strategies to improve enrichment 
protocols and significant advancements in characterising phosphopeptides using MOA 
materials. 
59
 Improvements in MS technologies have increased the number of 
phosphorylation sites characterised. Techniques such as electron-capture dissociation (ECD) 
and electron-transfer dissociation (ETD) allowed simpler mass spectra to be obtained, as 
fragmentation can be achieved without the neutral loss of phosphoric acid.  
 
The use of helium as a collision gas was first applied to studies of DNA but has been 
expanded to the analysis of phosphorus in phosphorylated proteins. 
20, 60, 61
 Profrock et al. 
20 
found that using helium as a collision gas and “kinetic energy discrimination” achieved by 
the octopole and quadrupole bias settings, decreased background at the 
31
P mass by 
approximately 2 fold. 
20
 In standard H2 mode with standard cell conditions background 
equivalent concentration (BEC) could not be achieved but by switching to He mode a BEC of 
4 µg/L was achieved.  It is also possible to reduce the polyatomic background by reducing the 
amount of solvent that reaches the plasma 
60 
and by introducing the liquid aerosol at a lower 
flow rate by using micro or capillary nebulisers. 
60
 The polyatomic background is created by 
dissolved atmospheric gasses giving rise to 
15
N
16
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+
, 
14
N
16
O
1
H
+
, 
14
N
14
N
1
H
+
, 
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, 
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 ions which overlap with the 
31
P
+
 signal.   
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Leitner 
62
 commented that one of the most powerful approaches to phosphopeptide analysis 
was that of metal oxide affinity capture (MOAC). The most popular theory explaining the 
binding mechanism of metal oxides to phosphate groups is by the bidentate binding between 
the phosphate anion and monosubtituted phosphates to the metal oxide surface. Metal oxides 
act as Lewis acids, interacting with the phosphate anion.   
 
2.4 INTERACTION OF SMALL PEPTIDES WITH PLATINUM BASED 
ANTI-CANCER DRUGS 
Out of the tens of platinum based anti-cancer drugs entered into clinical trials, only four are 
approved world-wide, cisplatin, carboplatin, oxaliplatin and nedaplatin. 
56
 The barrier to 
effective treatment of cancer with platinum based drugs remains adverse side effects 
including nephrotoxicity, renotoxicity, nausea and vomiting, ototoxicity and peripheral 
neuropathy and the development of chemoresistance. 
7, 8
  
 
In the search for new platinum based anti-cancer drugs, the focus has changed from 
identifying the most cytotoxic to identifying those with sufficient cytotoxicity, fewer side 
effects and reduced chemoresistance. This has also been reflected in the increase in interest of 
both in-silico and in-vitro experiments where the interaction between cisplatin and intra and 
inter-cellular proteins, peptides, enzymes and phospholipids has been investigated. This line 
of enquiry is supported by the fact that less than 5% of the total drug administered reaches the 
target DNA in the nucleus, 
63
 a similar situation occurs with other platinum based drugs such 
as oxaliplatin 
10
 demonstrating that improvement of the inefficient transport of these drugs to 
the target is the key to improving their efficacy.  
 
The transport and interactions of cisplatin and other platinum based drugs into and within 
cells are still not fully understood. However, based on previous work 
10
 we can assume that 
the majority of the administered drug, once it has entered the cell, is found in the cell cytosol. 
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Prior to entering the cell it is estimated that anywhere between 60-95% of the drug is 
involved in quasi-irreversible binding to human serum albumin (HSA). 
63
 The most simplistic 
route from blood to nuclear DNA involves the passive diffusion of cisplatin into the cell from 
the extracellular fluid, where the Cl
-
 concentration is high (> 100 mM), into the cytoplasm, 
where the Cl
- 
concentration is low (4-20 mM). 
64
 The low Cl
-
 concentration in the cytoplasm 
results in the solvation of cisplatin to its active forms [Pt(NH3)2(OH2)Cl]
+
 and 
[Pt(NH3)2(OH2)2]
2+
 
65
 which bind to nuclear DNA forming crosslinks between the purine 
bases forming Pt-DNA adducts, see Figure 6. The solvation of cisplatin has been investigated 
both experimentally 
66
 and theoretically indicating that the strong electrostatic interactions 
resulted in  cisplatin being a strong donor and acceptor of hydrogen bonds and that when 
cisplatin interacts with water it behaves in an aliphatic manner, as it can form strong 
hydrogen bonds as both a donor and acceptor.
65
 
2+
 
A) 
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Figure 6: A) The solvation of cisplatin in the cell, B) the interaction of cisplatin with GG bases and AG bases  
In its activated solvated form, cisplatin interacts with a plethora of non-DNA ligands; it is 
thought that the most likely sites for cisplatin interaction are the thiol groups of intracellular 
peptides and proteins; it is these interactions that are thought to be responsible for 
chemoresistance and many of the side effects. 
67, 68
 It is widely thought that the inefficient 
transport of cisplatin to the nucleus is attributed to the two most abundant sulfur containing 
peptides in the cell cytosol, glutathione (GSH) and methionine, and it has been estimated that 
approximately 60% of the total cellular platinum concentration is associated with GSH 
binding. 
69
 Recent studies have shown that the activated form of oxaliplatin forms very stable 
complexes with glutathione (GSH). 
68,
 
70
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Despite a large catalogue of evidence to suggest that cisplatin binds selectively to sulfur 
containing peptides within the cell cytosol, there has been very little investigation into the 
mechanisms by which this occurs and whether these complexes are energetically favourable. 
Whether glutathione plays a key role in increased sensitivity to cisplatin is still in debate with 
early studies showing that cancer cell lines resistant to cisplatin showed elevated levels of 
GSH 
71-73
, suggesting that GSH plays a protective role against the genotoxic effect of 
cisplatin. 
74
 Whilst other work has reported no correlation between the cellular levels of GSH 
and the cytotoxicity of platinum based drugs. 
75
 One possible mode of action for the decrease 
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in cisplatin cytotoxicity due to increased GSH levels is the inhibition of reactive oxygen 
species (ROS) generation and mitogen activated protein kinases (MAPK) activation, which 
are involved in cell apoptosis, proliferation, survival and differentiation. 
76
 Nephrotoxicity is 
believed to be caused by the production of glutathione S-conjugates with platinum, catalysed 
by gamma-glutamyl transpeptidase (GGT) and cysteine S-conjugate beta lyase. 
77-79
 
 
The use of carnosine as an anti-cancer therapeutic agent has been discussed by Gaunitz and 
Hipkiss. 
80
 The discussion focussed on carnosine as an anti-neoplastic agent in the treatment 
of brain tumours. The study was conceived on the evidence that carnosine inhibited the 
growth of glioblastoma-derived cells; this fact prompted an alternative route of 
administration, intranasal, which avoided bio-transformation of carnosine by carnosinase in 
the plasma. 
80
 Also, the blood brain barrier is often damaged in patients suffering from 
glioblastomas and it is debated whether carnosine is able to penetrate the blood brain barrier 
through uptake by PepT2. 
80
 Despite no experimental data being presented, the argument that 
carnosine would be a potential drug for gliobastoma treatment was well presented and 
considered, side-effects, dosage and bio-availability were discussed in detail.  
 
Iovine et. al. 
81
 presented a study which described the effect of carnosine on the growth of 
Kirsten rat sarcoma viral oncogene homolog (KRAS)-mediated hematocrit (HCT) 116 
colorectal cancer cells. They found that the administered 50-100 mM of carnosine decreased 
the concentration of adenosine triphosphate (ATP) and ROS, and the KRAS-mediated 
colorectal cells increased the level of mitochondrial ROS, responsible for cell proliferation. 
Levels of ATP were measured by bioluminescence as carnosine levels were increased from 5 
to 300 mM, the results showed a decrease by 50 % in the level of ATP detected at 100 mM of 
added carnosine compared to the control, this result was representative of the results found by 
cell growth of the HCT116 cells. Cell proliferation measured by MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) analysis, a colorimetric analysis, 
was found to decrease by 50 % to 60% with 50 and 100 mM administered carnosine 
respectively. 
81
 The reduction in cell proliferation was concluded to be due to the inhibitory 
effect of carnosine on glycolysis, which is vital for tumour proliferation and survival. 
81
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Horii et. al. 
82
 conducted a similar study to Iovine et. al. 
81
, in which Horii et. al. investigated 
the effect of carnosine on splenic sympathetic nerve activity and tumour proliferation. 
82
 They 
found that intraduodenal injections of 3.3 mg/Kg of body weight of carnosine into urethane-
anaesthetised rats significantly decreased splenic sympathetic nerve activity; they also found 
that 1 mg/mL carnosine solution inhibited tumour proliferation in rats. 
82
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3 RESEARCH METHODOLOGY 
 
 
3.1 INTRODUCTION 
 
This chapter details the research methodology applied in this thesis. In this thesis research is 
defined as a structured enquiry that utilises acceptable scientific methodology to solve 
problems or generate new knowledge that adds to the existing body of knowledge. The 
scientific methodology employed was designed to ascertain and discover facts, by generating 
and finding evidence through experiments in the laboratory setting and reporting theories 
based upon the evidence generated to the wider scientific community.  
 
3.2 OBJECTIVES OF RESEARCH 
 
The main objective of research is to uncover answers to questions which were previously 
unknown through the application of scientific procedures. 
83
 Although each research thesis 
has its own specific research objectives, the objectives can be generalised into four distinct 
categories:  
1. To gain familiarity with a phenomenon or to achieve new insights into the 
phenomenon. 
2. To test for causal relationships between variables.  
3. To portray accurately the characteristics of a particular situation, individual or group. 
4. To determine the frequency with which something occurs or with which it is 
associated with something else. 
83
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3.3 TYPES OF RESEARCH 
There are many different ways to classify research, but by identifying the main characteristics 
of the different types of research it simplifies the classification. Table 2 outlines the 
classification of research types based upon the criteria outlined above. 
84
 
 
Type of Research Basis of Classification 
Exploratory, descriptive, analytical or predictive research Purpose of the research 
Quantitative or qualitative research Process of the research 
Applied or basic research Outcome of the research 
Deductive or inductive research Logic of the research 
Table 2: Classification of the different types of research. 84 
 
As this thesis focuses on the outcome of the research, the type of research undertaken in this 
thesis can be classified as applied research and not basic research. The development of a new 
theory or law is classified as basic research, whereas applied research assesses the relevance 
of new or existing theories under certain circumstances. Applied research is also employed to 
find an immediate solution to problems being faced by society, an entity or organisation. The 
central aim of applied research is to identify and find a solution to a pressing practical 
problem, whereas basic research aims to find new knowledge or information that adds to the 
already existing body of scientific knowledge.  
83
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3.4 SCIENCE METHODOLOGY 
 
This section will describe scientific research methodology as a whole. Research methodology 
is defined as the investigation of research methods, determining which research methods are 
relevant and why.  
 
Despite the controversial belief of a few notable scientists including the Nobel laureate, Sir 
Peter Medawar, that there is no such thing as ‘The Scientific Method’, 85 to neglect the 
general principles of scientific methods can be extremely detrimental to the progression of 
research. The principles of the scientific method are not widely taught; Sir Peter Medawar 
commented that  
 
“If the purpose of scientific methodology is to prescribe or expound a system 
of enquiry or even a code of practice for scientific behaviour, then scientists 
seem to be able to get along very well without it. Most scientists receive no 
tuition in scientific method, but those who have been instructed perform no 
better as scientists than those who have not.”  86 
 
However, it is believed that understanding the principles of scientific method enhances 
scientific productivity and technological progress.  
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3.4.1 SCIENTIFIC RESEARCH METHODS 
In this thesis scientific research method refers to all the methods/techniques used for 
conducting the research:  
1. Methods used for selection of samples and collection of data. 
2. Statistical techniques used for establishing relationships between relevant variables. 
3. Methods used for evaluating the accuracy of the results obtained. 
 
A classical scientific approach was employed in order to conduct the research; this process is 
outlined in  
Figure 7.  
 
1. Observing a particular 
biological or physical 
phenomenon
2. Developing a hypothesis about 
the cause of the phenomenon
3. Designing an experiment to 
prove the hypothesis
4. Conducting the experiment to 
collect data
5. Analysis of the data to 
determine if the results prove or 
disprove the hypothesis
6. Reporting the 
results
 
Figure 7: The classical linear science method. 87 
 
3.4.2 FORMULATING THE RESEARCH PROBLEM  
In order to formulate the research problem, the problem needs to be thoroughly understood 
and translated into a meaningful task or series of tasks from an analytical point of view. This 
was achieved by undertaking a thorough survey of the literature and the MSc short course 
‘Atomic Spectroscopy’ was completed. Also during this initial stage a series of objectives 
were drawn up, these are summarised below: 
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1. Review current advances in analytical methods for the measurement of phosphorus-
containing bio-molecules by inductively coupled plasma mass spectrometry (ICP-
MS). 
2. Develop capabilities for the accurate quantification of phosphorus at low ppb levels in 
biological matrices by ICP-MS in transient signal mode.  
3. Investigate the performance of methods used for phosphorus quantification in 
biological matrices. 
4. Develop a micro or capillary high performance liquid chromatography HPLC method 
for the separation of DNA nucleotides assisted by ultra-violet-visible (UV-VIS) 
detection. 
5. Develop a HPLC-ICP-MS method for the accurate quantification of P-containing bio-
molecules. 
 
3.4.3 DEVELOPING WORKING HYPOTHESIS 
The working hypothesis is formulated to draw out and test the logical or empirical 
consequences of the research. It serves to sharpen the understanding of the problem and focus 
attention to the important aspects of the problem. It also helps to identify the type of data 
required and which methods of data analysis are appropriate. An ideal hypothesis is 
extremely specific and limited to the research problem so that it can be readily tested.  Three 
hypothesises were generated related to the three areas of enquiry. These were: 
1. Accurate quantification of DNA can be achieved by the digestion of whole DNA 
into its individual nucleotides and analysed by LC-ICP-MS. 
2. Quantification of a wide range of phosphopeptides can be achieved by tagging the 
phosphopeptides with lysine nitrilotriacetic acid gallium and analysing by LC-
ICP-MS.  
3. The binding of oxaliplatin to proteins within the cell is partly through the nitrogen 
rich amino acid residues within that protein.  
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 3.4.4 PREPARING THE RESEARCH DESIGN 
Preparing the research design refers to the process used to determine the methods and 
techniques used to collect data, evidence and information and the methods used to analyse 
and evaluate the data.  The techniques used to collect data are explained in more detail in 
Chapter 4, but briefly the techniques used to collect data were, HPLC coupled to both 
molecular mass and elemental mass spectrometers and fragmentation mass spectrometry. It 
was proposed that the data collected would be compliant with the requirements of standard 
statistical methods.  
 
3.4.5 COLLECTION AND ANALYSIS OF DATA 
There are 3 common methods of data collection used in collection of data for a research 
thesis; these are qualitative methods, quantitative methods and mixed-mode methods. A 
quantitative approach is one in which the researcher primarily uses measurement and 
observations to test theories. The researcher typically uses experiments and surveys to collect 
data on predetermined instruments that yield statistical data. 
88
  A qualitative approach is one 
in which the researcher makes a conclusion based upon individual or multiple experiences 
with the intent of developing a theory, pattern or perspective. Methods used in a qualitative 
approach include case studies, narratives, ethnologies and grounded theory studies. The data 
collected tends to be open-ended with the primary intent of developing themes from the data. 
88
 A mixed mode approach is one in which the researcher makes a conclusion based on 
pragmatic grounds. In the mixed mode approach both numeric information, from instruments 
and text information and from interviews is collected simultaneously or sequentially in order 
to understand the research problem.  
 
In this thesis a quantitative approach was used to gather data to answer the research problem. 
Following data collection, statistical and mathematical techniques including correlation, 
regression and analysis of variance (ANOVA) analysis were applied to support the outcomes 
of the research.  
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3.4.6 TESTING OF HYPOTHESIS 
Once the data were collected and analysed the initial hypotheses drafted in the early stages of 
the research were tested. The question asked was ‘do the findings support the hypothesis or 
are they contrary to it?’  
3.4.7 REPORTING RESULTS 
The real value in research lies in the ability to interpret the findings, which may lead to new 
theories, laws or principles in a particular context and to report these to the wider community. 
There are several ways of reporting research findings, the findings of the research conducted 
in this thesis were reported in scientific posters at an international conference ‘The Winter 
Plasma Conference’, Graz, 2009, a national conference ‘The 5th Nucleic Acids Forum’, 
Bristol, 2009 and on the National Measurement Institute website. It has been reported at a 
scientific conference as a verbal presentation, the Biennial National Atomic Spectroscopy 
Symposium, Brighton, 2008. The research has also been reported in the three journal papers 
summarised in Chapter 1 and a 4
th
, that draws on some of the methodology developed in this 
thesis is in preparation for publication. 
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4 INSTRUMENTATION 
 
 
4.1 INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY (ICP-MS) 
 
ICP-MS is a mass spectrometry technique used in the analysis of elements at ultra-trace 
levels. This analytical technique can provide multi-element analysis, high sample throughput 
and isotope ratios, it is highly sensitive, selective and quantitative over a large linear range. 
89-
91
 In addition to these characteristics ICP-MS is compatible with several sampling techniques 
including solution sampling, laser ablation and chromatographic techniques. 
92-94
 ICP-MS 
generates positive ions from a solution of an analyte(s) by a high-temperature plasma, which 
provides efficient ionisation and atomisation of the analyte.  These positive ions are detected 
by various methods depending upon the design of the mass spectrometer. The main principles 
of operation are summarised in Figure 8.  
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Analyte solution, typically in a 
mineral acid, in the ppt-ppb range. 
Analyte solution converted to 
fine aerosol by nebuliser. 
Larger aerosol droplets filtered 
out by spray chamber
Analyte atomised and ionised 
by plasma
Ion stream focused by optical 
lenses
Ions selected by mass-to-charge 
ratio by various methods 
depending on instrument
Ions detected and signal intensity 
reported 
 
Figure 8: Basic principle of the mode of ICP-MS operation. 
 
The sample solution containing the metal(s) or non-metal(s) of interest is drawn into a 
nebuliser, where it is converted to a fine aerosol with argon gas. The most widely used 
nebuliser is the concentric nebuliser which has a central capillary through which the sample is 
drawn. A stream of argon gas is introduced concentrically to the sample solution which 
breaks the sample into droplets due to the dynamic action of the gas as it meets the sample. 
95
 
Larger aerosol droplets are separated from the finer droplets by a spray chamber; the aerosol 
is introduced into the plasma torch by an injector. 
91
 The plasma is a partially or fully formed 
ionised gas, generated at atmospheric pressure by the interaction of an intense alternating 
current gives rise to a magnetic field on a flow of argon gas. 
91
 The magnetic field is 
generated by a radiofrequency wave passing through a copper coil, the radio frequency (RF) 
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generator is operated between 1100-1500 W, which ionises the gas which is seeded with 
electrons from an electrical spark and generates the high-temperature plasma. The high-
temperature (6000-7000 K in the central channel) plasma generates high numbers of 
positively charged ions by ionising and atomising the metal/non-metal atoms in the sample 
aerosol.  
Figure 9 shows the different region of the plasma in which the sample aerosol is dried, 
vaporised, atomised and ionised.  
  
 
 
 
 
 
Figure 9: Formation of the inductively coupled plasma, showing the different temperature regions. 
 
Once the ion stream is generated in the plasma, ions are directed into the mass spectrometer 
through a sampler and skimmer cone that form the interface region, maintained at 1-2 mbar 
by a roughing pump. 
91
 The interface region allows the ions to be transported efficiently from 
the plasma at atmospheric pressure to the mass spectrometer at typically 7x10
-6
 bar. The ion 
optics direct the positive ion beam towards the mass spectrometer, these electrostatic lenses 
focus the ion beam and stop photons and neutral atoms reaching the detector. The ion beam 
then enters the mass spectrometer region, maintained at a vacuum of around 10-
7
 mbar by a 
turbomolecular pump. The most commonly used mass spectrometers are quadrupoles, 
magnetic sectors and time of flight spectrometers. They all work in different ways and have 
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their own advantages and disadvantages, but their function is to allow ions of a particular 
mass-to-charge (m/z) ratio through to the detector. 
 
Finally the ion beam is converted into an electrical signal by the detector. The most common 
detector is an electron multiplier, which consists of a series of metal dynodes the length of the 
detector. Ions from the mass spectrometer collide with the first dynode and converted to 
electrons; the electrons are attracted to the next dynode and so on along the length of the 
detector.
91
 This results in a very high pulse of electrons being emitted from the final dynode 
which is transformed into an electrical signal and processed into an analyte concentration.  
 
4.1.1 HIGH RESOLUTION ICP-MS 
Whilst quadrupole instruments typically have a resolution of 300, high resolution mass 
spectrometers have mass resolution capabilities in the region of 10,000. 
91
 The improved 
resolution allows signal’s from elements to be separated from those resulting from 
polyatomic interferences. As a high resolution sector field mass spectrometer was the primary 
instrument used it will be discussed in further detail. The reverse Nier-Johnson design (shown 
in Figure 10) consists of two analysers, a traditional electromagnetic analyser and an 
electrostatic analyser (ESA). Ions are accelerated to a few kilovolts (kV) in the ion optic 
region before entering the magnet. Ions are focused in the magnetic field, which disperses 
ions based on their momentum and mass.  The ion beam then enters the ESA, which is 
dispersive with respect to ion energy. 
91
 The ions are focused onto the exit slit, where the 
electron multiplier detector is positioned. When the energy dispersion of the magnet and the 
ESA are equal in magnitude but in opposite directions, the ion beam is focused in both ion 
angle and ion energy. 
91
  Ions of certain m/z are selected when the electrical field is changed 
to the opposite direction during the cycle time of the magnet. Once a certain magnetic field 
strength is passed, the electric field strength returns to its original value and the next mass is 
frozen.  Scan times are slower than quadrupole instruments, but time can be saved by only 
scanning the mass peaks of interest by varying the voltage.  
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Figure 10: Diagram of the reverse Nier Johnson magnetic sector instrument. 91 
 
There are two main scan functions used with double-focusing mass spectrometers, a voltage 
scan (E scan) and a magnet scan (B scan). An E scan is a fast scan where the magnet field 
strength is constant at a fixed magnet mass and the voltage varied across a limited portion of 
the mass range.  The magnetic scan (B scan) is the opposite where the accelerating voltage is 
kept constant and the magnet jumps between masses by changing the current in the magnet 
coils.  It is a slower scan than the E scan but is not limited in range. 
91
 A combination of the 
two modes are used to make routine scans; all analysis (across a peak) and mass selections 
(mass jumps) are made by changing the accelerating voltage unless the measured mass lies 
outside the 30% range at which point the magnet moves to and settles at a new magnet mass 
and the electric scan begins again. 
91
 Polyatomic interferences can be removed by filtering 
Detector 
Exit slit 
Electrostatic 
analyser 
Magnetic 
analyser 
Plasma Focussing and 
accelerating optics 
Entrance slit 
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ions through optics and slits to achieve variable resolutions from 300 to 10,000 resolving 
power.  
 
4.1.2. COLLISION/REACTION CELL ICP-MS 
The collision reaction cell technology of the Agilent 7500ce removes interferences by using 
differences in the kinetic energy of small charged ions and larger charged molecules. A single 
set of cell conditions is capable of removing interferences on multiple elements. Removal of 
interferences takes place in a pressurised octopole reaction system (ORS), the cell is 
pressurised with a collision gas such as helium that reacts with the interference. Removal of 
the interfering species occurs through one of several processes depending on the reaction gas 
and interference. In the helium collision mode, polyatomic interferences are removed due to 
their size rather than their relative reactivity with a reactive gas. As all polyatomic 
interferences are larger in size than the analyte ion of similar mass they will collide more 
often with the collision gas. These collisions lead to a decrease in energy of the polyatomic 
ions as they move through the collision cell.  When the polyatomic ions reach the cell exit 
they have significantly lower ion energy than the analyte ions and can be prevented from 
leaving the cell by applying a stopping voltage. This type of separation is called kinetic 
energy discrimination (KED). The advantages of this type of interference removal is that the 
collision gas is inert therefore does not create any new interferences, no signal loss occurs as 
helium does not react with the analyte ions and several interferences can be removed from the 
analyte ion(s) at the same time. Other advantages include ease of use, there are no cell 
voltages to set up or optimise and the same cell conditions can be applied to every sample, 
every matrix with little being known about the sample matrix. In order for the collision cell to 
work effectively in He mode, the energy spread of the ions entering the cell must be small 
and the polyatomic ions must have a sufficient number of collisions to differentiate them 
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from analyte ions. The first of these two conditions is realised by having a physically 
grounded torch shield rather than an electrically grounded one. The second condition is 
realised by having an octopole cell, octopoles have a smaller diameter this allows the cell to 
operate a higher pressure than would be possible with a quadrupole or hexapole cell due to 
smaller entrance and exit cell aperture’s.  Octopoles also have better focussing efficiencies 
than hexapoles and quadrupoles.  
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4.2 ELECTROSPRAY MASS SPECTROMETRY – LINEAR ION TRAP 
MASS SPECTROMETER 
 
Molecular mass spectrometry offers complementary information to that gained during ICP-
MS analysis as structural information is retained. Linear ion-trap instruments have been used 
widely in the analysis of peptides and nucleic acid sequences. 
96-98
 Figure 11 shows a 
schematic diagram of a typical ion-trap instrument used as the primary molecular mass 
spectrometer in this research. As shown in the schematic the mass spectrometry used in this 
research consisted of an electrospray ionisation source, ion optics and a mass analyser to 
isolate ions of interest and a photomultiplier detector system. The following processes are 
carried out by the mass spectrometer:  
1. Production of ions from the sample in the ionisation source. 
2. Separation of these ions according to their mass-to-charge ratio in the mass 
analyser. 
3. Fragmentation of the selected ions and analysis of the fragments in a second 
analyser. 
4. Detection of the emergent ions from the last analyser and measurement of their 
abundance to convert into an electrical signal. 
5. Control of the instrument by feedback from the computer based on the signal 
transmitted from the detector. 
99
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Figure 11: Schematic diagram of a linear ion trap mass spectrometer. 
 
 
4.2.1 ELECTROSPRAY IONISATION 
Electrospray ionisation (ESI) is widely used for the ionisation of bio-molecules that are often 
highly charged and polar and was the ionisation source used in this research. A strong electric 
field at atmospheric pressure is applied to a liquid passing through a capillary tube in order to 
create the electrospray. 
99
 At the capillary end a charge accumulation is induced at the liquid 
surface by the electric field, which causes highly charged droplets to break from the liquid 
surface. A Taylor Cone is formed when the charge accumulation at the surface is great 
enough to breach the surface tension. Dispersion is controlled by a heated coaxial gas stream 
at a low flow rate. The droplets then pass through a heated capillary to remove the last of the 
solvent. A schematic is shown in Figure 12.  
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Figure 12: Electrospray ionisation source using a heated metal capillary for ion de-solvation and transfer. 
 
The process by which charged droplets generate ions is the central question in electrospray 
theory. There have been two theories presented; one by Thomson and Iribarne 
100
 known as 
the ion evaporation mechanism (IEM) in which small highly charged droplets are formed 
from the explosion of larger droplets due to Coulombic forces. The second theory is known 
as the charge residue model (CRM) put forward by Dole. 
101, 102
 
 
In the ion evaporation model, droplets produced at the capillary tip shrink due to evaporation 
of the solvent, when the field strength at the droplet surface is large enough solvated ions can 
be expelled. 
101, 103
 Energy required to enlarge the droplet at the surface and to expel a 
solvated ion is provided by the strong electric field at the surface. In the charge residue 
model, the highly charged droplet shrinks due to solvent evaporation until the field strength at 
the greatest point of curvature is large enough to cause the formation of a new Taylor Cone. 
At the tip of this new Taylor Cone smaller droplets are emitted, this process is repeated until 
droplets are formed that contain a single analyte molecule. 
104
 Larger molecules such as 
proteins will not desorb but are freed as the solvent is evaporated and are often multiple 
charged if they have more than one ionisable site. 
99
 The generation of multiple charged ions 
is advantageous with improved sensitivity at the detector and allowing the detection of larger 
molecules with mass spectrometers of lower nominal mass limit.  
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The Rayleigh equation is used to describe the liquid droplet’s structural integrity once 
airborne in relation to its surface tension and the electrostatic repulsion from the solvated ion. 
Due to evaporation the Rayleigh limit is reached as the charges become closer together 
increasing the repulsion between them. When the Rayleigh limit is reached the droplet 
undergoes Coulombic explosion splitting into daughter droplets and the process begins again.   
Figure 13, shows the difference in droplet formation by the two different models described 
above.  
           
  
Equation 1: Rayleigh equation for the limiting charge. 105, 106 
 
q = Rayleigh limit 
ε0 = permittivity of vacuum (F m
-1
)  
γ = liquid surface tension (N m-1)  
D = Diameter of the droplet (m)  
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Figure 13: A - The ion evaporation process, an individual ion leaves the charged droplet. B - The charged residue 
model. A charged molecule reduces in size due to evaporation, a new Taylor cone forms from which smaller highly 
charged droplets are emitted. 
 
4.2.2 LINEAR ION TRAP MASS ANALYSER 
Ions are transmitted via the heated transfer capillary to the mass analyser. The ions are 
focussed by the tube lens and then pass through the skimmer cone, which helps step down the 
pressure between the interface and the mass analyser. 
107
 After passing through the skimmer 
cone the ions travel through a series of ion guides and lenses guided by two quadrupoles and 
an Octopole to the mass analyser. The first two quadrupoles consist of four square profile 
rods with DC and RF voltages applied. Ions with a stable path pass through the first 
quadrupole, and then are guided to the second quadrupole by a lens. The ions are finally 
guided to the Octopole by the gate lens to the mass analyser. It is the gate lens that controls 
the number of ions injected into the mass analyser.  
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The linear ion trap confines ions by using an oscillating electric field, it uses a two-
dimensional radio frequency field to trap ions and reflect the ions back into the trap axially by 
a stopping potential applied to electrodes. 
99, 108
 Collisions with an inert gas cool the ions 
which travel along the z-axis between the end electrodes whilst oscillating in the xy plane due 
to the RF potential. 
99
 Linear ion-traps have several advantages over 3D Paul ion traps, 
including higher ion trapping capacity and higher ion volume capacity. Space charge effects 
result in the repulsion of ions of like charges and result in broad peaks, loss of resolution and 
reduced sensitivity. 
109
 Collisions with He gas reduce axial dispersion giving greater injection 
efficiencies than their three dimensional quadrupole trap counterparts. 
109
 These attributes 
increase both the sensitivity and dynamic range of the mass analyser. 
99, 108
 The Thermo LTQ 
trap ejects ions radially through two parallel slots (see  
Figure 14) into two detectors which further increases the sensitivity.  
 
 
 
 
 
 
 
 
 
 
Figure 14: Linear trap, with slots in opposite rods for radial ion ejection to two detectors. 
D1 
D2 
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Segmented quadrupoles are used rather than trapping by end electrodes to avoid producing 
fringe fields, the rods are cut into three sections, two smaller end sections and a longer central 
section, the ions are trapped by applying a DC voltage to the end sections. Ions are trapped in 
the central section which has a lower potential than the two end sections. A large potential 
well is created during the analysis in the central quadrupole section by an increased potential 
of +20 V on the two end sections. Negative ion storage is obtained by reversing the 
potentials. 
107
 Ions are ejected in a radial direction by applying an AC voltage between the 
two rods.
107
 The AC voltage remains constant, in the radio frequency range, the amplitude is 
varied to store and eject ions. To store ions, they are kept stable by making the main RF 
voltage low; during analysis the ions become unstable as the RF potential is ramped up at a 
constant rate. Once the ions become very unstable they are ejected through the exit rods. The 
voltage at which an ion of defined m/z is ejected is known as the resonance voltage. The 
ejected ions are then directed to the electron multiplier detectors. 
107
 
 The storage, isolation and fragmentation of ions and scan events are outlined below.  
i) Ion storage 
 DC voltages applied to all three sections of the rods the central section has 
lower voltage than the ends to create a potential well and trap ions in the 
axial (z) direction. 
 The main RF amplitude is low; the ions are kept stable in the radial (xy) 
direction and confined in the mass analyser. 
107
  
 
ii) Ion isolation 
 Used for single ion monitoring (SIM), selected reaction monitoring 
(SRM), consecutive reaction monitoring (CRM) and general tandem MS. 
 An AC voltage is applied to the exit rod (ion isolation waveform). 107 
 Ion of selected m/z is trapped by the main RF and ion isolation waveform; 
all other ions are ejected from the trap.  
 
iii) Collision/Fragmentation 
 Used for SRM, CRM and MSn.  
 Ion movement in the radial direction is controlled by applied voltages 
(resonance excitation voltages). 
107
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 This voltage causes ions to collide with He, but not sufficient for ions to be 
ejected.  
 The parent ion fragments into daughter ions due to the collisions with He.  
iv) Ion Scan Out 
 Ions are ejected due to the applied resonance ejection RF voltage to the 
exit rods. 
107
 
 The amplitude of the resonance ejection RF voltage is ramped up to 
resonate the ions. 
107
 
 During resonance the ion moves further away from the centre of the trap. 
The further away from the centre, the smaller the space charging effects, 
also the RF voltage is stronger which causes the ions to be ejected. 
107
 
 
The ion-trap allows ions with defined m/z to be stored, fragmented and then transmitted to 
the detector. Structure elucidation is achieved due to the collision of the analyte ions with He 
gas, unlike ICP-MS where fragmentation and secondary reactions are avoided. 
99
 MS/MS 
experiments involve two stages of ion selection and fragmentation followed by the analysis 
of the daughter ions. However, these stages can be repeated n times in MS
n
 in order to gain 
detailed structural information. He gas also induces collisional focusing; the kinetic energy of 
the injected ions is reduced in the ion trap preventing them from leaving the trap, but keeping 
them near the centre of the quadrupole. 
99, 107
 This has the effect of increasing sensitivity.  
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4.2.3 SCAN MODES 
The mass spectrometer used in this research can obtain information on a particular ion by 
several different scan modes including, full scan mode, single ion monitoring (SIM), selected 
reaction monitoring (SRM), consecutive reaction monitoring (CRM) and zoom scan.  
 
Full scan mode detects all ions within a set m/z range; all parent ions are sequentially ejected 
out of the ion trap and detected. This mode is useful for gaining a lot of information about the 
sample but lacks sensitivity and is slower than other scan types. 
107
 
 
In a SIM scan only ions of a selected m/z are detected resulting in faster acquisition and 
increased sensitivity compared to full scan mode. Parent ions of interest are stored in the ion 
trap and all other ions are scanned out of the mass analyser. SIM has poor specificity as if 
another compound other than the analyte of interest forms a parent ion of same m/z as the 
analyte they will be detected alongside the analyte. 
107
 
 
In a SRM scan parent ions are stored in the ion trap; whilst all other ions are scanned out, the 
parent ion of interest undergoes fragmentation with He gas to form daughter ions. The 
daughter ions of interest are then stored in the trap whilst all other daughter ions are ejected. 
A selected reaction monitoring mass spectrum is then generated by scanning out the daughter 
ions of interest. A SRM scan is more specific than a SIM scan as it is highly unlikely that an 
unwanted parent ion will form daughter ions of the same m/z as those belonging to the 
analyte. 
99, 107
 
 
A consecutive reaction monitoring (CRM) scan is similar to both a SIM and SRM but 
involves more MS steps provided MS
n 
can be achieved. As with SIM and SRM parent ions 
are stored in the trap whilst all other ions are scanned out of the mass analyser. The parent ion 
of interest then undergoes fragmentation with He gas to form daughter ions. The daughter 
ions of interest are then stored in the trap whilst all other daughter ions are ejected from the 
trap. The selected daughter then becomes the parent ion which is further fragmented to give 
new daughter ions; this process is repeated up to MS
10
 and as such has increased specificity. 
A CRM mass spectrum is only generated after the final mass analysis step, where the selected 
daughter ions are scanned out of the ion trap. 
107
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A high resolution zoom scan enables the molecular weight and charge state of an ion to be 
determined by analysing 
12
C/
13
C isotope separations. This scan type can allow the molecular 
weight of an unknown compound to be calculated.  
 
4.2.4 EXPERIMENT MODES 
As with scan types there are several different experimental modes available with this type of 
mass spectrometer, including general MS and MS
n
 , data dependent, ion mapping and ion 
tree. In general MS experiments only the mass(es) of the parent ion(s) need to be known 
whereas for MS
n 
experiments the masses of both the parent and daughter ions need to be 
known. The greater the number of stages of mass analysis the more information about the 
analyte is found. 
107
 
 
When very little is known about the analyte, very detailed structural information can be 
gained from a data dependent experiment. The most abundant parent ions are selected by the 
ion trap whilst minor parent ions are ejected.  The trapped parent ions are then fragmented 
and the most predominant daughter ions can then be trapped and fragmented further, within a 
defined mass range. 
107
 Parent ion masses can be specified and the ions selected and 
fragmented to give product ion mass spectra whilst unwanted parent ions can be specified and 
ignored. This type of experiment gathers detailed MS information on each mass analysis 
stage. 
107
 
 
Ion tree experiments can be data dependent where the instrument decides the next stage of the 
experiment by collecting and analysing the data, or the parent ion of interest can be specified 
for MS
n
. 
107
 A set number of MS experiments is performed by the instrument before moving 
onto the next most intense parent ion and performing the defined number of MS experiments 
on that ion, then onto the next most intense ion and so on, this is known as ‘depth focus’. 
Breadth focus will perform MS on all the specified parent ions and then move onto the next 
level of MS and analyse the product ions. 
107
 
 
Ion mapping experiments enable unknown compounds in a mixture to be analysed and 
characterised in detail. There are three main types of ion mapping experiments; total ion map, 
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parent ion map and neutral loss. 
107
 In a total ion map experiment, product ions scans are 
acquired, so that which parent ions were fragmented in order to produce specific product ions 
can be determined. In a parent ion map experiment the parent ions that produced specific 
product ions are identified. A neutral ion loss experiment provides evidence that a neutral 
fragment loss has occurred. As neither ion mapping nor ion tree experiments were carried out 
during this research the specific details have been omitted but can be found elsewhere. 
99, 107
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4.3 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
 
High performance liquid chromatography refers to the method for separating compounds 
based upon the interactions of each analyte within the liquid mobile phase with the stationary 
porous phase. The interaction of the analytes with the stationary phase is dependent on their 
structure, namely their size and polarity due to the presence of charges, polar groups or 
moieties. In the case of reverse phase high performance liquid chromatography (HPLC) the 
mobile phase is a liquid usually consisting of a polar (water) phase and a less polar phase 
(methanol or acetonitrile) and the stationary phase is a column filled with porous particles 
that are predominantly non-polar. The components that make up a HPLC system are as 
follows; an injection port, a pump which delivers the mobile phase, a stationary phase where 
the separation occurs and a detector. Various detectors can be coupled to the HPLC system 
including UV, fluorescence, refractive index, evaporative light scattering and electrochemical 
detectors as well as mass spectrometers. 
110
 The choice of stationary phase is dependent on 
the polarity of the analytes for separation, where the polarity of the stationary phase is 
roughly matched to that of the analytes and the mobile phase is different to both the analyte 
and stationary phase. 
110
 The ability of the column to separate two analytes is measured by 
the resolution (Rs), which is given by the relationship between the retention time (tR) and the 
width (W) of two consecutive peaks from two different specieas A and B, as shown by 
Equation 2, where retention time is defined as the time from injection of the analyte onto the 
column to detection at the detector. The rate of migration for an analyte through the column 
is referred to as the retention factor, k’ and is given by Equation 3, where tM is the time taken 
for the mobile phase to travel through the column.  
 
    
 [(  )  (  ) ]
      
 
Equation 2:  The resolution of two peaks is calculated from the difference in retention time of the two peaks divided 
by the combined widths of the eluted peaks. 
 
Instrumentation  Claire Camp 
4-20 
     
      
  
 
Equation 3: The equation used to determine the retention factor of an analyte based on its retention time and the 
time taken for the mobile phase to travel through the column. 
 
Resolution can be improved by lengthening the column therefore increasing the number of 
theoretical plates but this causes an increase in the retention time. Theoretical plates are used 
to describe the efficiency (N) of the column which is a measure of the peak width. The 
sample equilibrates between the mobile phase and each individual plate as it moves down the 
column. The number of theoretical plates, N, in a column is determined experimentally by 
examining the chromatographic peak, its peak width and retention time. N is given by 
Equation 4, where w
1/2
 is the peak width at half height.  
 
   
       
 
    
  
Equation 4: The number of plates can be calculated from the retention time and peak width. 
 
The rate at which an analyte moves through the column is determined by the rate at which it 
equilibrates between the mobile and stationary phases, and as such the resulting shape of the 
chromatographic peak is related to the rate of elution. The peak shape is also affected by the 
path through the column; these effects cause the peak to broaden in an effect known as band 
broadening. The Van Deemter equation (Equation 5) describes the effect of band broadening 
on the theoretical plate height (HETP). 
 
          ⁄     
Equation 5: The Van Deemter Equation describes the effects of band broadening in relation to the number of paths 
taken, the longitudinal diffusion and the rate of absorption and desorption. 
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Where A is the eddy diffusion, B is the longitudinal diffusion, C is the resistance to mass 
transfer and u is the average velocity of the mobile phase. The different paths the analyte 
molecules can take through the column result in different path lengths which gives rise to 
eddy diffusion. B describes the difference between the concentrations at the end and centre of 
the band. The concentration of the analyte at the end of the band is less than it is at the centre 
of the band and the longer the analyte spends on the column the greater the width of the band 
will become. Mass transfer refers to the time taken for the analyte to equilibrate between the 
stationary and mobile phase. If the analyte has a strong affinity for the stationary phase and 
the mobile phase is moving at a high rate then the analyte in the mobile phase will move past 
the analyte in the stationary phase, resulting in band broadening. 
110
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5 RESEARCH UNDERTAKEN AND KEY FINDINGS 
 
 
5.1 INTRODUCTION 
 
This section describes the main activities over the five years of the research programme and 
the findings of the research. The process is described in terms of experiments carried out in 
each theme, findings and outputs. The chapter should be read in conjunction with the 
published papers referenced throughout the text (see appended papers A1-A3).  
 
5.2 OVERVIEW  
 
The first four months of the research were spent gaining a broad understanding of the subject 
area by conducting an in-depth literature review on the quantification of DNA by ICP-MS 
and the enrichment and analysis of phosphopeptides.  
 
During the first two years of the research preliminary experiments were carried out on the 
enrichment of phosphopeptides using commercially available enrichment kits and tips, HPLC 
method development for the separation of nucleotides and  completing MSc modules (60 
credits) in Engineering Management and Innovation as part of the EngD programme. This 
meant that approximately 20% of the researcher’s time was spent at Loughborough 
University, undertaking different MSc modules, coursework and exams. The modules 
selected facilitated a better understanding of bio-analytical chemistry, atomic spectroscopy, 
management techniques and people skills, management and professional development and 
research innovation and communication skills. During this time period the Research Engineer 
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(RE) supervised several project students, providing training, and mentoring as part of the 
RE’s continued professional development. Two conferences were attended where the RE 
presented research results orally (BNASS 2008, Brighton) and in poster format (Winter 
Plasma Conference, 2009, Graz).  
 
The third year and the first part of the fourth year of the research was spent developing and 
validating the method for the quantification of DNA by ICP-MS, resulting in the first 
publication at the end of the fourth year. Also during this time period a further two project 
students were supervised by the RE and the RE presented research findings in poster format 
at the Nucleic acid forum (Bristol, 2010).  The second half of the fourth year was spent 
developing the labelling of phosphopeptides with gallium, the method was finalised in the 
first half of the fifth year, and research findings were sent for publication at the end of the 
fifth year. Also during this time period an in-depth literature review of the interaction of 
proteins and peptides with anti-cancer drugs was conducted and data was collected for the 
interaction of the anti-cancer drugs; cis-platin, oxaliplatin and carboplatin with the 
endogenous peptides carnosine and anserine. The research activities are summarised in 
Figure 15.  
Research Undertaken and Key Findings  Claire Camp 
5-3 
 
Figure 15: Overview of the research activities during the EngD programme. 
 
 
 
Research activities and preliminary work  2008 -2010 
• Completion of in-depth literature review 
• Completion of taught EngD programme 
• Preliminary experiments for research themes 1 and 2 
•  Research findings reported at two conferences 
 
 Method development  
2010-2012 
• Separation of nucleotides by HPLC-ICPMS achieved and validated 
• Tagging of phosphopeptides with galium preliminary work completed 
• Research findings reported at one conference 
Research finalisation and publication 2012-2013 
• In depth literature review for research theme 3 
• Data collection for research themes 2 and 3 
• Publication of research findings in academic journals  
Research Undertaken and Key Findings  Claire Camp 
5-4 
5.3 QUANTIFICATION OF DNA BY LC-ICPMS 
 
5.3.1 INTRODUCTION 
The aim of the research was to develop a LC-ICP-MS method for the quantification of DNA 
from an enzymatic digest of whole DNA to monophosphate nucleotides. An assay for the 
quantification of DNA would benefit many clinical diagnosis and forensic and biological 
studies. 
32
 Quantification of DNA is also important in the labelling of food stuffs; these 
measurements are needed in the determination of transgenic material in animal feed. 
European law requires labelling of imported foodstuffs containing more than 0.9 % 
transgenic material. 
111
 This is important for America which is the world’s largest exporter of 
agricultural wares and prepared foodstuffs. 
32
 The increase in genetically modified crops 
grown in America has increased the demand for a reliable analysis technique for a nucleic 
acid certified reference material. 
32
 Currently these measurements are made using real time 
PCR measurements. 
112
 This work was carried out in collaboration with Dr Heidi Goenaga-
Infante and Dr. John Entwistle from the sponsoring company LGC Ltd.  
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5.3.2 RESEARCH UNDERTAKEN 
The overall work-flow for the quantification of DNA is shown in  
Figure 16.  
 
 
 
 
 
 
 
 
Figure 16: Proposed quantification of calf thymus DNA work-flow. 
 
Each stage in the work-flow was developed and verified using standard analytical 
methodology. These stages were: 
1. HPLC method development for the separation of mono-phosphate nucleotides. 
2. Compete digestion of calf thymus DNA to mono-phosphate nucleotides. 
3. Verification of digestion products by molecular LC-MS. 
4. Determination of the method limit of detection for LC-ICP-MS. 
5. Mass balance of phosphorus. 
Purified DNA  Quantify whole 
DNA by ICP-MS 
Digested 
Nucleotides 
Quantify by LC-ICP-MS 
using external calibration 
Mass balance 
calculation 
N
u
clease P
1
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6. Method validation against a CRM. 
7. Quantification of calf thymus DNA.  
Method development for the separation of nucleotides began with the search for the most 
appropriate column, mobile phase, column temperature and pH. The three columns initially 
selected for evaluation were: Supelco R16 Amide column, Agilent Zorbax RX column and 
the Phenomenex Gemini NX. The method chosen for the separation was ion-pair 
chromatography and the ion-pair reagents initially tested were tetra-methyl ammonium 
hydroxide (TMAH), tri-ethyl ammonium acetate (TEAA) and ammonium acetate. The pKa’s 
for the four nucleotides are given in Table 3, the pH range for separation was from 5.5 to 7.0.  
 Nucleoside pKa 5’ Nucleotide pKa 
Adenosine (N1) 3.63 3.74 
Cytosine (N3) 4.11 4.30 
Uracil (N3) 9.25 9.43 
Guanine (N-7) 
Guanine (N-1) 
2.20 
9.50 
2.30 
9.36 
Thymine (N3) 9.80  
Table 3: pKa for bases in nucleosides and nucleotides at ~ 20 oC. 113 
 
Column testing was carried out by HPLC with UV detection, conditions for column tests are 
given in Table 4.  
Column Temperature (
o
C)  25 
Injection Volume (µL) 5- 25 
Flow Rate (mL/min)  Recommended flow rate of column 
Mobile Phase 5 - 25 mM ion-pair reagent and 5- 25% 
methanol 
Table 4: Column testing conditions used in preliminary work for the separation of monophosphate nucleotides. 
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Once the optimum separation conditions were determined, the method was used to separate 
the components of a DNA digest mixture. Several conditions were used to optimise the 
digestion of calf thymus DNA, including varying the temperature at which the digestion was 
performed, concentrations of the reagents and enzymes used. The digestion was also 
performed by microwave digestion. Each digest mixture was analysed by HPLC to compare 
against the chromatograms for the nucleotide standards.  
 
To further confirm that the enzymatic digest of calf thymus DNA produced all four 
monophosphate nucleotides, the digest was analysed by LC-ESI-MS. Comparison of 
retention times and mass spectra between the calf thymus DNA digest and nucleotide 
standards were made. Injections of each single nucleotide were made in order to record their 
retention time and parent ion m/z, after digestion of calf thymus DNA the digest mix was 
injected and its mass spectra recorded.  
 
Following the optimisation for the separation of both the nucleotide standards and the DNA 
digest mix, quantification by LC-ICP-MS was started. Firstly the limit of detection for 
phosphorus was determined by;  
1. direct nebulisation of an inorganic phosphate standard and 5’AMP, 
2. FIA of an inorganic phosphate standard, 
3. LC-ICP-MS of five nucleotide standards, 
4. blank inspection by direct nebulisation, FIA and LC-ICP-MS.  
 
To determine the completeness of digestion and degree of loss on the column for the 
nucleotides, the recovery for each nucleotide was calculated by flow injection analysis ICP-
MS (FIA-ICP-MS). Similarly the mass balance for phosphorus was achieved by analysis of 
whole DNA by FIA-ICP-MS. The flow injection conditions used for the recovery of each 
nucleotide and for the mass balance of phosphorus in DNA are given in Table 6.  The 
quantification of calf thymus DNA was performed on two separation systems, the first 
consisted of a Thermo Surveyor HPLC coupled to a Thermo Element 2 XR ICP-MS, the 
Research Undertaken and Key Findings  Claire Camp 
5-8 
second consisted of an Agilent 1100 HPLC system coupled to an Agilent 7500 ce ICP-MS. 
Prior to analysis the system suitability was checked by performing 6 repeat injections of 
d’CMP at a phosphorus concentration of 250 ppb. A calibration blend of the 4 
monophosphate nucleotides at concentrations of phosphorus ranging from 50 to 500 ng/g 
were run followed by several blanks and aliquots of the calf thymus DNA digest mixture. The 
column was then removed and the same experiment was repeated in order to determine the 
total phosphorus concentration of the digest mix in order to determine the mass balance.  
 
5.3.3. RESEARCH FINDINGS AND DISCUSSION 
The separation of nucleotides by HPLC is difficult due to their inherent amphoteric nature 
and the loss of phosphate groups due to either acidic or basic hydrolysis. At the operating pH 
of silica based columns, pH 2-8, 5’ monophosphate nucleotides are ionic molecules and so 
are poorly retained on non-polar stationary phases. As such ion-pair agents are needed to 
increase retention on non-polar columns. It has been documented that quaternary ammonium 
alkylates are suitable ion-pair reagents for 5’monophosphate nucleotides giving rapid 
separation of polar water soluble compounds on non-polar stationary phases. 
114
 Of the 4 ion 
pair reagents tested, TEAA was found to give the best separation of mono-phosphate 
nucleotides, a column temperature of 25
o
C and a flow rate of 0.25 mL/min gave the best 
results as shown in Figure 17.  
 
 
Figure 17: Separation of all 4 dNMP's on Phenomenex Gemini NX Column, Isocratic mobile phase - 15 mM TEAA, 
2.5 % MeOH, Flow rate – 0.25 mL min-1, Injection volume 20 µL, Column Temp 25 oC. 
5’CMP 5’GMP 
5’UMP 5’TMP 
5’AMP 
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A conventional digest procedure was found to be the best strategy for the digestion of calf 
thymus DNA, the protocol was based on that by Crain and is outlined below in Figure 18.   
 
 
 
 
 
 
 
 
 
Figure 18: Digestion protocol for the digestions of calf thymus DNA. 
 
To assess the suitability of the LC-ICP-MS method for the quantification of DNA, standard 
nucleotides were analysed several times on different days. Three calibration sets were run on 
the same day in order to make a comparison based on repeatability, two further calibration 
sets were run on two separate days to compare reproducibility.  Application of one-way 
ANOVA showed there was no statistical difference (n=4, p=0.95) between the slopes for the 
4 different nucleotides. The relative standard deviation (RSD) of the slopes for these 
calibration curves were 3.6% for the intra-assay and 6.5% for the inter-assay.  Repeatability 
of injection was calculated as 0.2% RSD (n=6).  
 
Double stranded calf thymus DNA.  
Single stranded calf thymus DNA. 
Heated at 100 
o
C for 5 minutes. 
Rapidly cooled on ice  
 
Rapidly cooled on ice.  
Mono-phosphate nucleotides. 
Nuclease P1, ammonium 
acetate, heated at 45 
o
C for 
4 hours.  
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Column recoveries were determined for each nucleotide standard from the injection of 5 µL 
of the nucleotide standard with and without the column in place, the recoveries ranged from 
95 to 98%, as shown in Table 5.  
Nucleotide % Recovery 
d’CMP 98.7 ± 0.5 
d’TMP 97.8 ± 1.1 
d’GMP 99.1 ± 1.2 
d’AMP 98.4 ± 1.2 
UMP 98.0 ± 3.1 
Table 5: Recoveries of individual nucleotides using FI-ICP-MS. 
 
Calibration blends of standard monophosphate nucleotides were prepared in mobile phase (20 
mM triethylammonium acetate (TEAA at pH 6.4) at 
31
P concentrations of 50 - 500 ng/g. Two 
calibration runs were made, followed by three repeats of each digested DNA sample and a 
final calibration set, three blanks were run between each calibration set and sample run. 
Figure 19 shows typical chromatograms obtained from both the calibration blend and a 
digested DNA sample analysed by LC-ICP-MS.  
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Figure 19: LC-SF-ICP-MS chromatograms of 31P, A: single monophosphate nucleotide standards, B:  digested calf 
thymus DNA. 
 
Figure 19 compares the separation of a mixture of mono-nucleotide standards and digested 
calf thymus DNA. The slight change in the observed retention times was due to the variation 
in the mobile phase pH, from non-consecutive chromatograms, however, the peaks were 
positively identified by LC-MS. The unknown peak observed in both the nucleotide standards 
and the DNA digest is thought to be the result of phosphate buffers used in the purification 
process. This peak was found to vary in magnitude reflecting some variability in the 
phosphate levels in the standards. The presence of these buffers did not affect the 
quantification of DNA when speciation was used, because the first peak can be ignored, but 
would affect an assay based on total P where it would be included. This was proven by 
d’CMP 
A 
d’CMP 
TMP 
d’GMP 
d’AMP 
B 
d’AMP 
TMP d’GMP 
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fraction collecting the individual nucleotide peaks from the Sigma standards, digesting to 
phosphate and quantifying by direct nebulisation into the ICP-MS. This experiment was also 
performed on the DNA digest. Chromatograms run including UMP in the mixture showed the 
UMP baseline separated with a retention time of approximately 4.8 minutes.  
 
Appropriate calibration curves, shown in Figure 20, were plotted, from which the 
31
P 
concentration for each monophosphate nucleotide was calculated. The molecular weight of 
each nucleotide was used to calculate the nucleotide concentration; these were then summed 
and back calculated to give the DNA concentration.  
 
 
 
Figure 20: A typical calibration chart for nucleotide standards. 
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At the end of the calibration and sample sequence, whole DNA was analysed by FIA-ICP-
MS in order to calculate the 
31
P mass balance. Four repeat injections of undigested DNA 
were run and the total peak area was used to calculate mass balance by comparing it to the 
combined peak areas of the digested samples analysed by LC-ICP-MS. Measuring total P as 
an indicator of DNA concentration is problematic as even in highly purified and well 
characterised samples, such as the National Institute of Standards and Technology (NIST) 
standard, there are likely to be P-containing residues from the purification procedure. 
 
The LC-ICP-MS results show that a mass balance of 97.2% ± 0.5% was achieved by this 
experiment, which was expected due to the high column recoveries observed. The mass 
balance calculation data is shown in Table 6 for both NIST SRM DNA and nucleotide 
standards. Errors were calculated from the standard error of the mean for each peak in the 
digest and for the repeated flow injection peaks, and then treated with the propagation of 
errors formula.  
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NIST DNA 
Run Total Peak Area / counts Run  FIA Peak Area / counts  
1 165538 1 169729 
2 160939 2 168705 
3 163915 3 167008 
Average 163464 4 167446 
  Average 168222 
  Mass Balance  97 % ± 0.5 % 
Nucleotide Standards 
Run Total Peak Area / counts Run  FIA Peak Area / counts  
1 11065522 1 11398135 
2 11155169 2 11849337 
3 11348798 3 11999767 
Average 11189830    
    Average 11749080 
    Mass Balance 95 % ± 0.5% 
 
Table 6:  Total peak areas for speciated nucleotide standards and digested NIST DNA and flow injection peak areas 
for nucleotide blend and undigested NIST DNA. 
 
5.3.6. CONCLUSIONS 
The phosphorus content of the 4 nucleotides was calculated by external calibration with 
standard nucleotides from Sigma as; d’CMP 11.2 ±0.1 ng/µL, d’GMP 13.1±0.1 ng/µL, TMP 
13.6 ±0.1 ng/µL and d’AMP 14.2 ±0.1 ng/µL, giving a total of 52.1 ng/µL. The stated DNA 
concentration for component B out the four different NIST DNA components was 53.6 ±0.4 
ng/µL, giving a recovery of 97.2%. 
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5.4 TAGGING OF PHOSPHOPEPTIDES WITH GALLIUM 
5.4.1 INTRODUCTION 
The aim of the research was to develop an LC-ICP-MS method for the quantification of 
phosphopeptides from an enzymatic digest of whole phosphoproteins by labelling the 
phosphate group with a metal ion, namely gallium. This proved to be more difficult than first 
thought and the quantification of phosphopeptides was not achieved; however, labelling of 
phosphopeptides with gallium was achieved. The quantitation of the proteome is of 
increasing importance as it is the amount of particular proteins or changes in their relative 
abundance that reflect a change in a biological system. 
115
 Relative quantification of 
phosphopeptides and proteins has been achieved by the incorporation of various isotopic 
labelling agents such as SILAC and ICAT. Alternatively naturally occurring tags such as 
phosphorus and sulfur can be utilised for relative quantification by ICP-MS analysis. 
115
 
However these elements are not efficiently ionised by the plasma and suffer from 
interferences, labelling with a metal tag would enable improved detection limits.  Labelling 
of the phosphate moiety with gallium was achieved and investigated using ESI-MS and 
molecular modelling.  This work was carried out in collaboration with Dr Tamer Shoeib and 
Eslam Moustafa from the American University in Cairo, who carried out the molecular 
modelling experiments and calculations.   
 
5.4.2 RESEARCH UNDERTAKEN 
The first stage in the tagging of phosphopeptides with gallium was the generation and 
characterisation of the ligand N,N-bis(carboxymethyl)lysine gallium (LysNTAGa). The 
ligand was based on the typical support medium found in a classic IMAC column. The 
starting materials, N,N-bis(carboxymethyl)lysine (LysNTA) and gallium(III) chloride were 
purchased (Sigma Aldrich, UK) and combined in a 1:2 molar ratio to form the ligand 
LysNTAGa, see Figure 17. To confirm that the ligand formation was successful, a series of 
mass spectrometry experiments were carried out, including MS
n 
and LC-MS. 
 
Excess cations 
were removed with ion exchange solid phase exchange cartridges prior to mass spectrometry 
analysis. A small phosphopeptide was chosen as a test molecule for the tagging process, 
platelet derived growth factor β-receptor (β-PDGF) which is a phosphopeptide that regulates 
Research Undertaken and Key Findings  Claire Camp 
5-17 
cell growth and division. β-PDGF is a pentapeptide phosphorylised on the terminal tyrosine. 
Prior to tagging β-PDGF with LysNTAGa, the pentapeptide was characterised by MS, MSn 
and LC-MS. LysNTAGa was combined with β-PDGF in a 2:1 molar ratio to ensure complete 
tagging of the phosphopeptide, see Figure 17.  The tagged phosphopeptide was characterised 
by MS and LC-CP-MS. To confirm that the tagged phosphopeptide is a thermodynamically 
possible molecule, the most energetically stable conformer was found by molecular 
modelling.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: The formation of LysNTAGa tagged β-PDGF from LysNTA, Ga(III)Cl and β-PDGF. 
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5.4.3. RESEARCH FINDINGS 
PDGF and LysNTA were investigated using molecular mass spectroscopy, the molecular ions 
were identified, these molecular ions were trapped and fragmented to give daughter ion 
spectra.  Following the characterisation of the two starting materials mentioned above, the 
gallium tagging reagent Ga-LysNTA was formed and investigated by MS.  The complete 
formation of LysNTA-Ga was shown by the absence of free LysNTA+H
+
 ion (m/z 263) in 
the ESI-MS spectrum of the metal ligand complex. The synthesis of the ligand was confirmed 
by comparing the isotopic pattern from experimentation to that generated by the Xcalibur 
software, this was performed on both the linear trap MS (Thermo LTQ) and the high 
resolution mass spectrometer (Thermo Xactive). See Figure 22 and Figure 23 for the 
comparison spectra.  
 
Figure 22: Comparison of the found isotopic pattern for LysNTAGa (top) compared to the theoretical isotopic 
pattern generated by Xcalibur software (bottom). 
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Figure 23: Formation of [LysNTAGa.H2O ]+; panel A experimental data, panel B theoretically predicted spectra by 
high resolution mass spectrometry performed on a Thermo Exactive Mass Spectrometer.  
 
Molecular modelling was employed to determine the lowest energy conformation of Ga- 
LysNTA and is shown in Figure 24. This structure shows that the gallium atom is bound to 
three carbonyl oxygen atoms and one nitrogen atom from the lysine backbone. This structure 
helps to disperse the highly positive charge on the metal atom and forms three distinct five –
membered heterocyclic rings with the gallium metal atom at the centre. A strong hydrogen 
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bond is also formed between the terminal amino group on lysine and the closest carbonyl 
group forming a pseudo nine membered ring. The large number of rings formed in the 
conformation shown in Figure 24 is responsible for this being the lowest entropy structure 
found from molecular modelling experiments.   
 
Figure 24: Structure for the Ga-LysNTA singly charged positive ions as calculated at the HF/STO3G and 
B3LYP/LANL2DZ (italicized numbers) levels of theory.  Bond lengths are in Angstroms, relative free energies (in 
kcal per mol) are indicated in parenthesis. 
 
On examination of the daughter ions, the presence of a water adduct to Ga-LysNTA was 
identified and confirmed by comparison of the experimental signal with the theoretical 
isotope pattern model and was found to be in excellent agreement with an average mass 
accuracy of 0.08ppm. The mass spectra of the water:LysNTAGa adduct is shown in Figure 
25. An interesting cluster was observed at m/z 361-370, which is proposed to be due to the 
signals of LystNTAGa•CH3OH and Ga-LysNTA•2H2O adducts. Closer inspection of this 
cluster and matching to modelled theoretical isotope patterns indicated that it consisted of a 
2:1 ratio of [Ga-LysNTA•MeOH]+: [Ga-LysNTA•2H2O]
+
. This suggests that the two acidic 
carbonyl groups have lost a hydrogen atom in order to form two ionic bonds to the gallium 
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cation in the Ga-LysNTA complex; therefore the Ga-LysNTA is unlikely to accept lone pairs 
from remaining water molecules in the gas phase. 
 
 
Figure 25: Panel A experimental signal due to [LysNTAGa]+  adducts with H2O and CH3OH, panel B theoretically 
predicted composite spectrum of a 1:2 ratio of [LysNTAGa.2H2O]
+  and [LysNTAGa.CH3OH]
+. 
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The formation of Ga-LysNTA with the phosphopeptide PDGF β-receptor, which has a 
primary structure of H-pTyr-Val-Pro-Met-Leu-OH, to form the Ga-LysNTA-β-PDGF adduct 
at m/z of 1030.3 alongside the Ga-LysNTA and β-PDGF reactants were observed in the mass 
spectrum shown in Figure 26. The isotopic pattern of Ga-LysNTA-β-PDGF is shown in 
Figure 27, this was confirmed by comparison with the theoretical isotope pattern and by 
accurate mass FT-MS with an average mass accuracy of 4 ppm (see Paper 2, Table 1).  
Several other species which were observed in the mass spectrum were identified and 
summarised in Table 7.  
 
Figure 26: Full scan spectrum of reaction mixture showing evidence of [LysNTAGaPDGF]+ formation from Thermo 
LTQ Mass Spectrometer, showing the formation of LysNTAGaPDGF at m/z 1030.25, and the starting materials 
PDGF at m/z 702 and LysNTAGa at m/z 361. 
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m/z or cluster Proposed assignment  
263 [LysNTA]
+
 
329 [LysNTAGa]
+
 
361 [LysNTAGa
.
2H2O]
+
[LysNTAGa
.
CH3OH]
+
 
515 [PDGFLysNTAGa]
2+
 
591 [LysNTAGaProLeu
.
CH3OH]
+
 
677 [(LysNTAGa)2
.
H2O]
+
 
702 [PDGF]
+
 
730 [(LysNTAGa)2
.
4H2O]
+
 
1030 [PDGFLysNTAGa]
+
 
Table 7: Proposed identification of the major ions found in the full spectrum scan of Ga-LysNTA-PDGF according to 
observed m/z values.  
 
Figure 27: Zoomed in scan showing the formation [LysNTAGaPDGF]+ at m/z 1030. 
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To further confirm the formation of Ga-LysNTA-β-PDGF, the resulting entire isotopic 
pattern was selected at an isolation width of 8 Da and fragmented at collision energy of 15 
eV, resulting in the MS/MS spectrum shown in Figure 28. Fragmentation of the complex 
resulted in daughter ions representing β-PDGF and the cluster at m/z 361-370 as described 
above. 
 
 
 
Figure 28: Product ion scan of [Ga-LysNTAPDGF]+  at m/z 1030 from LTQ Ion Trap MS. 
 
To confirm the structure of Ga-LysNTA-PDGF further molecular modelling was employed, 
this was used to confirm that the structure was energetically possible. The structure that was 
most favourable is shown in Figure 29. Due to the complexity of the molecule a two layer 
experiment was performed using an ONIOM calculation, which separated the study into real 
and model regions. The real region contains all the atoms in the molecule whereas the model 
region contains the reactive centre. The results of the ONIOM calculation showed that 
gallium is penta-coordinated to two carbonyl oxygen atoms from the LysNTA substrate and 
two carbonyl oxygen atoms from valine and methionine from the β-PDGF backbone, the 
final coordination bond was found to be to one of the phosphate oxygen atoms.  
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Figure 29: The lowest energy structure 2A calculated for the Ga-LysNTA-β-PDGF singly charged positive ions as 
calculated using the ONIOM method at B3LYP/LANL2DZ:PM6 level of theory.  Bond lengths are in Angstroms. 
 
The viability of this procedure as a tagging method for phosphopeptide analysis was 
investigated using LC-ICP-MS. Separation was achieved with gradient elution and post 
column dilution. Organic phase dilution was needed to reduce the effect of carbon on signal 
intensity and reduce carbon loading on the ICP-MS cones. The binding of PDGF to Ga in the 
form of LysNTAGa was investigated by LC-ICP-MS, using conditions as used for the 
separation of tryptic peptides from β-casein. The resulting chromatograms are shown in 
Figure 30. The first shows untagged PDGF with a high Ga background removed after column 
cleaning, the second is the 
31
P trace of tagged PDGF showing the shift in retention time of the 
PDGF peak, and the third shows both the 
69
Ga and 
31
P peaks co-eluting indicating that 
binding was successful.  
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Figure 30: LC-ICP-MS chromatograms of A –Unlabelled PDGF showing the 31P and 69Ga signals, B – PDGF labelled 
with LysNTAGa, showing the 31P signal only to highlight the unbound PDGF at the same retention time as in A and 
C – PDGF labelled with LysNTAGa showing both the 31P and 69Ga signals co-eluting. 
31
P Signal of PDGF  
PDGF-GaLysNTA  
Unbound PDGF 
A 
B 
31
P chromatogram of LysNTAGA-PDGF 
Ga background  
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5.4.4. CONCLUSIONS 
The successful labelling of β-PDGF with gallium was demonstrated in this work, the 
labelling with gallium allowed detection through LC- ICP-MS.  LC-ICP-MS data showed the 
co-elution of the 
31
P of the phosphorylated peptide and the 
69
Ga of the label, indicating 
successful Ga-LysNTA-β-PDGF formation. This was supported by identification of the 
labelled complex through ESI-MS
n
 and accurate mass FT-MS data. Molecular modelling 
supported the MS data and revealed that just one of the phosphate oxygen atoms was targeted 
by the Ga centre, the other analyte derived coordination sites being provided by electron 
donating groups on the amino acid residues. This suggests that complex stability will vary 
from peptide to peptide and may go some way to explaining why there are diverse and 
sometimes contradictory reports in the literature regarding the efficiency and selectivity of 
metal affinity techniques. 
 
5.5 INTERACTION OF OXALIPLATIN WITH CARNOSINE AND 
ANSERINE 
 
5.5.1 INTRODUCTION 
The aim of the research was to investigate the binding of endogenous peptides, namely 
carnosine and anserine with platinum anti-cancer drugs. The structure of oxaliplatin is shown 
in Figure 31. 
 
Figure 31: Molecular structure of oxaliplatin. 
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The interaction of anti-cancer drugs with DNA has been of interest to this research group and 
the work by Zayed et. al. 
10
 produced significant data to show that the majority of the 
administered drug is found in the cell cytosol. Recent studies have shown that the activated 
form of oxaliplatin forms very stable complexes with GSH. 
70
 However, work by this group 
116
 and other research groups suggests that Pt binding to intracellular peptides through their 
terminal amino nitrogen atoms and carbonyl oxygen atoms are possible and energetically 
competitive to sulfur attachment.  Due to these findings in research it was decided that 
investigating the binding between carnosine, anserine and oxaliplatin would be of significant 
interest as these peptides are small enough to allow in-depth investigation by mass 
spectrometry and molecular modelling and are found at high concentrations in cells.  
 
5.5.2. RESEARCH UNDERTAKEN 
To begin this investigation, carnosine and oxaliplatin were characterised by molecular mass 
spectrometry. The formation of the oxaliplatin:carnosine adduct was also characterised by 
mass spectrometry, the molecular ion was identified and subsequent daughter ions were 
investigated in order to determine the structure of the adduct. The exact m/z value of the 
parent ion and daughter ions were determined by high resolution mass spectrometry. This 
was performed to confirm the m/z of the daughter ions compared to theoretically calculated 
m/z values. Structures were elucidated from the m/z values, and from losses in mass due to 
collision induced dissociations. To further confirm that the carnosine:oxaliplatin adduct is a 
thermodynamically possible molecule, the most energetically stable conformer was found by 
molecular modelling. The in vitro effect of carnosine on oxaliplatin cytotoxicity was 
investigated by treating liver hepatocellular carcinoma (HepG2) cells, a perpetual carcinoma 
cell line. The viability of the cells was investigated by colleagues at The American University 
in Cairo. Finally density functional calculations were used to obtain structural information 
about the complex formed and starting materials.  
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5.5.3. RESEARCH FINDINGS 
Carnosine, anserine and N-acetyl-carnosine with oxaliplatin experiments were performed on 
four different mass spectrometers, a Thermo linear ion trap (LTQ), a Thermo high resolution 
Exactive mass spectrometer, a Thermo Orbitrap and a Waters XEVO TQ tandem quadrupole 
mass spectrometer.  The starting materials were first investigated and their mass spectra 
recorded. A mixture of oxaliplatin with carnosine, anserine and N-acetyl-canosine were 
electrosprayed in the positive ion mode generating the mass spectra. However, only the 
results for the interaction between carnosine and oxaliplatin are discussed in detail in this 
thesis as the pattern for interaction is believed to be common between all three dipeptides. 
The mass spectrum of oxaliplatin bound to carnosine is shown in Figure 32. 
 
 
Figure 32: Full scan MS spectrum of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol 
solution as obtained on the LTQ without allowing for incubation time.  
 
Carnosine_OxPt #6-155 RT: 0.02-0.67 AV: 150 NL: 4.83E5
T: ITMS + p ESI Full ms [50.00-1000.00]
250 300 350 400 450 500 550 600
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
227.17
624.08
453.00
398.08
239.17
x10
Research Undertaken and Key Findings  Claire Camp 
5-30 
 
Figure 33: Zoom in showing the isotope pattern of oxaliplatin obtained on the LTQ. 
 
Figure 34: Zoom in of the isotope pattern resulting from the ion [carnosine+oxaliplatin+H]+ obtained on the LTQ. 
 
The cluster shown at m/z 624 is the parent ion [Carnosine+OxPt+H]
+
, also seen in the mass 
spectra were ions belonging to oxaliplatin, m/z 398, shown in Figure 33 and carnosine, m/z 
227 and the carnosine dimer, m/z 453. A MS2 mass spectrum is shown in Figure 35. 
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Figure 35: MS2 scan of carnosine coupled to oxaliplatin obtained on the LTQ. 
The ion clusters shown in Figure 35 are expanded and shown in detail in Figure 36. The loss 
of carbon dioxide produced the first cluster at m/z 580, loss of the six membered ring leaving 
just diaminocyclohexane (dach) resulted in the second cluster at m/z 534, protonated 
oxaliplatin and the loss of carbon dioxide from oxaliplatin  resulted in the last two clusters at 
m/z 398 and 354, respectively.  
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Figure 36: Zoomed in views of the daughter ions from carnosine:oxaliplatin with  assignments, from the MS2 mass 
spectra obtained on the LTQ. 
 
Molecular modelling experiments can be divided in two categories involving either direct Pt 
bonding to carnosine or electrostatic interactions between protonated carnosine and OxPt.  In 
the first category, bonding involves the exchange of a single Pt-oxygen to a formal Pt-
coordination to one of the electron rich sites such as one of the imidazole nitrogen atoms, a 
carbonyl oxygen or the terminal amino nitrogen of the dipeptide.  The electrostatic category 
involves electrostatic interactions between the oxaliplatin molecule and protonated carnosine 
through hydrogen bonding which are responsible for keeping the resulting [Carnosine + OxPt 
+ H]
+
.   The found structures from these two categories of experiments can be found in 
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Appendix C, Figure S12. The global minimum on the gas phase potential energy surface is 
structure 1A as shown in Figure 37, this structure is internally stabilised by four strong 
hydrogen bonds.  In the gas phase structure 1A, the hydrogen bond between one of the NH 
hydrogen atoms of the dach ligand and the carboxylic oxygen of the terminal carboxylate 
group is replaced by external solvation in solution.  The strongest hydrogen bonds in 
structure 1A, are between each of the hydrogen atoms of the protonated oxalate moieties and 
their respective terminal amino nitrogen atom of each of the carnosine dipeptides.   
 
 
Figure 37: Structures for [Carnosine + OxPt + H]
+
 ions in which a formal Pt coordination to carnosine is observed as 
calculated at the B3LYP/LANL2DZ level of theory.  Bond lengths are in Angstroms, relative free energies are 
indicated in parenthesis. Italicized numbers are for solvated species. 
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2A is the lowest energy structure calculated for the [Carnosine + OxPt – CO2 + H]
+
 species 
observed as the m/z cluster around 580 in the MS
2
 spectra shown in Figure 36.  Structure 2A 
is stabilised by three internal hydrogen bonds and is shown in  
 
 
 
Figure 38.  
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Figure 38: Structure for the lowest energy [Carnosine + OxPt – CO2 + H]
+
 ion as calculated at the B3LYP/LANL2DZ 
level of theory.  Bond lengths are in Angstroms. 
 
Structure 3A is calculated to be the lowest structure for the [Carnosine – H + Pt(dach)]+ 
species assigned as the cluster centered on m/z 534 in Figure 36. This assignment was further 
confirmed by the isotopic pattern obtained on the high resolution Q-Exactive FT-MS shown 
in S10 of Appendix C.  The formation of the [Carnosine – H + Pt(dach)]+ species from the 
[Carnosine + OxPt – CO2 + H]
+
 precursor is supported by the MS
3
 spectrum in Figure S7 
clearly showing the cluster centred on m/z 534 being the dominant fragment due to the 
dissociation of the[Carnosine + OxPt – CO2 + H]
+
 precursor.   
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Figure 39: Structure for the lowest energy [Carnosine – H + Pt(dach)]
+
 ion as calculated at the B3LYP/LANL2DZ 
level of theory.  Bond lengths are in Angstroms. 
 
The in-vitro investigation between carnosine and oxaliplatin, was carried out by colleagues at 
The American University in Cairo. The carcinoma HepG2 cells showed decreased viability 
with exposure to increased concentrations of OxPt. To examine the in vitro effect of 
carnosine on OxPt cytotoxicity, several solutions were prepared at a fixed OxPt concentration 
while varying the molar equivalent of carnosine.  The results of these experiments indicated a 
positive correlation between cell viability and increasing molar equivalence of carnosine 
relative to OxPt.  This suggested that carnosine can interact with the OxPt drug to form 
complexes that reduce the drug’s action.   
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To investigate the ability of carnosine to be passively diffused through cells, the same set of 
experiments were repeated. However the cells were first incubated with various 
concentrations of carnosine for 24 hours, after this time the media containing carnosine was 
discarded and replaced with carnosine free media and incubated for a further 24 hours. The 
results of these in vitro experiments indicate slightly increased cell viability upon the 
exposure to carnosine.  The much less pronounced effect shown in Figure 3 relative to that 
shown in Figure 2 is most likely due to the inability of carnosine to effectively passively 
diffuse through the cells.  The results obtained by the in-vitro experiments indicated that 
carnosine has the ability to interact with OxPt most likely through the chelation of the 
platinum metal.   
 
5.5.4. CONCLUSIONS  
The research carried out to investigate the interaction of oxaliplatin and carnosine suggested 
that the dipeptide carnosine may inhibit the cytotoxic action of OxPt, through the formation 
of complexes that are less cytotoxic than OxPt alone.  Mass spectrometry with both 
electrospray ionization and chip nanospray were employed to study the interaction of 
oxaliplatin with carnosine and two of its derivatives, anserine and N-acetylcarnosine. The 
formation of a complex between oxalipltin and the three dipeptides investigated was shown 
in this chapter and in Appendices 3 and 4. The majority of species observed were 
unambiguously assigned and compared to their theoretical isotopic patterns.  It was found 
that the three complexes formed followed a common fragmentation pattern due to the 
collisionally-activated protonated complexes of each of the ligands examined with OxPt. The 
common fragmentation products were; [OxPt – CO2 + H]+, [OxPt + H]+, [M – H + 
Pt(dach)]+, [M + OxPt – CO2 + H]+ and [M +H]+.  Density functional calculations were used 
to obtain structural information and relative free energies of different isomers of the observed 
precursor [Carnosine + OxPt + H]+ and the fragments produced.  Data presented showed 
several binding modes between electron rich sites such as N and O centers of Carnosine and 
the Pt metal of OxPt.   
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5.6 SUMMARY  
 
The aim of this chapter was to describe the key results of the research undertaken. The 
research undertaken was able to produce findings in three important bio-analytical areas by 
mass spectrometry. The research undertaken has demonstrated a reliable, accurate and 
sensitive method for the quantification of DNA, utilising the 
31
P label by LC-ICP-MS. 
Phosphate was further investigated as a binding moiety for gallium in a novel heterogeneous 
metal affinity tagging scheme, from which the binding strategy was shown to be mono-
dentate with respect to phosphate as opposed to bi-dentate. Metal-peptide interactions were 
further investigated between platinum based anti-cancer drugs and small peptides; carnosine 
anserine and N-acetylcarnosine. The research illustrated the structures formed between the 
three small peptides and oxaliplatin by mass spectrometry with confirmation by molecular 
modelling. 
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6 CONCLUSIONS, IMPLICATIONS AND OPPORTUNITIES FOR 
FURTHER RESEARCH 
 
 
6.1. INTRODUCTION 
This chapter concludes this thesis by discussing the implications of the research on both the 
industrial supervisor and the wider industry. A critical evaluation of the overall research is 
also provided, together with the contribution offered by this research and recommendations 
for further improvements. The research conducted has been diverse, although under the 
common theme of mass spectrometry of small endogenous biomolecules. Findings and 
conclusions can be drawn under three themes, namely: 
 
• Quantification of DNA 
• Heterogeneous tagging of phosphopeptides with gallium 
• Interaction of endogenous peptides with anti-cancer drugs  
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6.2. KEY FINDINGS OF THE RESEARCH 
 
The key findings of the research by theme are discussed below. 
 
6.2.1. QUANTIFICATION OF DNA 
A successful methodology for the separations of all 5 common nucleotides was developed 
and used to quantify calf thymus DNA and validated against the SRM (NIST 2372).  Limits 
of detection for phosphorus within individual nucleotides were calculated at comparable 
levels in other studies and mass balance for monophosphate nucleotides is possible. The 
research provided the sponsoring company with a method that could quantify DNA at low 
concentrations by measuring the total P signal from DNA by FIA-ICP-MS and by the 
summation of the P signal from the individual nucleotides following a simple digestion 
protocol of whole DNA and analysis by LC-ICP-MS.  
 
6.2.2. HETEROGENEOUS TAGGING OF PHOSPHOPEPTIDES WITH GALLIUM 
The research conducted showed that the metal ligand LysNTAGa successfully bound the 
phosphopeptide β-PDGF. Due to the nature of ICP-MS, the research demonstrated that Ga-
LysNTA is a sensitive and highly selective label for the detection and analysis of 
phosphopeptides by LC-ICP-MS. Confirmation of the complex was achieved with ESI-MS
n
 
and accurate mass FT-MS data and by comparison with theoretical spectra.  Molecular 
modelling supported the MS data and revealed that just one of the phosphate oxygen atoms 
was targeted by the Ga centre, the other analyte derived coordination sites being provided by 
electron donating groups on the amino acid residues. This suggests that complex stability will 
vary from peptide to peptide and may go some way to explaining why there are diverse and 
sometimes contradictory reports in the literature regarding the efficiency and selectivity of 
metal affinity techniques. 
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6.2.3. BINDING OF CARNOSINE AND ANSERINE WITH OXALIPLATIN 
The research showed that oxaliplatin does interact with both anserine and carnosine, which 
may be significant in determining why 80% of the administered drug remains in the cytosolic 
portion of cancer cells.  This hypothesis was supported by the in-vitro experiment involving 
oxaliplatin and carnosine which suggested that carnosine may inhibit the cytotoxic action of 
oxaliplatin, through the formation of complexes that are less cytotoxic than oxaliplatin alone.  
The various mass spectrometry experiments between carnosine and oxaliplatin showed that 
there several binding modes between the electron rich sites such as N and O of Carnosine and 
the Pt metal of oxaliplatin.   
 
6.3. CRITICAL EVALUATION OF THE RESEARCH 
 
The aim of this research was to investigate the interaction of small bio-molecules with 
metals, in the form of tagging agents and drugs and also to quantify DNA. The above, 
coupled with the limited timeframe available for the EngD project, mean that there are certain 
limitations associated with this research, in addition to the many contributions and benefits to 
the sponsoring company and the research community, as discussed below. 
 
6.3.1. CONTRIBUTION TO KNOWLEDGE 
The quantification of DNA discussed in this thesis (Section 5.3) was the first that showed the 
conservation of mass by analysing the total 
31
P signal from single nucleotides peaks 
following digestion of calf thymus DNA and comparing it to whole DNA. It also provided 
the first quantification of DNA by LC-ICP-MS using a sector field instrument without the 
need for a specialised introduction system such as DIHEN.  
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The binding of the phosphate to gallium was shown by this research to be mono-dentate, 
previous studies have thought that the binding was bi-dentate through two oxygen atoms of 
the phosphate group. 
117, 118
 Many enrichment protocols for use in the analysis of 
phosphopeptides are compromised by non-selective binding by non-phosphopeptides that 
contain carboxylic acid groups in the peptide chain, the molecular modelling carried out in 
conjunction with this research suggests that the metal preferably binds to carboxylate groups.  
The research conducted which shows that the binding between the phosphate group and 
gallium is only mono-dentate could explain why there is so much variation in the enrichment 
strategies employed by other research groups. The benefit of this to other research groups is 
that it indicates other strategies for enrichment of phosphopeptides is needed and that 
combinations of enrichment strategies are likely to give a greater coverage of the 
phosphoproteome. Although this knowledge was already shown through studies using 
combinations of strategies, the reason why this was the case was not fully understood.  
 
Other studies conducted in this research group showed that 75-78% of the total administered 
oxaliplatin drug remains in the cytosolic fraction of the cancer cell. Therefore the interactions 
of oxaliplatin with the peptides and proteins that make up the cytosol are of great importance. 
The research carried out in this thesis is the first time that the interaction between oxaliplatin 
and carnosine has been investigated.  
 
6.3.2. IMPLICATIONS/IMPACT ON INDUSTRIAL SPONSOR 
LGC Ltd’s main objective for sponsoring this research was to develop assays in line with 
their role as a National Measurement Institute. In view of this, the EngD project has not made 
as much of a positive contribution to the sponsoring company as hoped due to time 
limitations and instrument issues. However, the sponsor has been able to apply the 
methodology developed to another assay in order to improve the quality of the results, which 
facilitated the publication of a further research paper. This research paper quantifies 
oxaliplatin-nucleotide adducts by LC-ICP-MS with isotopically labelled oxaliplatin, the LC 
separation and the DNA digest conditions used in this work were based upon the findings 
from preliminary work carried out in this thesis.  
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6.3.3. IMPLICATIONS ON WIDER COMMUNITY AND INDUSTRY 
 The quantification of phosphopeptides is important as it allows the assessment of cellular 
phosphorylation due to the activity of kinases and phosphatases and cellular signal 
transduction pathways which is an important aspect of cell dynamics. Current methodologies 
for the quantitation of phosphopeptides are suited to analysis by molecular mass spectrometry 
by the inclusion of heavy isotopes, 
13
C, 
2
H, 
15
N. The advantages of a quantitation method for 
phosphopeptides by ICP-MS is that quantification can be achieved with inorganic standards 
as ICP-MS is non-species specific, which negates the need to create phosphopeptide 
calibration standards. Improvements in the heterogeneous tagging of phosphopeptides with a 
metal such as gallium could lead to a simple absolute quantitation method by LC-ICP-MS. 
The research described in this thesis is a basis from which this goal can be built on, by 
showing that the LysNTAGa tagging method is successful and that it can be used for LC-
ICP-MS analysis of phosphopeptides.  
Due to the work started in this thesis, the interaction of several small peptides and their sulfur 
analogues with oxaliplatin is being investigated by ESI-MS by the research group. These 
interactions are hypothesised to be of significance due to being N-rich, therefore acting as 
binding sites for oxaliplatin. It is thought that oxaliplatin is bound by a wide range of peptides 
and proteins in the cytosol and not just by a few select ’sulfur sinks’ such as methionine.  
 
6.4. RECOMMENDATIONS 
 
As a result of the EngD research the following recommendations are made:  
1. Apply methodology developed for the quantification of DNA to clinical DNA sample, to 
establish if the method is robust enough for clinical samples and not affected by 
extraneous sources of phosphate from DNA extraction methods.   
2. Digest DNA to phosphate with acid digestion and compare to whole DNA 31P 
concentration by FIA-ICP-MS and enzymatically digested DNA 
31
P concentration. The 
method for digesting DNA to phosphate by acid digestion has been used in studies 
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estimating the number of nucleotide bases per Pt atom in cancer studies. This experiment 
would prove if the digestion of patient DNA to phosphate is a true indicator for DNA 
concentration.  
3. Determine structure of the LysNTAGa-PDGF complex by NMR and X-ray 
crystallography, this will confirm the structure predicted by computational methods.  
4. Tag different phosphopeptides with LysNTAGa and analyse by ESI-MS and compare the 
binding with non-phosphopeptides containing several carboxylic acid groups. More 
experiments to compare the binding efficiencies are needed to see if competition from 
carboxylate groups would compete with phosphopeptides. 
5. Apply LysNTAGa tag to tryptic digest of β-casein and other phosphoproteins in a whole 
cell digest to assess how effective the tag is in a complex sample. 
6. Develop LC-ICP-MS and LC-MS method for the analysis of carnosine-oxPt and 
anserine-oxPt this will allow these adducts to be identified and quantified from an 
enzymatic digest of cancer cell cytosol.  
7. Identify specific binding points between oxaliplatin and carnosine by NMR and X-ray 
crystallography.  
 
6.5. SUMMARY 
 
This research project has investigated several small bio-molecules by both molecular and 
elemental mass spectrometry and their interactions with metals. Experiments have been 
performed to look at how to quantify these molecules and how they interact with metals, the 
findings show that bio-molecules can be quantified by LC-IC-MS with good accuracy, 
repeatability and not affected by extraneous sources of phosphate including RNA. 
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Abstract 
The determination of total deoxyribonucleic acid (DNA) concentration is of great importance 
in many biological and bio-medical analyses. The quantification of DNA is traditionally 
performed by UV spectroscopy; however the results can be affected greatly by the sample 
matrix. The proposed method quantifies phosphorus in digested calf thymus DNA and human 
DNA by high performance liquid chromatography (HPLC) coupled to inductively coupled 
plasma mass spectrometry (ICP-MS). The method presented showed excellent baseline 
separation between all 4 DNA mono-nucleotides and 5’UMP. Column recoveries ranging 
from 95% to 99% for phosphorus resulted in a mass balance of 95% ± 0.5% for standard 
nucleotides, determined by LC-ICP-MS, compared to total DNA determined by flow 
injection coupled to ICP-MS (FI-ICP-MS). The ability of LC-ICP-MS to act as an internal 
check that only DNA derived phosphorus was counted in the assay was demonstrated by 
establishing a mass balance between the total phosphorous signal from undigested DNA and 
that from the speciated DNA. The method for quantification was evaluated by analysis of 
NIST SRM 2372; a total speciated DNA recovery of 52.1 ng/µL, compared with an expected 
value of 53.6 ng/µL, was determined by external calibration. From repeat measurements a 
mass balance of 97% ± 0.5% for NIST DNA was achieved.   The method limits of detection 
for individual nucleotides were determined between 0.8 to 1.7 µg L
-1
 (
31
P) for individual 
nucleotides by LC-ICP-MS, and 360 ng L
-1
 for 5’AMP by direct nebulisation. 
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Introduction  
As one of the most important life elements, phosphorus is an integral part of a wide range of 
biochemical functions and structures, most notably protein phosphorylation and as the 
backbone of DNA. The backbone of both RNA and DNA is formed from phosphodiester 
linkages and due to the fixed stoichiometry of phosphorus; the quantification of such macro-
molecules can be obtained via the 
31
P signal by ICP-MS. Accurate quantification of DNA is 
of great importance for many biological, clinical and microbiological studies. Traditionally 
the quantification of phosphorus in bio-molecules has been achieved by UV absorbance, 
fluorescence via the incorporation of dyes, or by counting β radiation emission from 
radioisotope labelled 
32
P and 
33
P. Results acquired with spectrometric methods can be 
compromised by impurities in the sample, from RNA and metabolic molecules such as 
adenosine triphosphate (ATP) and require relatively large sample volumes [1]. The method 
presented here is able to distinguish contaminants of the DNA sample by differentiating 
between retention times. Recently, 
31
P, determined by ICP-MS, was used to estimate DNA 
yields in samples from patients undergoing Pt-based chemotherapy [2]. A robust and more 
accurate analytical method based on LC-ICP-MS could improve the reliability of such 
results.  
Over the last ten years elemental mass spectrometry has been increasingly used for the 
quantification of metals and heteroatoms within biomolecules, including the quantitation of 
phosphorus within nucleotides, oligonucleotides and DNA. Elemental analysis is preferred 
over other techniques as it offers lower detection limits, a larger dynamic range, a response 
that is to a first approximation independent of molecular form, and potentially more accurate 
quantification at low concentrations by isotope dilution analysis. Both ICP-MS and ICP-OES 
have been utilised for the quantification of nucleotides, DNA, oligonucleotides and DNA 
adducts [3-15].  The quantification of oligonucleotides has been achieved by two different 
methods by Yang et al. [4] and Donald et al. [7], with the latter group digesting the 
oligonucleotides to mono-nucleosides and quantifying by isotope dilution electrospray mass 
spectrometry (ES-ID-MS), and comparing that value to the total 
31
P signal obtained from 
ICP-OES and the gravimetric value.  Styrene oxidate and mephalen DNA adducts have been 
investigated by elemental mass spectrometry, by Edler et al. [12, 13] and styrene -7,8-oxide 
adducts by Siethoff et al. [11].  
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One of the most attractive characteristics of quantification by ICP-MS is the ability to mass 
balance the element of interest before and after speciation, however, because of the many 
different species of phosphorus within cells, quantifying total cell phosphorus content prior to 
separation is of limited value, as mass balance would not be achieved. Additionally, the 
quantification of phosphorus containing bio-molecules is hindered by the lack of suitable 
molecular internal standards and significant levels of background phosphorus within 
biological buffers. Furthermore, the detection of phosphorus by ICP-MS is difficult due to its 
high first ionisation potential (10.5 eV), resulting in only ~33% of the element being ionised, 
and polyatomic interferences caused by 
14
N
16
O
1
H
+
 and 
15
N
16
O
+
. 
 
These molecular 
interferences can be removed in a collision/reaction cell by the addition of a collision/reaction 
gas such as He or H2, alternatively the element of interest can be reacted, e.g with O2, so that 
the product ion is in an area of less interference, in the case of phosphorus by the formation 
of 
31
P
16
O. The preferred solution is to use a sector field mass spectrometer that can resolve 
the spectral interferences and provides superior sensitivity. 
 
Despite several publications citing the analysis of phosphorus from enzymatic digests of 
nucleic acid, the quantification of each nucleotide within such a digest had not been 
established until recently by Fujii et al [16] who employed capillary electrophoresis coupled 
to ICP-MS.  Accurate quantification of phosphate within each nucleotide from a DNA digest 
requires complete and reproducible enzymatic digestion, under conditions compatible with 
the separation and detection method chosen. This work demonstrates for the first time that 
mass balance can be achieved for total DNA and the speciation of all 4 nucleotide standards 
by LC-ICP-MS.  
 
Experimental Section 
Instrumental  
Two ICP-MS instruments were used in this study, the first being an Agilent 7500 ce (Agilent 
Technologies, Berkshire, UK) equipped with an octopole reaction cell system (ORS) and the 
second a Thermo Element 2 XR, sector field instrument (Thermo Scientific, Hemel 
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Hempstead, UK); operating conditions are given in Table 1. The Agilent 7500ce was 
optimized with a standard solution of 1 ng mL
–1
 Be, Co, In, Pb, and U in normal mode, and 
further optimized in ORS mode for the flow rate of the reaction gases. The Element 2 XR 
was optimised with a standard solution of 1 ng mL
-1
 containing In, Li and Pb. An LTQ linear 
ion trap mass spectrometer was used in this study (Thermo Scientific, San Jose, USA) 
equipped with an electrospray ionisation (ESI) source operated in positive mode at 5.5 kV 
and 280 ºC. N2 was used as the nebulisation gas with sheath, auxiliary and sweep gas flows 
set at 50, 10, and 10 arbitrary units, respectively. 
Table 1: Instrumental parameters for the elemental mass spectrometers 
 
LC-ICP-MS was conducted using an Agilent 1100 system connected to the Agilent 7500 ce 
using a micro-flow nebuliser (Agilent), with a cooled Scott double pass spray chamber. The 
Element 2 XR was connected to an HPLC system, consisting of a solvent delivery pump and 
micro auto-sampler (Surveyor, Thermo Scientific, Hemel Hempstead, UK), via a 0.005’’ 
peek tube, a cyclonic spray chamber (ESI) and poly(fluoroalkoxy) (PFA) nebuliser 
(Elemental Scientific, Omaha, USA).  
 
  
ICP-MS system Thermo-Scientific Element 2 
XR 
Agilent  7500ce 
Power (kW) 1.25 1.57 
Gas Flows (L min
-1
)    
Plasma 15.5  15.00 ( Make-up – 0.27) 
Auxiliary 
Nebuliser  
0.80 
1.13 
1.00  
0.87 (carrier) 
Reaction gas (ORS mode) N/A Helium (3.1 mL min
-1
)  
O2 (25% in Argon, 3.1 mL min
-1
)  
Resolution Medium  
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Reagents 
Ultra-pure water (> 18 MΩ) was obtained from a Milli Q Element system (Millipore, Herts, 
UK). Mobile phases were prepared by diluting triethylamine acetate (TEAA, HPLC grade, 
Fluka, Dorset, UK) in ultra-pure water; the pH was monitored using a Jenway pH meter. All 
other reagents and standards were purchased from Sigma Aldrich (Dorset, UK) including 
thymidine-5'-monophosphate  (5’TMP > 98-100%), cytidine-5'-monophospate sodium salt 
(5’CMPNa ≥ 99%), guanosine-5'-monophosphate sodium salt (5’GMPNa ≥ 97%), uridine-5'-
monophosphate disodium salt (5’UMPNa2 ≥ 97%),  adenosine-5'-monophosphate (5’AMP 
Na ≥ 98%), Nuclease S1 and calf thymus DNA.  
 
Optimisation of separation conditions: The chromatographic method was developed from 
that of Profrock et al. [5], by altering the conditions to improve separation and changing the 
mobile phase from ammonium acetate to triethylamine acetate to improve compatibility with 
ICP-MS and using a C18 column, with high mechanical strength due to a unique organo-silica 
grafting process making it compatible with high aqueous loading. All separations were made 
using a Phenomenex Gemini NX column (150x2.1mm, 5µm) at a flow rate of 0.20 mL/min 
and the column was kept at a constant 25
o
C. Isocratic separations were made using TEAA 
(5mM, pH 6.5) as the mobile phase and samples were injected onto the column at a volume 
of 2µL.  
 
Calf thymus DNA enzymolysis. After parametric optimization, a total of 20 μg Plasmid 
DNA was heated to 80 °C for 5 min at 200W, cooled on ice and was then incubated at 50 °C 
for a further 5 minutes with 20 U μg–1 Nuclease P1 at 55W.  
Quantification Strategy  
This strategy exploited the compound independent signal sensitivity of ICP-MS which allows 
quantification of complex organic molecules by calibration with inorganic metal salts. Thus 
prior to speciation, the flow-injected signal magnitude (area under curve) measured by ICP-
MS should be equal to the total signal magnitude after speciation, provided that there is 
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efficient recovery of species from the separation column. The proposed strategy for the 
quantification of calf thymus DNA is detailed in Figure 1.  
 
 
 
 
 
 
 
 
Figure 1: Proposed quantification of calf thymus DNA work-flow 
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Results and Discussion 
Linearity and Robustness: The data presented here were collected using LC-SF-ICP-MS, 
calibration curves were prepared for all 5 mono-phosphate nucleotides in the range of 5-15 ng 
P/g for inter-assay (n=3) and intra-assay (n=3).  Figure 2 shows typical calibration data 
collected for d’AMP, d’CMP, d’GMP and TMP exhibiting good linearity with correlation 
coefficients of greater than 0.997. Application of one-way ANOVA showed there was no 
statistical difference (p=0.95) between the slopes for the 4 different nucleotides. The relative 
standard deviation (RSD) of the slopes for these calibration curves were 3.6% for the intra-
assay and 6.5% for the inter-assay.  Repeatability of injection was calculated as 0.2% RSD 
(n=6).  
Limits of Detection: LOD’s for phosphorus for the standard nucleotides were calculated 
using the standard error of the regression data, as ranging from 0.8 to 1.7  µg/L, by LC-SF-
ICP-MS,  which are similar to results reported by Fujii et al. [17] from µLC-ICP-MS. A limit 
of detection of 20 pg of P on column was achieved. This is significantly higher than that 
reported by Fujii et al. [18], but if the method reported here were to be scaled down, further 
improvement in the absolute limits of detection would be obtained. Limits of detection were 
calculated as ranging from 2.4 to 9.1 µg/L, by ORS-ICP-MS with oxygen addition to the 
reaction cell, and 2.0 to 3.1 µg/L with helium addition.   LOD’s ranging from 0.3 to 2.7 µg/L 
were calculated from the standard deviation of the blank, with helium addition to the octopole 
reaction cell. Whilst it was expected that the LOD’s obtained by the SF-ICP-MS instrument 
would be up to an order of magnitude lower than those obtained with the ORS-ICP-MS 
instrument, it was not observed as such. The high blank concentrations of phosphorus 
negated the better signal to noise ratio of sector field instrument.  
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Figure 2: A typical calibration chart for nucleotide standards 
 
Column recoveries: These were determined for each nucleotide standard from the injection 
of 5 µL of the nucleotide standard with and without the column in place, the recoveries 
ranged from 95 to 98%, as shown in Table 2.  
 
Table 2: Recoveries of individual nucleotides using FI-ICP-MS 
Nucleotide % Recovery 
d’CMP 98.7 ± 0.5 
d’TMP 97.8 ± 1.1 
d’GMP 99.1 ± 1.2 
d’AMP 98.4 ± 1.2 
UMP 98.0 ± 3.1 
 
d'CMP   R² = 0.9952 
TMP   R² = 0.9979 
d'GMP     R² = 0.9981 
d'AMP    R² = 0.9983 
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Mass Balance  
A solution containing 200 ng/g of each nucleotide was prepared in 20 mM TEAA at pH 6.4 
and analysed by LC-ICP-MS using the conditions stated in Table 1. The total peak areas for 
the individual nucleotide standards and that of the void volume peak were summed and 
compared to the peak area of a flow injection peak for the same standard solution in order to 
calculate the mass balance. The LC-ICP-MS results show that a mass balance of 97.2% ± 
0.5% was achieved by this experiment, which was expected due to the high column 
recoveries observed. The mass balance calculation data is shown in Table 3 for both NIST 
SRM DNA and nucleotide standards. Errors were calculated from the standard error of the 
mean for each peak in the digest and for the repeated flow injection peaks, and then treated 
with the propagation of errors formula.  
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Table 3: Total peak areas for speciated nucleotide standards and digested NIST DNA and flow injection 
peak areas for nucleotide blend and undigested NIST DNA. 
NIST DNA 
Run Total Peak Area / 
counts 
Run  FIA Peak Area / 
counts  
1 165538.4 1 169729.4 
2 160938.8 2 168704.7 
3 163914.6 3 167007.8 
Average 163463.9 4 167446.2 
  Average 168222.0 
  Mass 
Balance  
97.2% ± 0.5 % 
 
Nucleotide Standards 
Run Total Peak Area / counts Run  FIA Peak Area / counts  
1 11065522 1 11398134.9 
2 11155169 2 11849337.3 
3 11348798 3 11999766.6 
Average 11189830    
    Average 11749079.6 
    Mass Balance 95.2% ± 0.5% 
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Measuring total P as an indicator of DNA concentration is problematic as even in highly 
purified and well characterised samples, such as the NIST standard, there are likely to be P-
containing residues from the purification procedure. 
 
 
Figure 3: LC-SF-ICP-MS chromatograms of 31P, A: single monophosphate nucleotide standards, B:  
digested calf thymus DNA 
 
Figure 3 compares the separation of a mixture of mono-nucleotide standards and digested calf 
thymus DNA. The slight change in the observed retention times was due to the variation in 
the mobile phase pH, from non consecutive chromatograms, however, the peaks were 
positively identified by LC-MS. The unknown peak observed in both the nucleotide standards 
d’AMP 
d’CMP 
d’CMP 
TMP 
TMP 
d’GMP 
d’GMP 
d’AMP 
B 
A 
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and the DNA digest is thought to be the result of phosphate buffers used in the purification 
process. The presence of these buffers did not affect the quantification of DNA when 
speciation was used, because the first peak can be ignored, but would affect an assay based 
on total P where it would be included. This was proven by fraction collecting the individual 
nucleotide peaks from the Sigma standards, digesting to phosphate and quantifying by direct 
nebulisation into the ICP-MS. This experiment was also performed on the DNA digest. 
Chromatograms run including UMP in the mixture showed the UMP baseline separated with 
a retention time of approximately 4.8 minutes.  
 
 LC-ESI-MS, using the same separation conditions as for LC-ICP-MS, was used to 
positively identify each peak by analysis of a mixture containing all 4 DNA nucleotide 
standards as seen in Table 4.   Comparison of parent ions from the standard run and that of 
the digest allowed the identification of 4 out of the 5 peaks in the DNA digest LC-ICP-MS 
chromatogram. As indicated above, it is believed that the unknown peak observed in both the 
standards and the digest are phosphates from biological buffers.  
 
Table 4:  DNA digest positive peak identification by LC-ESI-MS 
 Nucleotide Standards DNA Digest 
 m/z Identification m/z Identification 
Peak 1  Unknown   Unknown  
Peak 2 323 [M]
+ = 5’CMP 323 [M]+ = 5’CMP 
Peak 3 348 [M]
+ = 5’GMP 348 [M]+ = 5’GMP 
Peak 4 322 [M]
+ = 5’TMP 322 [M]+ = 5’TMP 
Peak 5 331 [M]
+ = 5’AMP 331 [M]+ = 5’AMP 
 
 
Accuracy of the quantification method was evaluated by the analysis of NIST SRM 2372, 
component B. Component B was digested using the procedure outlined above, diluted to a 
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final volume of 65µL and analysed by LC-ICP-MS.  The phosphorus content of the 4 
nucleotides was calculated by external calibration with standard nucleotides from Sigma as; 
d’CMP 11.2 ±0.1 ng/µL, d’GMP 13.1±0.1 ng/µL, TMP 13.6 ±0.1 ng/µL and d’AMP 14.2 
±0.1 ng/µL, giving a total of 52.1 ng/µL. The stated DNA concentration for component B 
was 53.6 ±0.4 ng/µL, giving a recovery of 97.2%. To further confirm the mass balance, 3 
repeat flow injection analyses and two repeats digest analyses (n=6) were performed. The 
summation of the peak areas of the digested DNA were compared to the peak area of 
undigested NIST DNA analysed by FI-ICP-MS which yielded a mass balance of 97 ± 0.5%. 
The unknown phosphate peak observed in the digest was included in the mass balance 
calculation.  
Conclusions  
Successful separation and P-selective detection of all 5 common DNA nucleotides within a 
timeframe of 20 minutes was achieved using reversed phase HPLC with ICP-MS detection. 
Limits of detection for phosphorus associated with individual nucleotides were found to be 
comparable with previously reported values, ranging between 0.8 to 1.7 µg L
-1
. Furthermore, 
it has been shown that a full mass balance for monophosphate nucleotides with the newly 
developed method is achievable. The method was validated against NIST SRM 2372 with 
recoveries of 97.2 %. The results presented here have demonstrated that DNA can be 
quantified at low ng/g concentrations by measuring the total P concentration from DNA using 
FI-ICP-MS versus the summation of the P signal peak area from the individual nucleotides 
following a simple digestion of whole DNA and HPLC-ICP-MS analysis.  
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Abstract 
Protein phosphorylation and de-phosphorylation is one of the most common signalling 
pathways within cells, it is involved in regulating cellular processes, mediating enzyme 
inhibition, protein-protein recognition and protein degradation. Compared with normal 
proteomics, phosphoproteomics poses some additional challenges requiring more initial 
separation and additional sensitivity to detect and quantify potentially ultra-low abundance 
species. In this work, a novel approach to the selective detection of phosphopeptides is 
described based on the incorporation of a metal tag, gallium–N,N-biscarboxymethyl lysine 
(Ga-LysNTA), in solution before separation and detection by liquid chromatography coupled 
to inductively coupled plasma mass spectrometry (LC-ICP-MS).  Linear ion trap electrospray 
ionisation mass spectrometry (ESI-MS) was employed to study the interaction of the gallium 
tag with platelet derived growth factor beta receptor (β-PDGF), a small phosphopeptide. In 
addition high resolution Fourier transform mass spectrometry (FT-MS) was used for accurate 
mass determination and multistage tandem mass spectrometry of the gallium-β-PDGF 
complex identified the fragmentation pathway.  Finally, molecular modelling was used to 
investigate the energetically favoured structures of both the Ga-LysNTA material and the β-
PDGF-Ga-LysNTA complex.  
 
Keywords: Phosphopeptides, metal tagging, ICP-MS, Ion-trap ESI-MS, DFT, ONIOM 
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Introduction 
Protein phosphorylation is an important post-translational modification and plays an 
important role in the regulation of many systems within organisms.  Irregular protein 
phosphorylation can result in diseases such as chronic myelomonocytic leukaemia and 
papillary renal cancer.[1] The characterisation of phosphorylation sites has been widely 
investigated by the use of tandem mass spectroscopy.[2-11] A typical phosphoproteome 
work-flow involves the purification of the protein of interest by gel electrophoresis or 
reversed phase chromatography, trypticdigestion, enrichment of phosphopeptides followed by 
analysis using liquid chromatography coupled to tandem mass spectrometry. Phosphopeptide 
identification by triple quadrupole mass spectrometry is achieved by two methods; neutral 
loss scans that identify phosphopeptides from the loss of H3PO4 or HPO3 on collisional 
activation from phosphorylated serine and threonine residues or parent ion scans for the 
common product ions H2PO4
-
 or PO3
- 
.[12-14] 
It is often necessary to enrich phosphopeptides following digestion of the target protein, due 
to their low concentrations and poor ionisation efficiencies in positive mode mass 
spectrometry.[15-29] Many different analytical techniques have been developed to 
specifically enrich phosphopeptides including Immobilised Metal Affinity Chromatography 
(IMAC), utilizing iron, gallium, and more recently titanium and zirconium. [15, 18, 29-46] 
The efficiency of each of these metals in selectively binding phosphopeptides has been 
extensively investigated many times with varying success. This has been attributed to the 
non-specific binding of the acidic amino acid residues asparagine and glutamine to the metal 
ions, the binding of hydrophobic residues to the gel bed and the elution of multiply 
phosphorylated peptides and impurities in the metal oxide material. [47,48] Research 
suggests that selectivity can also be dependent on the combination of resin bed and metal ion, 
with several studies showing that nitrilotriacetic acid (NTA) combined with Fe
3+
 gave higher 
specificity for phosphopeptides than iminodiacetic acid (IDA) with Fe
3+ 
[49,50] however, 
when Ga
3+
 was used the reverse was found to be true and IDA gave better specificity than 
NTA, [51] although Ga
3+
 was found to have better selectivity overall. [51-54] Selectivity can 
also be improved by blocking acidic amino acid residues by methyl-esterification, [55] 
however there were two problems reported with this approach these being incomplete 
esterification [56] and increased complexity due to side reactions. [39] Additionally, 
selectivity for mono- and multiply-phosphorylated peptides is dependent on both the metal 
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ion and the pH of the loading and elution buffers.  Reports have shown that Ti
2+
 and Fe
3+
 
have a higher selectivity for mono-phosphorylated peptides. [57, 58] Peptides containing 
phosphorylated serine and threonine residues can be enriched and modified by methods based 
on Isotope Coded Affinity Tags, [10, 59] in which the phosphate group is eliminated by base 
hydrolysis and a biotin or mercaptoethanol group is introduced by Michael addition, then 
selectively detected by capture/elution with streptavidin or with sulphur specific antibodies. 
[12] 
 
Blacken et al. [12, 58] reported the use of post separation column tagging of phosphopeptides 
with N,N-biscarboxymethyl-lysine ligand (Ga-LysNTA, C10H16N2O6Ga) prior to analysis by 
tandem mass spectrometry. We hypothesized that this tag could be used homogeneously in 
solution to selectively tag phosphopeptides followed by separation and analysis employing 
the very high selectivity and sensitivity of ICP-MS to quantify the Ga.  For this to work as a 
viable analytical method the requirement is for a stable stoichiometry between the Ga and the 
phosphopeptide (notionally a 1:1 complex) and high selectivity to the phosphate group. In the 
original papers it was claimed that binding to the phosphate group was independent of the 
amino acid to which the phosphate group is bound.  Because of the potential complexity of 
working with mixtures of phosphopeptides derived from tryptic digests, a model system was 
chosen that would lend itself to careful analysis by mass spectrometry supported by 
molecular modelling. We did not here consider using conventional structural analysis 
techniques such as XRD or NMR because in the analytical context this method has to work at 
the nmol level if it is to be useful and therefore we have restricted the experimental work to 
techniques that can function at that level. 
 
The feasibility of using this homogeneous metal affinity tagging ‘HMAT’ of 
phosphopeptides in solution was investigated.  HPLC coupled to high resolution, sector-field 
ICP-MS was used for the separation of the resultant complexes and detection of both 
69
Ga 
and 
31
P signals. Elemental mass spectrometry is preferred over other techniques as it offers 
lower detection limits, a larger dynamic range, a response that is to a first approximation 
independent of molecular form, and potentially more accurate quantification at low 
concentrations by isotope dilution analysis. Linear ion trap electrospray ionisation mass 
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spectrometry (ESI-MS) was employed to study the interaction of the gallium tag with platelet 
derived growth factor beta-receptor (β-PDGF) which is a cell surface receptor that is 
important in the regulation of cell proliferation, growth and development and is linked to 
many disease states including cancer. In addition high resolution Fourier transform mass 
spectrometry (FT-MS) was used for accurate mass determination and multistage tandem mass 
spectrometry of the gallium-β-PDGF complex formation and determination of the fragment 
pathway.  Finally, molecular modelling was used to complement the experimental results and 
to obtain more detailed structural and thermodynamic data for the complexes formed.  
 
Materials and methods 
Instrumentation 
Electrospray-MS. An LTQ linear ion trap mass spectrometer (Thermo Scientific, San Jose, 
USA) and a high resolution Q-Exactive Fourier transform mass spectrometer (Thermo 
Scientific, San Jose, USA) were used in this study for mass spectrometric determinations. 
The LTQ-MS was equipped with an electrospray ionisation (ESI) source operated in positive 
mode at 5.5 kV and 280 ºC for the capillary temperature.  Nitrogen was used as the 
nebulising gas with sheath, auxiliary and sweep gas flows set at 50, 10, and 10 arbitrary units, 
respectively. The Q-Exactive was equipped with a Tri Versa NanoMate ESI chip nanospray 
(Advion, New York, USA). Both instruments were calibrated using Ultramark
®
 1621, 
caffeine and Met-Arg-Phe-Ala (MFRA) in accordance with the manufacturer’s 
recommendations. 
ICP-MS. Thermo Element 2 XR (Thermo Scientific, Hemel Hempstead, UK), with operating 
conditions as follows, an operating power of 1.25 kW,  plasma gas flow of 15.50 L min
-1
, 
nebuliser gas flow of 1.18 L min
-1
 and an auxiliary flow of 0.85 L min
-1
.  The instrument was 
optimised with a standard solution containing 1 ng mL
-1
 of In, Li and Pb. For LC-ICP-MS 
analysis, the column outlet was directly connected via a 0.005’’ peek tube to a 
poly(fluoroalkoxy), (PFA) LC nebuliser (Elemental Scientific, Omaha, USA). A cyclonic 
spray chamber (Elemental Scientific, Omaha, USA) was used throughout all analyses.  
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Reversed-Phase HPLC system. Reversed-phase separations were carried out using a Thermo 
Surveyor MS Pump Plus (San Jose, Ca, USA) and sample injections were performed by a 
Thermo Micro AS (San Jose, Ca, USA). The HPLC column used for the separation was a 
Supelco Ascentis Express Peptide C18 column (150 x 2.1mm, 2.7 µm).  
 Materials  
Nα,Nα-Bis(carboxymethyl)-L-lysine hydrate (LysNTA,C10H18N2O6 .xH2O > 97%), Gallium 
(III) chloride (anhydrous, 99.99% trace metals free), ammonium acetate (99.99% trace metals 
free) and acetic acid were purchased from Sigma Aldrich (Dorset, England). Trypsin Gold 
(mass spectrometry grade) was purchased from Promega (Southampton, UK). Methanol 
(HPLC grade) was sourced from Thermo Fisher (Loughborough, UK). Water was purified to 
18 MΩ using an Elix and Element System (Millipore, Billerica, Massachusetts, USA).  
 
Sample Preparation and Procedures 
Formation of β-PDGF-Ga-LysNTA: LysNTA (5.2 mg), Ga2Cl6(4.7 mg) and β-PDGF (0.5 
mg) were dissolved in 5 mL of 50:50 (v/v) methanol:water solution to give a final 
concentration of 0.1 mg mL
-1
 of β-PDGF-Ga-LysNTA with a10 fold excess of LysNTA and 
Ga2Cl6.  For ESI-MS
n
 analysis further dilution was not necessary, for LC-ICP-MS analysis 
the sample was diluted in 50:50 (v/v) methanol:water solution to a concentration of 10 µg 
mL
-1
 of β-PDGF-Ga-LysNTAassuming a 100% tagging efficiency.  
 
Confirmation of β-PDGF-Ga-LysNTA formation by ESI-MSn.  To optimise signal intensity 
for the ions of interest, the LTQ Ion Max auto-tune optimisation was performed to set the 
values for the lens, quadrupole and Octopole voltages.  Helium gas was used as the collision 
gas for collision-induced dissociation (CID) with the ion-trap held at a pressure of 
approximately 10
-3 
Torr.  Fragmentation experiments were conducted by selecting the ion of 
interest with an isolation width of 8 Daltons, collisional activation was applied by setting the 
activation amplitude (the amplitude of the radiofrequency (RF)) at 15 – 25 % of the 
maximum voltage available (determined empirically) and an activation Q set at 0.25 units. 
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Sample solutions were infused at a flow rate of 10 µL min
-1
 through an electrospray probe 
using nitrogen as the nebulising gas, with sheath gas flows set to 10 arbitrary units.  
 
Confirmation of β-PDGF-Ga-LysNTA formation by LC-ICP-MS.  To confirm successful 
binding of Ga-LysNTA to β-PDGF, HPLC separation coupled to ICP-MS detection was 
performed employing a linear gradient over 15 mins from 5 % aqueous (Eluent A: 100 % 
H2O with 0.05 % acetic acid) to 70 % organic (Eluent B: 100 % CH3OH with 0.05 % acetic 
acid) at a total flow rate of 100 µL min
-1
. The column was allowed to re-equilibrate for 5 
minutes between injections.  Both mobile phases were spiked with 500 ppt of Mo to act as an 
internal standard to monitor changes in sensitivity due to the increase in organic solvent.  The 
sample injection volume was 5 µL, which gave 50 ng of β-PDGF-Ga-LysNTA (34 ng of β-
PDGF) on column.  The column was heated to 30 
o
C for the length of the run. To decrease 
the concentration of organic solvent in the plasma, an additional flow of 700 µl min
-1 
of H2O 
was added post-column. For the ICP-MS analysis; the power was set to 1.25 kW, nebuliser, 
auxiliary and plasma gases to 1.18, 0.85 and 15.50 L min
-1 
respectively and operated in 
‘speed mode’ in medium resolution. 
 
Computational Methods 
All calculations were performed with Gaussian 09. [60] Initially structures were optimized 
without symmetry constraints by means of Hartree–Fock (HF) calculations using the STO3G 
basis set.  These initial optimisations were then used as starting geometries for higher level 
calculations employing density functional theory (DFT) at the B3LYP level, [61] in 
conjunction with the electron core potential (ECP) double-zeta LANL2DZ basis set. [62, 63]  
All critical points were characterized by harmonic frequency calculations and were shown to 
be at minima.  Total energies, zero point energies, thermal corrections and entropies are given 
in supplementary material.  The relative computational tractability of this theoretical method 
makes it suitable for calculations of systems containing relatively large numbers of heavy 
atoms such as those under study here.  Much more importantly however are the results of 
DFT calculations in systems involving transition metals, which are in many cases in better 
agreement with experimental data than those obtained from Hartree–Fock (HF) calculations. 
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[64] A two-layer ONIOM (Quantum Mechanical (QM):Semi-Empirical (SE)) calculation at 
the (B3LYP/LANL2DZ:PM6) level was conducted on the lowest energy species found for 
the β-PDGF-Ga-LysNTA complex.  In a two-layered calculation the complex under study is 
separated into model and real regions.  The real region contains all the atoms of the complex 
and is thus calculated only at the lower level being the PM6 semi-empirical method.  The 
PM6 method was chosen here as it has been shown to have suitable parameterization for 
biochemical systems and the capabilities of carrying out calculations on molecules containing 
transition metals such as the complex investigated here. [65] The model region on the other 
hand contains the reactive centre and any other part of the system that is of particular interest.  
Both higher level of theory employing the B3LYP/LANL2DZ method and lower level 
calculations using PM6 were carried out for the model region.  The total energy of this 
system was obtained from these three independent calculations: 
 
                                             (    )  
 
When dividing the complex into the real and model regions care was exercised not to cut 
through multiple covalent bonds or aromatic systems.  However, because there are single 
covalently bonded interactions between the two regions, hydrogen link atoms were chosen to 
saturate the open valence created.    
 
Results and Discussion 
 
Evidence for Ga-LysNTA tag formation  
Evidence for the formation of Ga-LysNTA can be observed in the experimental data shown 
in Panel A of Figure 1. This experimental isotopic pattern compares very favourably with the 
theoretical isotopic pattern of Ga-LysNTA shown in Panel B of Figure 1. The formation of 
Ga-LysNTA was further confirmed by means of accurate mass FT-MS where the average 
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mass deviation was only 0.08 ppm (See Table 1) (as calculated according to equation 2 
shown below) for the observed isotopic peaks that make up the experimental pattern for Ga-
LysNTA. 
      (
            
     
)           (    ) 
 
Calculations on the Ga-LysNTA
+
 species were initially performed at HF/STO3G, the lowest 
five energy species from these calculations were re-optimised at the B3LYP/LANL2DZ level 
of theory.  The lowest energy conformation calculated for this species is structure 1A as 
shown in Figure 2.  In this structure the gallium metal is tetra-coordinated, binding to three 
carbonyl oxygen atoms as well as to the backbone nitrogen of the LysNTA substrate.  This 
binding arrangement, while serving to dissipate the large positive charge on the metal centre, 
also results in the formation of three distinct five membered heterocyclic rings with the 
gallium metal being at their intersection.  Highlighted in Structure 1A is a strong hydrogen 
bond (1.595 Å as calculated at B3LYP/LANL2DZ) where the hydrogen atom formally 
resides on the terminal amino nitrogen and is shared with the closest carbonyl oxygen atom.  
This hydrogen bonding results in the formation of a pseudo-nine membered ring along the 
LysNTA backbone.  The large number of rings that result due to this conformational 
geometry is responsible for one of the lowest entropy terms calculated out of all 
conformations considered for the Ga-LysNTA species as listed in supplementary materials 
(see Table S1).  The next lowest energy species on this surface is Structure 1B being 10.3 
kcal mol
-1
 higher in free energy, in this structure the gallium centre is also tetra-coordinated 
and is also at the intersection of three distinct heterocyclic rings.  The coordinating sites to 
the gallium metal in Structure 1B are the terminal amino nitrogen, the backbone nitrogen as 
well as two of the carbonyl oxygen atoms of the LysNTA substrate.  This geometric 
arrangement results in the formation of two of the smaller five membered heterocyclic rings 
and one larger eight membered heterocyclic ring.  Structure 1C is calculated to be 37.6 kcal 
mol
-1
 higher in free energy on the potential energy surface relative to Structure 1A.  This 
higher energy species shows a similar gallium metal coordination as that of Structure 1A 
being tetra-coordinated and binding to three carbonyl oxygen atoms as well as to the 
backbone nitrogen of the LysNTA substrate.  The lack of formal coordination and the 
absence of any hydrogen bonding at the amino nitrogen in Structure 1C allows for a much 
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more extended backbone arrangement relative to that of Structure 1A.  This is evident in the 
larger entropy term listed in supplementary materials for Structure 1C.  Structure 1D is nearly 
identical to Structure 1C with the former having a gallium hydroxyl oxygen coordination 
substituting for a stronger coordination of the metal to one of carbonyl oxygen atoms of the 
LysNTA substrate in the latter.  This difference in coordination makes Structure 1D seven 
kcal mol
-1
 higher in free energy relative to Structure 1C.  The lowest energy structure 
calculated on this surface is Structure 1E, where the gallium metal is tri-coordinated, the 
metal centre binding to two carbonyl oxygen atoms and the backbone nitrogen of the 
LysNTA substrate.  The gallium-carbonyl oxygen bonds in Structure 1E are calculated to be 
1.758 and 1.754 Å which are much shorter and thus stronger than those found in Structure 1A 
being 1.787, 1.794 and 1.841 Å respectively.  Structure 1E also features a strong hydrogen 
bond (1.493 Å as calculated at B3LYP/LANL2DZ) between a hydrogen atom which formally 
resides on the terminal amino nitrogen and a carbonyl oxygen atom.  This hydrogen bonding 
helps to stabilise Structure 1E, however, the lower coordination number of gallium in this 
structure makes it nearly 60 kcal mol
-1 
higher in energy relative to Structure 1A. The 
remaining structures 1F, 1G and 1H shown in Figure 2 were the highest energy species 
calculated at HF/STO3G being 48.8, 57.0 and 127.3 kcal mol
-1
 higher in free energy 
respectively relative to Structure 1A and were thus not considered at the higher level of 
theory.    
 
The presence of a water adduct to Ga-LysNTA was identified and confirmed by comparison 
of the experimental signal with the theoretical isotope pattern model and was found to be in 
excellent agreement with an average mass accuracy of 0.08 ppm (see Figure 3 and Table 1). 
An interesting cluster was observed at m/z 361-370, which is proposed to be due to the 
signals of LystNTAGa•CH3OH and Ga-LysNTA•2H2O adducts (see Figure 4). Closer 
inspection of this cluster and matching to modelled theoretical isotope patterns indicated that 
it consisted of a 2:1 ratio of [Ga-LysNTA•MeOH]+:[Ga-LysNTA•2H2O]
+
. This suggests that 
the two acidic carbonyl groups have lost a hydrogen atom in order to form two ionic bonds to 
the gallium cation in the Ga-LysNTA complex; therefore the Ga-LysNTA is unlikely to 
accept lone pairs from remaining water molecules in the gas phase. 
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Evidence for β-PDGF Ga-LysNTA complex formation  
The complexation of Ga-LysNTA with the phosphopeptide PDGF β-receptor, which has a 
primary structure of H-pTyr-Val-Pro-Met-Leu-OH, to form the Ga-LysNTA-β-PDGF adduct 
at m/z of 1030.3, was confirmed by comparison with the theoretical isotope pattern (see 
Figure 5) and by accurate mass FT-MS with an average mass accuracy of 4 ppm (see Table 
1). The Ga-LysNTA and β-PDGF reactants are also visible in the mass spectrum (see Figure 
5). Several other species which were observed in the mass spectrum were identified and 
summarised in Table 2. To further confirm the formation of Ga-LysNTA-β-PDGF, the 
resulting entire isotopic pattern was selected at an isolation width of 8 Da and fragmented at 
collision energy of 15 eV, resulting in the MS/MS spectrum shown in Figure 6. 
Fragmentation of the complex resulted in daughter ions representing β-PDGF and the cluster 
at m/z 361-370 as described above.  
 
Complementary evidence for the formation of Ga-LysNTA-β-PDGF was obtained by means 
of HPLC-ICP-MS, using the conditions outlined in the methods section.  The chromatogram 
obtained shows a single peak in the 
31
P signal trace at a retention time of 3.89 mins which 
corresponded to an exact retention time match to that of the complexed 
69
Ga signal peak, 
confirming the formation of Ga-LysNTA-β-PDGF, see Figure 7. The earlier eluting 69Ga 
peak at 3.13 mins, was most likely due to unbound Ga-LysNTA as confirmed from a separate 
LC-ICP-MS run of Ga-LysNTA in the absence of β-PDGF (data not shown). The sample 
introduction system was not optimised for sensitivity and so an 8 fold post column dilution 
was employed to reduce plasma instability due to the high concentration of methanol in the 
mobile phase. The detection limit for Ga (calculated from three times the standard error in the 
curve) was 0.5 ng ml
-1
 which for a 10 l injection equates to 5 pg Ga or ~50 pg of PDGF. 
The 
98
Mo signal remained constant throughout the chromatographic run as would be expected 
given that the gradient eluent was diluted 8 fold post column. 
 
Computational modelling of this complex between the Ga-LysNTA species and the 
phosphopeptide PDGF β-receptor was performed in order to gain insight into the structure.  
Three conformations of this complex were calculated at HF/STO3G while only two of these 
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structures were calculated at the higher B3LYP/LANL2DZ level (see the results listed in 
Table S1).  As observed before for the Ga-LysNTA species calculated in this work, the 
relative free energy ordering of the conformers calculated did not change from the lower HF 
method to the higher level of theory employed here.  The most favoured of the three 
structures energetically is Structure 2A as shown in Figure 8 in which the gallium metal is a 
penta-coordinate centre.  In this structure the gallium centre binds to two carbonyl oxygen 
atoms of the LysNTA substrate which does not exhibit any formal binding or hydrogen 
bonding at its terminal amino nitrogen resulting in an extended open arrangement for 
backbone of the LysNTA substrate in the formed complex.  Structure 2A also shows the 
gallium centre binding to the two carbonyl oxygen atoms of the valine and methionine 
residues of the phosphopeptide PDGF β-receptor while the last coordinating site to the 
gallium metal is one of the oxygen atoms of the phosphate moiety which replaces the 
hydrogen of the hydroxyl group of the tyrosine residue.  This observation is extremely 
important as it throws some light on why the literature offers diverse and sometimes 
contradictory information about the efficiency and selectivity of IMAC (and in this case the 
related HMAT) techniques.  Whilst the Ga certainly does target the phosphate group, it only 
uses one of the phosphate oxygens with the other analyte derived coordination sites being 
provided by electron donating centres on the amino acid residues of the peptide. The 
inference here (which would take a much larger study to verify) is that Ga tagging 
complexes, such as the one described here, can successfully target the phosphate group, but 
that the stability of the complex will also depend on the residue sequence of the peptide.  It is 
also possible, though not investigated here, that weaker complexes could form with peptides 
that do not contain phosphate. This would be revealed by an increased complexity in the 
elemental chromatogram, but could be controlled by varying the experimental conditions or 
chemical blocking of competing groups.  A group of five internal hydrogen bonds help not 
only to stabilize Structure 2A but also to result in a somewhat constricted configuration.  
Although we expect 6 coordination for Ga, efforts to obtain structures with higher 
coordination at the gallium centre were not successful; in fact, the other two structures 
calculated for this complex each involved either a tri- or a tetra-coordinated gallium metal 
and were shown (see HF data listed in Table S1) not to be very energetically competitive. 
This is most likely due to steric crowding given the bulky ligands that are surrounding the 
Ga.  The complex in which the gallium metal is tetra-coordinated was calculated at the higher 
level of theory employed here.  This structure 2B (not shown, see Table S1) featured a near 
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tetrahedral gallium centre binding to two carbonyl oxygen atoms of the LysNTA ligand and 
two of the oxygen atoms of the phosphate group on the PDGF β-receptor.  It also features six 
internal hydrogen bonds making for a very compact geometry and was calculatedto be 27.5 
kcal mol
-1
 higher in free energy relative to Structure 2A.  Finally, a two layer ONIOM 
method was used to model Structure 2A shown in Figure 8, predominantly in order to 
determine the feasibility of this method for examining larger transition metal containing 
complexes to be investigated in future works.   The selection of the high layer, modelled at 
B3LYP/LANL2DZ, included the active portion of the system the gallium centre and its 
coordinating sites, the phosphate group as well as all atoms involved in hydrogen bonding, 
the remainder of the complex on the other hand was treated using semi-empirical techniques 
employing the PM6 method.  Of major interest are the ONIOM obtained geometries which 
were shown in Figure 8 to be very similar to those resulting from the B3LYP/LANL2DZ 
calculations.  This provides us with good indications that such two layered calculations may 
be used in the future to obtain relative energies of different conformers of larger transition 
metal-containing complexes provided that adequate care is taken to include exactly the same 
numbers and types of atoms in the high layer in each of the conformers examined.     
 
Conclusions 
This work demonstrates that Ga-LysNTA can be used to tag the phosphate moiety in a model 
phosphopeptide thereby enabling the detection of the peptide through the Ga atom by ICP-
MS.  LC-ICP-MS data showed the co-elution of the 
31
P of the phosphorylated peptide and the 
69
Ga of the label, indicating successful Ga-LysNTA-β-PDGF formation. Unambiguous 
identification of the labelled complex was achieved through ESI-MS
n
 and accurate mass FT-
MS data. Excellent correlation with the theoretically predicted spectra were shown (see 
Figure 5). Molecular modelling supported the MS data and revealed that just one of the 
phosphate oxygen atoms was targeted by the Ga centre, the other analyte derived 
coordination sites being provided by electron donating groups on the amino acid residues. 
This suggests that complex stability will vary from peptide to peptide and may go some way 
to explaining why there are diverse and sometimes contradictory reports in the literature 
regarding the efficiency and selectivity of metal affinity techniques. 
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Future work will aim to investigate further the issue of selectivity using different peptide 
sequences and tryptic digests of phosphopetides.  The ultimate aim is to quantify 
phosphopeptides by elemental mass spectrometry using isotope dilution analysis with spiked 
gallium.  
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Figure 1: Signal due to Ga-LysNTA tag from LTQ Ion Trap MS; Panel A experimental data, 
Panel B theoretically predicted spectrumat a resolving power of 1500 m/Δm. 
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Figure 2: Structures for the Ga-LysNTAsingly charged positive ions as calculated at the 
HF/STO3G and B3LYP/LANL2DZ (italicized numbers) levels of theory.  Bond lengths are 
in Angstroms, relative free energies (in kcal per mol) are indicated in parenthesis.   
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Figure 3: Formation of [Ga-LysNTA.H2O ]
+
 from Q-Exactive FTMS; Panel A experimental 
data, Panel B theoretically predicted spectra. 
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Figure 4: Panel A experimental signal due to [Ga-LysNTA]
+
  adducts with H2O and CH3OH 
from LTQ Ion Trap MS, Panel B theoretically predicted composite spectrum of a 1:2 ratio of 
[Ga-LysNTA.2H2O]
+
 and [Ga-LysNTA.CH3OH]
+at a resolving power of 1000 m/Δm.  
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Figure 5: Full scan spectra of reaction mixture from LTQ Ion Trap MS showing evidence of 
[Ga-LysNTAPDGF]
+
 formation (main figure, insert A experimental data, insert B 
theoretically predicted spectra) at a resolving power of 1700 m/Δm. 
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Figure 6: Product ion scan of [Ga-LysNTAPDGF]
+
  at m/z 1030 from LTQ Ion Trap MS. 
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gure 7: LC-ICP-MS chromatogram of [Ga-LysNTAPDGF]
+
 from Element 2XR;Panel A 
signal from 
31
P, Panel B signal from 
69
Ga. 
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Figure 8: the lowest energy structure 2A calculated for the Ga-LysNTA-β-PDGF singly 
charged positive ions as calculated using the ONIOM method at B3LYP/LANL2DZ:PM6 
and the B3LYP/LANL2DZ (italicized numbers) levels of theory.  Bond lengths are in 
Angstroms, relative free energies are indicated in parenthesis.   
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Table S1: Electronic energies, Zero-Point Vibrational Energies, Thermal Energies, Entropies 
and relative free energies for species calculated at HF/STO3G and B3LYP/LANL2DZ 
(italicized values). ONIOM values for species 2A are listed in bold within and underneath the 
table. 
Structure 
Electronic 
energy 
(Hartrees) 
ZPE 
(kcal mol
-1
) 
    
    
  
(kcal mol
-1
) 
Entropy 
(cal mol
-1
 K
-1
) 
Relative free 
energy at 298 K 
(kcal mol
-1
) 
1A -2834.8816135 204.4 10.8 130.3 0.0 
 
 
1B 
 
 
1C 
 
 
1D 
-953.3907574 
 
-2834.8678164 
-953.3728666 
 
-2834.8555209 
-953.3229606 
 
-2834.8480638 
175.7 
 
204.6 
175.0 
 
203.2 
172.5 
 
203.1 
12.2 
 
11.6 
12.4 
 
11.9 
13.1 
 
12.0 
141.1 
 
136.5 
142.3 
 
141.9 
149.7 
 
142.4 
0.0 
 
7.8 
10.3 
 
12.8 
37.6 
 
17.4 
 
 
1E 
 
 
1F 
 
 
1G 
 
 
1H 
 
 
2A 
 
-953.3104025 
 
-2834.8099823 
-953.2955212 
 
-2834.7960201 
--- 
 
-2834.7911950 
--- 
 
-2834.6674103 
--- 
 
-5722.4171784 
-3167.9951469 
171.9 
 
204.8 
174.3 
 
202.4 
-- 
 
204.7 
-- 
 
201.4 
-- 
 
787.1 
673.6 
13.3 
 
11.5 
12.4 
 
12.3 
-- 
 
11.1 
-- 
 
12.6 
-- 
 
42.6 
45.6 
150.6 
 
136.0 
140.7 
 
145.2 
-- 
 
131.8 
-- 
 
150.0 
-- 
 
376.7 
390.7 
44.7 
 
44.4 
58.6 
 
48.8 
-- 
 
57.0 
-- 
 
127.3 
-- 
 
0.0 
0.0 
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2B 
 
 
2C 
-1334.8454825 
 
-5722.1362298 
-3167.9520199 
 
-5722.1339100 
--- 
624.0 
 
786.4 
675.8 
 
785.8 
-- 
47.2 
 
43.8 
45.3 
 
44.7 
-- 
408.8 
 
399.2 
395.8 
 
424.2 
-- 
-- 
 
170.0 
27.5 
 
164.3 
-- 
 
ONIOM: PM6 model system energy: -0.612107102528 
ONIOM: B3LYP/LANL2DZ model system energy: -1334.375450261843 
ONIOM: PM6 real system energy: -1.082139387972 
ONIOM: extrapolated energy: -1334.845482547287  
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Table 1: Summary of the mass accuracy for all proposed assignments of LysNTAGa with 
methanol and water adducts and PDGF. 
 
Ion or cluster (m/z) Experimental m/z Theoretical m/z Mass 
Accuracy 
(ppm) 
329.0259 329.0259 
330.0292 
331.0250 
332.0284 
329.0259 
330.0292 
331.0250 
332.0283 
0.0 
0.0 
0.0 
0.3 
347.0364 347.0364 
348.0398 
349.0355 
350.0389 
347.0364 
348.0398 
349.0356 
350.0389 
0.0 
0.0 
-0.3 
0.0 
361.0520 361.0520 
362.0554 
363.0513 
364.0556 
361.0521 
362.0554 
363.0512 
364.0546 
-0.3 
0.0 
0.3 
2.7 
1030.3118 1030.3118 
1031.3152 
1032.3109 
1033.3143 
1030.3109 
1031.3118 
1032.3196 
1033.3105 
0.9 
3.3 
-8.4 
3.7 
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Table 2: Summary of the proposed assignments of LysNTAGa-PDGF full mass spectra scan, 
showing both starting materials. 
 
m/z or cluster Proposed assignment  
263 [LysNTA]
+
 
329 [LysNTAGa]
+
 
361 
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2
O]
+
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3
OH]
+
 
515 [PDGFLysNTAGa]
2+
 
591 
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3
OH]
+
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2
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Oxaliplatin Complexes with Carnosine and its Derivatives: In Vitro cytotoxicity, Mass 
Spectrometric and Computational Studies with a focus on Complex Fragmentation. 
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Abstract 
The complexation of the Pt-based anti-cancer drug oxaliplatin (OxPt) with biological ligands 
other than DNA is believed to be a major cellular sink for the drug reducing its therapeutic 
potential and acting as a potential cause of toxicity.  In this paper, an in vitro study on 
hepatocellular carcinoma HepG2 cells suggests that the naturally abundant cytoplasmic 
dipeptide ligand β-alanyl-L-histidine dipeptide (carnosine) may inhibit the cytotoxic action of 
OxPt most likely through the formation of complexes that are less cytotoxic than OxPt alone.  
Evidence is provided to suggest that pre-exposure of HepG2 cells to elevated levels of 
carnosine appears to have a lasting effect on reducing the cytotoxicity of OxPt even after the 
removal of the carnosine.  This effect, however, is shown to be under kinetic control as its 
magnitude was shown not to vary significantly with the level of carnosine exposure within 
the concentration range used in this study.  Various mass spectrometry techniques employing 
electrospray ionization and chip nanospray were employed to study the interaction of 
oxaliplatin with carnosine as well as two of its derivatives being β-alanyl-N-methylhistidine 
(anserine) and N-Acetylcarnosine (NAC).  Evidence of complexation between OxPt and each 
of the three ligands examined is presented.  Most species observed were unambiguously 
assigned and compared to their theoretical isotopic patterns.  Common fragmentation 
products due to the collisionally-activated protonated complexes of each of the ligands 
examined with OxPt, [M + OxPt + H]
+
 where M= carnosine, anserine or NAC were reported.  
Density functional calculations at B3LYP/LANL2DZ were used to obtain structural 
information and relative free energies of different isomers of the observed precursor 
[Carnosine + OxPt + H]
+ 
both in the gas phase and in solution as well as to probe its 
fragmentation, highlighting plausible fragmentation mechanisms that account for all the 
experimental results.   
Data are presented to show several binding modes between electron rich sites such as N and 
O centers of carnosine and the Pt metal of OxPt.  Calculations were also employed to obtain 
proton affinities and free energies of key reactions. The proton affinities of carnosine, 
Anserine and NAC at 298 K were calculated to be 254.4, 255.9 and 250.2 kcal mol
-1
  
respectively.  To the best of our knowledge the proton affinities of anserine and N-acetyl-
carnosine are the first reported values in the literature.   
Introduction 
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Oxaliplatin (OxPt) is a third generation chemotherapeutic drug used in the treatment of 
colorectal cancer and cisplatin resistant cancers, [1-13] it was developed to overcome the 
nephrotoxicity of cisplatin and myelosuppression with carboplatin treatment. [14] Oxaliplatin 
has a broader range of activity than cisplatin and increased cytotoxicity over cis and 
carboplatin due to increased inhibition of DNA synthesis and greater efficiency in DNA 
repair. [13, 15, 16] The amine groups of cisplatin are replaced by diaminocyclohexane (dach) 
to form [Pt(dach)oxalate], oxaliplatin. The dach ligand is not recognised by mismatch repair 
complexes, which may explain its effectiveness in the treatment of cisplatin and carboplatin 
resistant cancers. [15] 
The transport and interactions of oxaliplatin within cells is still not fully understood 
however,the simplistic route from blood to nuclear DNA involves the passive diffusion of 
oxaliplatin into the cell from the extracellular fluid where the Cl
-
 concentration is high (> 100 
mM) into the cytoplasm, where the Cl
- 
concentration is low (4-20 mM). [17] The low Cl
-
 
concentration in the cytoplasm results in the solvation of oxaliplatin, to its active forms 
[Pt(OH2)Cl(dach)]
+
 and [Pt(OH2)2(dach)]
2+
[11,13], shown in Figure 1 and can interact with a 
plethora of non-DNA ligands. Based on previous work by Zayed et. al.[18] we can assume 
that the majority of the administered drug is found in the cell cytosol.  It is thought that the 
most likely sites for oxaliplatin interaction are the thiol groups of intercellular peptides and 
proteins.  Recent studies have shown that the activated form of oxaliplatin forms very stable 
complexes with glutathione, being the most abundant low molecular weight thiol containing 
molecule in human cells. [19-21] However, work by this group [21, 22] and elsewhere [22, 
23] suggests that Pt binding to intercellular peptides through their terminal amino nitrogen 
atoms and carbonyl oxygen atoms are possible and energetically competitive to sulphur 
attachment.  This in combination with the large excess of these binding sites over those of 
sulphur raises the possibility of Pt adduction to non-thiol containing ligands in the proteome.  
All such non-DNA interactions are responsible for chemo-resistance and many of the side 
effects; including sensory-motor neuropathy, myelosuppression, gastrointestinal toxicity, 
idiosyncratic and hypersensitivity reactions. [24]   
The endogenous dipeptide L-carnosine (β-alanyl-L-histidine) was discovered by Gulewitsch 
and Amiradzibi [25] from muscle tissue extracts in 1900 [26, 27] and is found in several 
organs including the brain (olfactory bulb and hippocampus) [28], cardiac muscle, kidney and 
stomach.[29, 30]  In the skeletal muscle and nerve cells it is found at concentrations of up to 
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20 mM.[31, 32]  Since its discovery there have been many investigations into its biological 
function and it is now known that carnosine acts as an anti-oxidant, scavenger of free radicals 
and active oxygen species [30], as a biological buffer, a source for histidine, an immuno-
stimulant and transition metal ion chelator, especially for Zn
2+
 and Cu
2+ 
[33] and heavy 
metals. [34]  The ability of carnosine to bind Zn
2+ 
helps modulate neuronal excitability by 
preventing the Zn
2+
 inhibition of neurotransmitter receptors. [35] Carnosine is also effective 
in the prevention and partial reversal of cataracts [36] and in the treatment of Wilsons disease 
[37] and Alzheimers due to its metal chelating and free radical scavenging ability and also 
acting as a β-amyloid toxicity inhibitor. [35, 38] It has also been shown that carnosine acts as 
a neuroprotector [39, 40] and can retard tumour growth in mouse models. [41]  More recently 
it has been reported that carnosine can prevent cell proliferation in colon cancer cells. [47, 
48]  The related dipeptides N-acetlycarnosine and anserine share many of the beneficial 
characteristics of carnosine. The N-acetyled form of carnosine, N-acetyl-carnosine has been 
shown to be effective in the treatment of stomach ulcers [42] and similarly to carnosine has 
been used in the treatment of cataracts. [43, 44] Anserine on the other hand, acts a chelator 
for copper and as an antioxidant as well as enhances the anti-tumour activity of doxorubicin. 
[45] Due to its presence in high abundance in the cytosolic fractions of cells [30] and its 
ability to scavenge transition metal elements we believe that the interactions between 
carnosine and oxaliplatin are of important scientific value.  The investigation of the 
coordination chemistry of carnosine and oxaliplatin may provide new understanding in the 
mechanism of the cellular response to these drugs. Given that there are 1-5 Pt adducts per 10
6
 
nucleotides in patient white blood cells which represents approximately 10% of the total 
administered drug. [18] Assuming all nuclear Pt is bound to DNA, representing 
approximately 10
5 
Pt atoms per cell, the majority of the administered drug is available to bind 
to other ligands such as proteins and peptides within the cell. With a large concentration of 
proteins per cell,  approximately 10
6
-10
7
, [46] many with multiple binding sites, the potential 
for a wide range of Pt adducts to exist within the cell rather than specific Pt targets is a 
possible scenario.  The interactions of carnosine and the related dipeptides anserine and N-
acetylcarnosine with Oxaliplatin are therefore of great interest.  By using a simple highly 
abundant dipeptide, such as carnosine to act as a simplified model of the broader Pt-
meallome, we present detailed structural analysis of carnosine and the hydrolysed forms of 
oxaliplatin.  
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Instrumentation 
An LTQ linear ion trap mass spectrometer with an electrospray source and a high resolution 
Q-Exactive Fourier transform mass spectrometer (Thermo Electron, San Jose, CA, USA) 
were used. Both instruments were calibrated using Ultramark
®
 1621, caffeine and Met-Arg-
Phe-Ala (MFRA) in accordance with the manufacturer’s recommendations. The Q-Exactive 
was equipped with a Tri Versa NanoMate ESI chip nanospray (Advion, New York, USA). 
For the LTQ Resolving powers achieved were in the order of 1500 while the upper 
instrumental error limit in measurements was 0.2 m/z units. The LTQ auto-tune routine was 
used to obtain lens, quadrupole and Octopole voltages for maximum transmission of the ions 
of interest. Helium gas, admitted into the ion trap at a maintained pressure of approximately 
10
-3
Torr, was used as the buffer gas to improve the trapping efficiency andas the collision gas 
for collision-induced dissociation (CID) experiments performed here at 15 eV in the lab 
frame. Experiments designed to elucidate ion structures or fragmentation pathways on the 
LTQ were performed as follows: the ion of interest was selected then collisionally activated 
by setting the activation amplitude at 25–35% of the maximum voltage available (determined 
empirically), and the activation Q setting (used to adjust the frequency of the RF excitation 
voltage) was set at 0.25 units. Sample solutions were continuously infused at a flow rate of 5 
µl min
-1
 into the pneumatically assisted electrospray probe using dry nitrogen as the 
nebulising gas. Auxiliary and sheath gases were tuned daily for maximum signal 
transmission.  Two tandem quadrupole mass spectrometers, An Acquity TQ and A XEVO 
TQ (Waters, MA, USA) both equipped with electrospray ionisation interface were also used 
in this work.  Both triple quadrupoles were operated in positive ion mode, with typical values 
of cone, capillary and extractor voltages set to 30, 2500, and 3 respectively. The desolvation 
gas was usually set at a flow of 250 L h
−1
 and a temperature of 150 ºC.  Argon was used as 
the collision gas at a typical flow rate of 0.15 ml min
-1
. Tandem mass spectra were obtained 
at collision energies in the range 5-25 eV in the lab frame having both Q1 and Q3 operated at 
unit resolution with typical a dwell time of 25 millisecond per transition. 
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Reagents 
Carnosine, Anserine, HPLC-grade water and methanol were all purchased from Sigma-
Aldrich, UK. N-Acetyl carnosine was purchased from Nanjing Gemsen international, China 
while oxaliplatin was obtained from Sanofi-Synthelabo Limited (Guildford, UK). 
 
In Vitro cell viability assays  
To determine the in vitro effect of carnosine, the hepatocellular carcinoma cell line HepG2 
was exposed to varying concentrations of OxPt, as well as several solution mixtures of OxPt 
and carnosine. The viability of HepG2 was assessed through MTT assay, which utilizes the 
conversion of the tetrazolium salt MTT (dimethylthiazol diphenyl tetrazolium bromide 
purchased from Serva, Germany) to formazan by dehydrogenase enzymes in living cells. [49] 
In brief, cells were cultured in 96-well plate (30,000 cells/well) at 37 ºC humidified with 5% 
CO2 in DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% FBS (Fetal 
bovine serum) and 5% Penicillin-Streptomycin mixture (Lonza, Switzerland). Cell counting 
was performed using Countess
®
 Automated cell counter (Invitrogen). Solutions of OxPt at 8, 
12, 16, 20, 24 and 28 μg ml-1, as well as solution mixtures at varying molar ratios of 
carnosine at a fixed OxPt concentration of 24 μg ml-1 were made in the culture media. Each 
of the sample solutions made was incubated with the HepG2 cells for 24 hrs, wells containing 
cells treated only with media served as controls. After incubation the media was discarded, 20 
µl MTT (5 mg/ml) and 100 µl fresh media were added to each well and incubated for 3 
hours, all media was then discarded, and the purple formazan crystals formed were 
solubilized via the addition of 100 µl DMSO (Sigma-Aldrich, USA). The absorbance of each 
well was measured at 595 nm using a microplate reader FLUOstar OPTIMA (BMG LabTech, 
Germany).  Cell viability was determined by calculating the absorbance of the test wells as a 
percentage of the control wells. 
Results and discussion    
HepG2 cells showed decreased viability with exposure to increased concentrations of OxPt as 
shown in Figure 1. The most significant changes in cell viability were observed at exposure 
to OxPt concentrations of 16 μg ml-1 and greater as indicated by P values < 0.00001.  To 
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examine the in vitro effect of carnosine on OxPt cytotoxicity, several solutions were prepared 
at a fixed OxPt concentration of 24 μg ml-1 while varying the molar equivalent of carnosine.  
While the choice of OxPt concentration in these experiments was arbitrary, a value was 
chosen that corresponds to relatively low cell viability in order to easily observe the effects of 
subsequent addition of carnosine.  It is also important to note that the OxPt concentration 
value chosen for these set of experiments was one that brought the most statistically 
significant decrease in the viability of the treated HepG2 cells as indicated by P values < 
0.00001 (see Figure 1).  The results of these experiments is shown in Figure 2 which points to 
a positive correlation between cell viability and increasing molar equivalence of canosine 
relative to OxPt.  These differences were much less pronounced past the initial incremental 
addition of carnosine where a significant increase in cell viability was shown due to the 
exposure of a 1:1 molar ratio of carnosine to Oxpt relative to cells only exposed to OxPt at 
the same concentration and for the same incubation time.  This was shown to be statistically 
significant with P value < 0.00001 at all non-zero molar ratios of carnosine to OxPt used.  
This result suggests that carnosine can interact with the OxPt drug forming complexes that 
reduce the drug’s action.   
In order to investigate the ability of carnosine to be passively diffused through cells, the same 
set of experiments were repeated but now cells were first incubated for 24 hours with 
carnosine at various concentrations.  After this incubation period, the media containing 
carnosine was discarded and fresh media containing 24 μg ml-1 of OxPt were added and 
allowed to incubate with the cells for a further 24 hour period.  The results of these last set of 
in vitro experiment shown in Figure 3 indicate slight increased cell viability upon the 
exposure to carnosine.  The much less pronounced effect shown in Figure 3 relative to that 
shown in Figure 2 is most likely due to the inability of carnosine to effectively passively 
diffuse through the cells.  This also suggests that the process is kinetically controlled and is 
consistent with the near constant cell viability data obtained whenever the carnosine was 
present irrespective of the concentration at which it was allowed to incubate with the cells.  
While no claim is made that the in vitro data presented here replicates biological conditions 
in which OxPt and carnosine might interact, they do however indicate that the dipeptide 
carnosine has the ability to interact with OxPt most likely through the chelation of the 
platinum metal and thus if such interaction were present it may reduce the cytotoxic action of 
OxPt and thus warrants the investigation of such complexes.   
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To study the complexes of each of carnosine and its derivatives, anserine and N-acetyl-
carnosine with oxaliplatin experiments were performed on four different mass spectrometers 
as detailed in the Instrumentation section.   For the interest of conciseness, only selected 
representative results are shown here, however, all data are available in supplementary 
material.  All sample solutions employed in this work were a 2 : 1 mM mixtures of either 
carnosine, anserine or N-acetyl-carnosine with oxaliplatin in a 1 : 1 (v/v) water/methanol 
solutions. Electrosparying each of these three solutions in the positive ion mode generated the 
mass spectra shown in Figures 4-6 (also see Figures S1 and S2 in supplementary material).  
In all cases, irrespective of the instrument used, the base peaks obtained were due to [M + 
H]
+
 ions where M = carnosine, anserine or N-acetyl-carnosine.  These ions corresponded to 
the signals at m/z values of 227, 241 and 269 shown in Figures 4, 5 and 6 (also see Figures 
S1 and S2) respectively.  Three other common ions were observed in each of the full scan MS 
spectra of the three solution mixtures examined here.  Signals due to protonated oxaliplatin, 
[OxPt + H]
+
, were always present as evidenced by the clusters observed in all full scan MS 
spectra obtained at around m/z 398.  The lowest energy structure calculated for this 
protonated species was previously reported to have the external proton located on the ‘inside’ 
position of one of the oxalate carbonyl oxygen atoms. [21]  Protonated ligand dimers, [M2 + 
H]
+
 ions, were also observed at m/z 453, 481 and 537 as seen in Figures 4, 5 and 6 (also see 
Figures S1 and S2).  The third ion observed in all full scan MS spectra obtained was due to 
the [M + OxPt + H]
+
 species as seen in the clusters around m/z 624, 637 and 666 in Figures 4 
(also see Figure S1), 5 (also see Figure S2), and 6. 
The assignments of these ions were confirmed by comparing the observed isotopic patterns to 
those theoretically modelled for each of the proposed species.    For further confirmation the 
isotopic patterns for the proposed [Carnosine + OxPt + H]
+
 and [Anserine + OxPt + H]
+
 
species being the focus of this study were obtained on the Q-Exactive FT-MS at a resolving 
power of about 60,000 and compared to their theoretical isotopic patterns at an equivalent 
resolution, the average error obtained over all the isotopic peaks observed were 2.13 and 1.48 
ppm for [Carnosine + OxPt + H]
+
 and [Anserine + OxPt + H]
+
 respectively.  This mass 
accuracy obtained without the use of lock masses provided unequivocal identifications as 
seen in Figures S3 and S4 of the supplementary material.   
The significantly lower signal intensities of the [OxPt + H]
+
 ion cluster centered at m/z 398 
relative to the [M + H]
+
 ions observed here as the base peaks in Figures 4-6 (also see Figures 
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S1 and S2) was also observed previously where similar conditions were used but where M 
was glutathione. [21]  Several explanations were given for this observations including the 
difference in proton affinities of OxPt and M. [21]  The proton affinity of OxPt at 298 K was 
previously reported to be 233.5 kcal mol
-1
 [21] whereas the proton affinities for Carnosine, 
anserine and N-acetyl-carnosine is calculated here to be 254.4, 255.9 and 250.2 kcal mol
-1
  
respectively.  To the best of our knowledge the proton affinities of anserine and N-acetyl-
carnosine are the first reported values in the literature while three previously calculated 
values for the proton affinities of carnosine were given at 256.5 (at 0 K), [50] 245.4, [51] and 
232.98, [52] kcal mol
-1
. The latter of these values most likely needs to be revisited as it is 
significantly lower than all other calculated values and the only available experimental value 
for the proton affinity of carnosine of 244.59 kcal mol
-1
 obtained by the Graham Cooks 
method [51].  The proton affinities for Carnosine , anserine and N-acetyl-carnosine calculated 
here are in agreement with the lower [OxPt + H]
+ 
signal intensity relative to each of their 
respective protonated [M + H]
+
 ions observed here.  
Figures 7-9 and S5 of the supplementary material show the MS
2
 spectra obtained by the mass 
selection followed by the subsequent fragmentation of each of the three [M + OxPt + H]
+
 
species, where M= carnosine, anserine and N-acetyl-carnosine.  These spectra indicate 
common fragmentation pathways leading to the generation of several common ions being [M 
+ H]
+
, [OxPt + H]
+
, [M + OxPt – CO2 + H]
+
, [M – H + Pt(dach)]+ where M= carnosine, 
anserine and N-acetyl-carnosine; OxPt is oxaliplatin and dach is diaminocyclohexane as 
indicated earlier in the text.             
The precursor ion [Carnosine + OxPt + H]
+
 were theoretically examined in great detail in the 
gas phase and in solution as this complex is most likely formed initially in the solution 
mixture used here.  The potential energy surfaces of this complex in the gas phase and in 
solution were found to be relatively flat with several low lying minima as listed in Table 1 
and shown in Figures 10 and 11.  The calculated structures on these potential energy surfaces 
can be divided in two categories involving either direct Pt bonding to carnosine or 
electrostatic interactions between protonated carnosine and OxPt.  The bonding category 
involves the substitution of a single Pt-oxygen bond of the oxalate moiety of OxPt by a 
formal Pt-coordination to an electron rich site on the carnosine substrate; this typically being 
one of the imidazole nitrogen atoms, a carbonyl oxygen or the terminal amino nitrogen of the 
dipeptide as shown in Figure 11.  The electrostatic category on the other hand involves 
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electrostatic interactions between the oxaliplatin molecule and protonated carnosine through 
hydrogen bonding which are responsible for keeping the resulting [Carnosine + OxPt + H]
+
 
complex together as shown in Figure 11.  It is interesting to note that all the structures 
constituting this category involve the formal protonation of the carnosine ligand as opposed 
to OxPt.  This is consistent with the higher calculated proton affinity of carnosine relative to 
Oxpt as discussed earlier.  Structures in the first and latter of these categories calculated to be 
within about 15 kcal mol
-1
 in free energy of both the gas phase and solution global minina 
found are shown in Figures 10 and 11 respectively, while all structures calculated on this 
potential energy surface are listed in Table S1 in supplementary material. Seven of the eleven 
structures shown in Figure  involve Pt coordination to either the pros or tele nitrogen atoms 
of the histidine ring of carnosine.  Structures 1A, 1B and 1D in Figure 10, all resulting in the 
cluster centred on m/z 624 as seen in Figure 4 and Figures S1 and S3 of the supplementary 
material, comprise the two lowest energy conformers in the gas phase and the lowest two 
energy conformers in solution on these potential energy surfaces.  These three structures all 
involve Pt coordination to the pros nitrogen atoms of the histidine ring of carnosine and 
formal protonation on one of the carbonyl oxygen atoms of the oxalate moiety of oxaliplatin.  
This is consistent with an earlier study examining the silver ion binding energies of all 20 α-
amino acids, showing that histidine had the third highest silver ion binding energy being 
lower than that of arginine and only slightly lower than that of lysine. [53] The lowest energy 
conformer of the Ag
+
-histidine complex in that perious study also showed Pt-coordination to 
the pros nitrogen atoms of the histidine ring. [53] Here, the global minimum on the gas phase 
potential energy surface is structure 1A as shown in Figure 10, this structure is internally 
stabilised by four strong hydrogen bonds making it 3.4 kcal mol
-1
 lower in energy in the gas 
phase relative to 1D and only 0.8 kcal mol
-1
 removed from the lowest energy structure 
calculated on the solution phase potential energy surface being structure 1D as shown in 
Figure 10.  Structure 1D is also stabilised by two internal hydrogen bonds.  It is interesting to 
note that in the gas phase structure 1A the hydrogen bond between one of the NH hydrogen 
atoms of the dach ligand and the carboxylic oxygen of the terminal carboxylate group being 
at 1.886 Å becomes none existent in solution (distance of 5.297 Å as shown in Figure 10) as 
it is replaced by external solvation.  The strongest hydrogen bonds in either the two gas phase 
structures, 1A and 1D, is between each of the hydrogen atoms of the protonated oxalate 
moieties and their respective terminal amino nitrogen atom of each of the carnosine 
dipeptides.  This is determined based on the shortest hydrogen bonding distance calculated in 
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either gas phase structure being 1.315 and 1.328 Å for structures 1A and 1D respectively as 
well as on the resulting hydrogen bonding angles being closest to the ideal linear arrangement 
calculated to be 166º for the N-H-O in both cases.  
In the solution phase on the other hand structures 1A and 1D both have their terminal amino 
nitrogen atoms protonated while forming strong hydrogen bonds to a carboxylic oxygen atom 
of the oxalate moiety in each case at 1.509 and 1.496 Å respectively.   If the solution phase 
structures 1A or 1D being the two lowest energy structures on that potential energy surface 
are transferred to the gas phase by solvent evaporation through the soft electrospray 
ionisation technique while maintaining the protonation on the terminal amino nitrogen atom a 
structure 1K or 1I would result, this structure is similar to 1C with the noted difference that 
structure 1C involves Pt coordination to the tele nitrogen of the histidine ring.  Structure 1K 
is calculated to be energetically competitive in the gas phase and in solution being only 8.7 
and 2.7 kcal mol
-1
 removed from either global minina respectively.   Alternatively, the gas-
phase transfer of the hydrogen atom of the protonated oxalate moiety to the terminal amino 
nitrogen atom in either gas phase structure 1A or 1D while maintaining the Pt coordination to 
the pros nitrogen of histidine would also results in the formation of structure 1K or 1I.   The 
loss of CO2 from the deprotonated oxalate moiety of this resulting structure, 1K or 1I, 
followed by a proton transfer from the formally protonated NH3
+
 group of the carnosine 
dipeptide to the carbon atom of the remaining CO2 group of the oxalate moiety of results in 
the formation of structure 2A shown in Figure 12.  Structure 2A is the lowest energy structure 
calculated for the [Carnosine + OxPt – CO2 + H]
+
 species observed as the m/z cluster around 
580 in the MS
2
 spectra shown in Figure 4 and as the signals at m/z 579, 580 and 581 for 
194
Pt,
 
195
Pt and 
196
Pt  as shown in panels A, B and C of Figure S5 respectively.  Structure 2A is 
shown to contain three internal hydrogen bonds which help stabilise it.  It is interesting to 
note that the lowest three energy structures calculated for the [Carnosine + OxPt – CO2 + H]
+
 
species, assigned as the cluster centred on m/z 580 as seen in Figure 7 and resulting in the 
signals at m/z 579, 580 and 581 in panels A, B and C respectively of Figure S5 of the 
supplementary material also all involve Pt-coordination to the Pros nitrogen atom of the 
hystidine ring of the carnosine dipeptide.   Structures 2B and 2C are calculated to be only 2.6 
and 5.9 kcal mol
-1
 higher in free energy relative to structure 2A respectively.  The gas phase 
inter-conversion between these three structures is expected to be rapid and well within the 
energies available under the collision induced dissociation conditions employed here as they 
involve simple rotations about single bonds.  Interestingly, structure 2C involves a hydrogen 
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bond at 1.765 Å between the OH hydrogen of the carboxylate group of the carnosine 
dipeptide and the Pt-bound oxygen atom of the remaining HCO2 group of the oxalate moiety.  
The transfer of this hydrogen atom from the OH group to the carboxylate group of carnosine 
followed by the neutral loss of the resulting H2CO2 group and the subsequent binding of the 
resulting carboxylic oxygen to the Pt center results in structure 3A shown in Figure 13.  
Structure 3A is calculated to be the lowest structure for the [Carnosine – H + Pt(dach)]+ 
species assigned as the cluster centered on mz/534 in Figure 7 and the signals at m/z 533, 534 
and 535 in panels A, B and D respectively in Figure S5 of the supplementary material. This 
assignment was further confirmed by the isotopic pattern obtained on the high resolution Q-
Exactive FT-MS shown in Figure S6 of the supplementary material.  The formation of the 
[Carnosine – H + Pt(dach)]+ species from the [Carnosine + OxPt – CO2 + H]
+
 precursor is 
supported by the MS
3
 spectrum in Figure S7 clearly showing the cluster centred on m/z 534 
being the dominant fragment due to the dissociation the[Carnosine + OxPt – CO2 + H]
+
 
precursor.   
The two other signals observed at significantly lower intensities in Figure S7 are the clusters 
centred on m/z 517 and 354.  These signals were also weak signals observed in the MS
2
 
spectrum of [Carnosine + OxPt + H]
+
 shown in Figures 7 and S5 of the supplementary 
material and were assigned as [Carnosine – NH3 – H + Pt(dach)]
+
 and [OxPt – CO2 + H]
+
 
respectively.  The latter of these species is most likely produced via the neutral loss of 
carnosine from [Carnosine + OxPt – CO2 + H]
+
 species clustered on m/z 580 generating the 
ion [OxPt – CO2 + H]
+
, Structures 5A and 5B in Table 1.  The lowest energy of these two 
structures contains a Pt centre that is dicoordinated to the dach ligand while forming two 
other symmetrical bonds to either oxygen atom of the COOH moiety.   
The species observed as a cluster centred on m/z 517 assigned as [Carnosine – NH3 – H + 
Pt(dach)]
+
 is most likely due to the loss of NH3 from [Carnosine – H + Pt(dach)]
+
 as 
confirmed by MS
4
 data (not shown).  Here, a 1,3 hydride shift to the terminal amino nitrogen 
atom of the lowest energy species on the [Carnosine – H + Pt(dach)]+ surface, Structure 3A, 
and the subsequent loss of the resulting NH3 group results in the formation of the lowest 
energy structure calculated for the [Carnosine – NH3 – H + Pt(dach)]
+
 species, structure 4A, 
being the lowest energy species on this surface as shown in Figure 14.   
Conclusions 
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In this paper, in vitro studies on hepatocellular carcinoma HepG2 cells suggest that the 
dipeptide carnosine may inhibit the cytotoxic action of OxPt most likely through the 
formation of complexes that are less cytotoxic than OxPt alone.  Evidence was provided to 
suggest that pre-exposure of HepG2 cells to elevated levels of carnosine appears to have a 
lasting effect on reducing the cytotoxicity of OxPt even after the removal of the carnosine.  
This effect, however, was shown to be under kinetic control as its magnitude was shown not 
to vary significantly with the level of carnosine exposure within the concentration range used 
in this study.   Various mass spectrometry techniques employing electrospray ionization and 
chip nanospray were employed to study the interaction of oxaliplatin with the naturally 
abundant cytoplasmic dipeptide ligand β-alanyl-L-histidine (carnosine) as well as two of its 
derivatives being β-alanyl-N-methylhistidine (anserine) and N-Acetylcarnosine (NAC).  
Evidence of complexation between OxPt and each of the three ligands examined is presented.  
Most species observed were unambiguously assigned and compared to their theoretical 
isotopic patterns.  Common fragmentation products due to the collisionally-activated 
protonated complexes of each of the ligands examined with OxPt, [M + OxPt + H]
+
 where 
M= carnosine, anserine or NAC were shown to be [OxPt – CO2 + H]
+
, [OxPt + H]
+
, [M – H + 
Pt(dach)]
+
, [M + OxPt – CO2 + H]
+
 and [M +H]
+
.  Density functional calculations at 
B3LYP/LANL2DZ were used to obtain structural information and relative free energies of 
different isomers of the observed precursor [Carnosine + OxPt + H]
+ 
and the fragments 
produced  highlighting plausible fragmentation mechanisms that account for all the 
experimental results.  Data presented showed several binding modes between electron rich 
sites such as N and O centers of Carnosine and the Pt metal of OxPt.  Values for proton 
affinities of carnosine, anserine and NAC at 298 K were calculated to be 254.4, 255.9 and 
250.2 kcal mol
-1
 respectively.    
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Structure 
 
Electronic 
energy 
(Hartrees) 
ZPE 
(kcal mol
-
1
) 
    
    
  
(kcal mol
-1
) 
Entropy 
(cal mol
-1
 K
-
1
) 
Relative free 
energy at 298 
K (kcal mol
-1
) 
1A -1639.2886242 312.6 19.6 196.8 0.0 
 -1639.4050202 314.6 19.9 201.1 0.8 
1B -1639.2858222 312.8 20.0 203.4 0.4 
 -1639.3913698 314.5 20.1 204.5 8.5 
1C -1639.2867573 314.4 19.6 197.5 2.7 
 -1639.3956112 315.2 19.8 200.1 7.6 
1D -1639.2796868 312.7 20.0 205.4 3.4 
 -1639.4041530 314.2 20.0 204.7 0.0 
1E -1639.2784107 313.5 19.8 203.6 5.4 
 -1639.4015638 314.5 19.7 201.5 2.6 
1F -1639.2732867 312.9 20.7 213.8 5.9 
 -1639.3731196 312.8 20.8 215.6 15.6 
1G -1639.2758092 312.9 20.1 204.4 6.5 
 -1639.3914762 314.0 20.3 207.1 7.3 
1H -1639.2729851 312.2 20.1 207.4 6.7 
 -1639.3770276 314.2 20.5 213.3 14.9 
1I -1639.2778140 312.9 19.7 198.0 6.7 
 -1639.3970803 313.9 20.1 203.7 4.5 
1J -1639.2760210 313.7 19.8 202.3 7.4 
 -1639.3961354 314.9 19.9 202.4 6.3 
1K -1639.2716859 312.5 20.2 204.9 8.7 
 -1639.3958654 314.3 20.3 214.4 2.7 
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1L -1639.2723656 312.9 20.3 206.1 8.3 
 -1639.3651803 312.2 20.3 207.8 21.9 
1M -1639.2680874 312.9 20.4 210.2 9.9 
 -1639.3712658 312.5 20.5 212.7 17.0 
1N -1639.2702447 314.2 20.1 202.5 11.8 
 -1639.3699854 314.1 20.3 206.5 21.1 
1O -1639.2751572 314.9 19.4 192.0 11.9 
 -1639.3845742 313.7 19.7 197.0 13.7 
1P -1639.2677622 313.4 20.2 204.1 12.2 
 -1639.3703845 313.5 20.4 205.0 20.8 
1Q -1639.2640107 313.8 19.6 200.3 15.5 
 -1639.3799232 313.8 19.9 204.8 14.6 
1R -1639.2631978 313.4 20.0 201.1 15.8 
 -1639.3842329 315.0 20.3 208.0 12.6 
1S -1639.2554539 314.0 20.2 207.2 19.6 
 -1639.3634689 313.5 20.3 209.7 23.6 
1T -1639.2554538 314.0 20.2 207.2 19.6 
 -1639.3634688 313.5 20.3 209.7 23.6 
1U -1639.2500998 312.1 20.6 212.9 19.8 
 -1639.3468289 311.9 20.7 214.6 31.4 
1V -1639.2855972 313.4 20.1 204.5 0.8 
 -1639.3803957 313.2 20.4 208.5 13.1 
1W -1639.2750738 312.9 20.7 216.3 4.0 
 -1639.3730479 312.7 20.8 217.2 15.2 
1X -1639.2806661 313.8 20.0 202.2 5.0 
 -1639.3792743 313.5 20.3 206.4 14.8 
1Y -1639.2698582 313.8 20.6 219.8 7.1 
 -1639.3745151 314.0 20.7 218.0 15.1 
2A -1450.7542132 304.6 18.5 192.5 0.0 
2B -1450.7521575 304.7 18.1 187.2 2.6 
2C -1450.7488908 305.0 18.2 184.3 5.9 
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2D -1450.7396653 304.6 18.2 186.7 10.5 
2E -1450.7359210 304.2 18.4 189.4 11.9 
2F -1450.7356931 304.0 18.2 186.5 12.5 
2G -1450.7278354 303.5 18.6 198.1 13.9 
2H -1450.7225517 305.3 18.3 190.2 21.0 
2I -1450.7156471 305.4 18.5 193.8 24.6 
2J -1450.6987011 302.4 18.6 191.6 33.0 
2K -1450.6951026 303.3 18.8 199.0 34.1 
2L -1450.6961826 302.4 18.3 188.4 35.3 
2M -1450.6910914 302.8 18.4 189.3 38.6 
2N -1450.6692231 302.7 19.0 199.4 49.9 
3A -1260.9744123 282.5 15.8 168.1 0.0 
3B -1260.9646407 281.5 16.4 174.2 3.9 
3C -1260.9499510 283.0 15.7 171.6 14.8 
3D -1260.9471698 282.5 15.6 164.1 18.1 
3E -1260.9382042 283.1 15.3 159.5 25.4 
3F -1260.8792520 280.7 16.1 171.0 57.3 
3G -1260.8353995 281.2 15.5 163.5 86.9 
4A -1204.3891678 256.0 15.1 162.6 0.0 
4B -1204.3888797 256.2 14.7 157.3 1.6 
4C -1204.3795752 255.7 15.1 164.3 5.2 
4D -1204.3716679 255.2 15.1 166.1 9.3 
4E -1204.3753032 256.7 14.6 159.2 10.0 
4F -1204.3612046 255.2 14.9 161.7 16.8 
4G -1204.3318604 255.0 14.9 162.3 34.9 
4H -1204.3247413 254.8 15.1 166.2 38.2 
4I -1204.3241914 255.0 15.0 163.8 39.4 
4J -1204.3113922 254.7 14.8 158.9 48.4 
4K -1204.2953955 255.0 14.7 158.5 58.8 
4L -1204.2460587 253.0 15.6 169.7 85.3 
4M -1204.2346476 252.8 15.7 166.6 93.2 
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5A -654.6722639 148.4 8.1 109.6 0.0 
5B -654.6344513 145.8 9.0 121.9 18.4 
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